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“If your experiment needs statistics,     
you ought to have done a better experiment.” 
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ABSTRACT
Migraine is the most common cause of chronic episodic headache, affecting 12%-
15% of the Caucasian population (41 million Europeans and half a million Finns). 
Migraineurs suffer a considerable loss in quality of life and have increased risk for a 
wide range of conditions, from depression to stroke. Migraine is characterized by 
episodic attacks of headache accompanied by sensitivity to external stimuli lasting 4-
72 hours, and in a third of cases by neurological aura symptoms, such as loss of 
vision, speech or muscle function. No biochemical markers identifying migraine have 
been found and its underlying pathophysiology (including the triggers of migraine 
onset and individual migraine attacks) is largely unknown. The aim of this study was 
to identify genetic factors associated with the hereditary susceptibility to migraine in 
order to gain a better understanding of migraine mechanisms. 
We report the first whole genome association study of migraine, as well as genetic 
linkage and association analyses of patients drawn from a large Finnish migraine 
patient collection, along with migraineurs from similar collections in Australia, 
Denmark, Germany, Iceland and the Netherlands. Overall, we studied the genetic 
information of over 6,500 migraine patients and some 50,000 population-matched 
controls. We also developed a new migraine analysis method called the trait 
component analysis, which is based on individual patient responses instead of clinical 
diagnoses. Using this method, we detected a number of new genetic loci for migraine, 
including loci on 17p13 (HLOD 4.65) and 10q22-q23* (female-specific HLOD 7.68) 
showing significant evidence of linkage and five other loci (2p12, 8q12*, 4q28-q31, 
18q12-q22*, and Xp22*) having suggestive evidence of linkage (four of which, 
indicated by asterisks, replicated previous findings). The 10q22-q23 locus was the 
first genetic locus found to show linkage with migraine in multiple populations and 
studies and has been consistently detected in six different genome-wide linkage scans. 
In a candidate gene study of 155 ion transport genes, we found that common variants 
played no significant roles in migraine susceptibility. The role of common variants 
was further examined by the first genome-wide association study in migraine, 
conducted on 2,748 migraine patients and 10,747 matched controls followed by 
replication in 3,202 patients and 40,062 controls. In this study, we detected the first 
common variant associated with migraine, which is carried by approximately 20% of 
the general population. A follow-up expression quantitative trait study suggested that 
the detected variant has a functional effect on the transcription of the nearby gene 
MTDH/AEG-1, providing an interesting link to the dysregulation of glutamate 
clearance from the synaptic cleft.  
In summary, in this thesis we found several promising genetic loci for migraine, 
detected the first gene affecting common migraine susceptibility, through a variant 
estimated to account for 2.5% of total migraine heritability and 10.7% of the 
population attributable risk for migraine. We also report a promising hypothesis for a 
biological mechanism for migraine. 
V. Anttila - Identification of genetic susceptibility loci for migraine 
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INTRODUCTION
Diseases with complex etiology form the most challenging problems faced by doctors 
and geneticists as well as patients, and conditions such as high blood pressure, 
diabetes, depression and migraine are very much part of daily life. Advances in the 
understanding of the genetics of these so-called “complex diseases” promise major 
improvements in quality of life for large segments of the population, but have proved 
to be difficult to study due to complicated interrelationships between environmental 
and innate factors involved in their pathophysiology. A recent discussion in the 
British Medical Journal even discussed the validity of the whole field of modern 
genetics to medicine (Le Fanu, 2010, Weatherall, 2010).  
Neuropsychiatric conditions, including migraine (MIM 157300), are the most 
important cause of disability in all regions of the world, accounting for more than 37 
percent of total years lived with disability (YLD) among adults aged 15 years and 
older. Migraine forms a major part of that burden, ranking 19th in YLD in the general 
population and 9th among women (Lopez et al., 2006). In Europe, migraine is the 
most common and costly neurological disease (Andlin-Sobocki et al., 2005). In a 
large US study, half of migraine patients reported at least one emergency room visit 
per year due to migraine, while 90% had at least one clinic visit and 15% had done so 
more than five times in the previous year (Osterhaus et al., 1992).
Migraine is the most common cause of chronic episodic headache. It affects 
approximately 12%-15% of the population (Hagen et al., 2000). Most of the common 
migraine spectrum is formed in two subtypes: migraine without aura and migraine 
with aura (previously known as common migraine and classical migraine, 
repectively). Both conditions are complex diseases, and so far no genetic variants 
influencing the susceptibility to either condition have been convincingly identified. 
There are no quantifiable laboratory measurements or radiological or performance 
changes for use in the study of migraine, and the migraine diagnosis is based solely on 
a patient’s description of attacks.  
In recent years, advances in analysis methods and genotyping technologies have 
enabled detailed genetic studies in hundreds and thousands of individuals at a time. 
This is the key to studying diseases with complex inheritance, as the effects of 
individual variants within the population are small and thus require more samples to 
reach sufficient statistical power for detection. In this thesis, we introduce a new 
method of stratifying different types of migraine, which we use to investigate the 
genetic susceptibility and background of the disease. We also present the first 
genome-wide association study in migraine. 






Migreeni on yleisin kroonisen kohtauksellisen päänsäryn syy ja siitä kärsii 12-15% 
väestöstä (Hagen et al., 2000). Monitekijäisten kansantautien - kuten migreenin, 
diabeteksen ja masennuksen - etiologian ymmärtäminen on eräs nykylääketieteen ja -
genetiikan vaikeimmista haasteista. Nämä taudit ovat osa päivittäistä elämää niin 
lääkärin vastaanotolla kuin kotonakin ja niiden tutkimuksen edistysaskeleilla on 
mahdollisuus parantaa monien potilaiden elämänlaatua. Monitekijäisten tautien 
tutkimus on kuitenkin osoittautunut hankalaksi moninaisten ympäristö- ja 
yhteisvaikutusten vuoksi ja tulokset ovat usein jääneet heikoiksi. Tuore keskustelu 
British Medical Journalissa jopa kyseenalaisti nykygenetiikan arvon lääketieteelle (Le 
Fanu, 2010, (Weatherall, 2010). 
 
Neuropsykiatriset taudit, johon ryhmään migreenikin (MIM-koodi 157300) kuuluu 
ovat johtava elämänlaadun laskun syy kaikkialla maailmassa ja ne muodostavat 37 
prosenttia toimintakyvyttömyyden kanssa eletyistä elinvuosista (YLD, years lived 
with disability) yli 15-vuotiailla. Migreeni muodostaa merkittävän osan tästä 
sairaustaakasta, ja on 19. vakavin elämänlaadun laskija koko väestössä ja 
yhdeksänneksi vakavin naisten keskuudessa (Lopez et al., 2006). Euroopassa 
migreeni on eniten kustannuksia ja elämänlaadun laskua aiheuttava neurologinen tauti 
(Andlin-Sobocki et al., 2005). Eräässä amerikkalaistutkimuksessa todettiin, että puolet 
migreenipotilaista joutuu käymään sairaalapäivystyksessä kerran vuodessa migreenin 
vuoksi, 90% kertoi tarvinneensa ainakin yhden terveyskeskuskäynnin viimeisen 
vuoden aikana aikana sen vuoksi ja 15% tarvitsi vähintään viisi käyntikertaa 
(Osterhaus et al., 1992).  
 
Yleisellä migreenillä on kaksi päätyyppiä: auraton ja aurallinen migreeni, jossa 
jälkimmäisessä kohtaukseen liittyy kivun lisäksi erilaisia neurologisia oireita, kuten 
näkö- ja puhevaikeuksia. Tällä hetkellä käytössä ei ole laboratorio- tai 
kuvantamistutkimuksia, joilla migreeni voitaisiin osoittaa. Molemmat muodot 
kuuluvat edellä mainittuun monitekijäisiin tauteihin, eikä ennen tätä tutkimusta yhtään 
yleiseen migreenialttiuteen vaikuttavaa geneettistä tekijää ole varmuudella tunnistettu. 
Viime vuosien aikana analyysi- ja genotyypitysteknologian kehitys on ensimmäistä 
kertaa mahdollistanut satojen ja jopa tuhansien potilaiden geneettisen tiedon 
tutkimisen yksittäisessä tutkimuksessa. Näin suuret potilasmäärät ovat ehdoton 
vaatimus monitekijäisten tautien tutkimuksessa, koska yksittäisten muutosten 
merkitys on vähäinen ja siksi riittävän tilastollisen voiman saavuttaminen vaatii 
laajojen potilasaineistojen tutkimista. Tässä väitöskirjatutkimuksessa esittelemme 
uudenlaisen lähestymistavan, oirekomponentti-analyysin, migreenin luokitteluun sekä 
sovellamme sitä uusien geneettisten alttiusalueiden tunnistamiseen suomalaisessa ja 
kansainvälisessä potilasaineistoissa. Tätä analyysiä käyttämällä tunnistimme kaksi 
tärkeää migreenille altistavaa geenialuetta sekä toistimme useita muita. Tärkeimmät 
genomin ionikanavat kattanut geenitutkimus poissulki näiden roolin yleisessä 
migreenissä. Suorittamamme ensimmäinen migreenin kokogenomin 
assosiaatiotutkimus (käsittäen n. 5 700 potilasta ja 50 000 verrokkia) tunnisti 
ensimmäisen migreenialttiuteen vaikuttavan variantin, jonka osoitimme säätelevän 
lähellä sijaitsevan geenin ilmaisua. Tämän variantin säätelyvaikutus on ensimmäinen 
geneettiseen migreenialttiuteen populaatiotasolla ehdotettu mekanismi. 




REVIEW OF THE LITERATURE 
 




“Despite the ever-accelerating pace of biomedical research, the root causes of 
common human diseases remain largely unknown, preventative measures are 
generally inadequate, and available treatments are seldom curative. Family history is 
one of the strongest risk factors for nearly all diseases – including cardiovascular 
disease, cancer, diabetes, autoimmunity, psychiatric illnesses and many others – 
providing the tantalizing but elusive clue that inherited genetic variation has an 
important role in pathogenesis on disease”. These are the starting lines of the 
International HapMap Consortium’s first paper in 2005 (The International HapMap 
Consortium, 2005), which marked the beginning of the genome-wide association era. 
 
In the few years since, impressive strides have been made in the genetics of common 
diseases. Large international consortia, which genotype tens and even hundreds of 
thousands of patients per study, have discovered numerous disease-associated variants 
and uncovered many new pathways associated with disease. For some conditions, like 
Crohn’s disease (Barrett et al., 2008) and type II diabetes (Sladek et al., 2007), 
entirely new mechanisms have been detected. In the age of genome-wide association 
studies, tens of thousands of individuals have had a portion of their common variants 
genotyped, thereby forming a treasure trove of genetic information. However, many 
challenges remain in using the information to shape meaningful biological insights, 
especially due to the relatively small individual impacts of most detected variants. 
Therefore, a critical issue is coming up with new geno- and phenotyping methods to 
improve detection power. Due to the various challenges, most variants and pathways 
probably still remain to be found. Especially among diseases of the brain, knowledge 
of the genetic etiologies is weak. 
 
Up until the late 1990’s, technological and financial restrictions severely limited the 
size – and thus the attainable statistical power – of genetic studies. Typical studies 
used up to ten families and a few dozen affected individuals. This study size provided 
sufficient statistical power for the study of rare recessive Mendelian diseases – 
conditions where a mutation in the primary gene is necessary for the condition to 
occur, although its effects may be affected by one or more modifier genes. Indeed, 
genes and mechanisms for many such diseases were discovered in the 1990’s, a 
notable example of this being identification of genes for the conditions forming the 
“Finnish disease heritage” (Norio, 2003a) – a group of roughly 40 genetic diseases 
more common in Finland than elsewhere in the world (Peltonen et al., 2000).  
 
The completion of the main part of two key projects in early part of the first decade of 
the 21st century, the Human Genome Project (Lander et al., 2001) (HGP) and the 
International HapMap Project (The International HapMap Consortium, 2005) (see 
later in this Chapter) raised great hopes of understanding the basis of common 




Figure 1. The human karyotype, showing 
chromosomes aligned along the location of the 
centromere. Image courtesy of the NHGRI. 
diseases. Huge amounts of both public and private funding were spent mapping a 
complete sequence (HGP) and to understand how the sequence behaves in different 
populations (HapMap), ushering in the era of genome-wide association studies. Now, 
more than 500 reported genome-wide association studies later (Hindorff et al., 2009), 
the conclusion appears to be that evolution has been remarkably successful in 
removing completely or at least limiting the contribution of penetrant mutations with 
large effects for common diseases (Goldstein, 2009). While this is good news for the 
species as a whole, it means that more comprehensive approaches such as whole 
genome and whole exome sequencing are needed, and that a lot of work remains in 




It has long been observed that many discrete characteristics of offspring correspond 
more closely to those of their parents than to those in the general population; for 
example, people with blue eyes will have more blue-eyed offspring than average, and 
offspring of plants with larger fruits are likely to bear larger fruits compared to 
average. Darwin’s formulation of the concepts of natural selection and evolution in 
1859 introduced a new theory of inheritance (Darwin, 1859), whereby evolution of 
species was shown to give rise to completely new features and traits. Mendel showed 
in 1865 that inheritance patterns in peas followed certain mathematical rules (Mendel, 
1866), thus suggesting that small, discrete units of heredity exist. With the biological 
basis of heredity established, attention turned to its role in human features and 
disease. Galton had 
identified the usefulness 
of twins for genetic 
studies in 1875, and 
Garrod identified the first 
human disease with a 
Mendelian inheritance 
pattern, alkaptonuria, in 
1902 (Garrod, 1902). The 
discovery of the structure 
of DNA in 1953 (Watson 
and Crick, 1953b) and the 
resulting implications for 
understanding the genetic 
code opened the study of 
genetics to chemical 
analysis. Shortly after, the 
correct number of human 
chromosomes were 
identified in 1956 
(Harper, 2006, Tjio and 
Levan, 1956). The first 
gene sequence was 
described in 1972 (Min 
Jou et al., 1972) and the 
first genome sequenced (a 




bacteriophage) in 1977 through Sanger sequencing (Sanger et al., 1977). However, 
DNA analysis was painstaking, slow and difficult work, until it was made much easier 
by polymerase chain reaction (PCR) in 1983, which allowed easy amplification of 
DNA, necessary for large-scale experiments.  
 
The human genome consists of roughly three billion pairs of nucleotides, divided into 
22 pairs of autosomal (i.e. not sex-dependent) chromosomes and one pair of sex 
chromosomes (X and Y for males, X and X for females) which reside in the cell 
nucleus. A complete set of chromosomes is called a karyotype (Figure 1). Half of the 
chromosomes, 22 autosomal and one X chromosome are inherited from the maternal 
parent, and 22 autosomal and either an X or a Y from the paternal parent. In addition, 
small cell organelles called mitochondria, maternally inherited along with the 
maternal chromosomes, contain mitochondrial DNA (mtDNA). By comparison, 
mtDNA is minuscule, at 15,000 to 17,000 bases long. 
 
A chromosome is comprised of one very large DNA molecule as well as DNA-
associated proteins. The associated proteins package and organize the DNA into the 
tight space of the nucleus. The two complementary strands of DNA form a double 
helix, consisting of a phosphate backbone on the outside of the helix, and pairs 
formed of four bases on the inside: adenine (A), cytosine (C), guanine (G), and 
thymine (T). Typically, the most energy-efficient configuration is attained by linking 




The elements making up the variation in the human genome can be divided into 
different classes that vary in size. There is some overlap among groups due to 
historical reasons. The classes are listed below and those directly measured in and 
therefore most relevant to this thesis are 1 and 3b.  
1. Single nucleotide polymorphism (SNP) is a difference in a single base 
pair and is the most common variation in the human genome. For instance, for 
an A/C SNP some individuals in the population carry an A-T pair at a given 
locus while others carry a C-G pair. A variant more frequent than 5% in the 
population is considered a common variant, while variants less than 0.5% 
frequent are considered rare variants. Current estimates place the number of 
SNPs with a population frequency of greater than 1% in the human genome at 
around 10,000,000 – one variant per every 300 bases, and roughly 1% of these 
are thought to be of functional importance (The International HapMap 
Consortium, 2005). It is estimated that the common SNPs are responsible for 
90% of all genome variation. SNP data is used for Studies III and IV. 
2. Insertions and deletions are changes to the length of the sequence due 
to the addition or removal, respectively, of one or more base pairs. Because of 
the three-base reading frame of the translation process, changes in length not 
divisible by three corrupt the reading frame, usually resulting in major changes 
to the protein, often through a premature termination of the protein chain. 
Traditionally, changes in size less than 571 bp were referred to as indels, but 
this definition has considerable overlap with the subsequent classes. 
3. Repeat sequences (interspersed repeats, simple sequence repeats, 
segmental duplications, tandem repeats and copy number variants) are 




various forms of sequence that have been copied over and over into the 
genome, by transposable elements, a group of genomic hitchhikers. Even 
though the repeats have been historically considered “junk DNA” in terms of 
translation to proteins, repeating/duplicating/transposing a piece of the 
genomic sequence is a major evolutionary force (Lander et al., 2001), that 
facilitates the formation of new genes by recombining the existing sequence in 
new ways. Similarly,  
a. Interspersed (or transposon-derived) repeats estimated to 
comprise about 45% of the sequence of the human genome, but they are 
probably considerably more common. These repeats are a type of 
genomic parasite, a short piece of sequence which encodes for a few 
proteins required to bring the code into the cell nucleus and then 
randomly insert it into the DNA, where it is then ready for a new round 
of translation and re-entry.  
b. Simple sequence repeats are a class of repeats where one or 
more nucleotides is repeated over and over (e.g. [CATG]n for 
CATGCATGCATG… sequence). They comprise 3% of the human 
genome and occur about once every two kilobases. Occasionally, 
mistakes in the DNA copying process (as the copying enzymes are more 
susceptible to mistakes when copying repeated sequences (Tautz and 
Schlotterer, 1994)) result in the lengthening of repeats. These differences 
in length can be used as a distinguishing feature between individuals, as 
well as being the causative mechanism in various expansion repeat 
disorders. In these disorders, extension of the repeat past a certain 
threshold causes disease, in cases where past a certain threshold the 
structure of the created protein is sufficiently different to alter its 
behavior in the cell. This group of diseases includes conditions such as 
the Fragile X syndrome (De Boulle et al., 1993), Huntington’s disease 
(Walker, 2007) and various spinocerebellar ataxias (Orr et al., 1993). 
These repeats are further divided based on the length of the repeated 
sequence into satellite DNA (>500 bases), minisatellites (14-500 bases), 
and microsatellites (1-13 bases). Microsatellite length data of (di-, tri-, 
and tetranucleotide repeats) is used for Studies I and II. 
c. Segmental duplications are 1-200 kb pieces of sequence that 
have been transferred in bulk from one location in the genome to another 
(intra- or interchromosomally), forming an estimated 5% of the genome. 
Segmental duplications located in close proximity are the basis for 
contiguous gene syndromes, such as the Smith-Magenis syndrome 
(Chen et al., 1989) and Charcot-Marie-Tooth syndrome 1A (Reiter et al., 
1997). The syndromes involve known nearby duplications on 
chromosome 17 that align during replication, resulting in loss of the 
DNA sequence between the duplications. Large parts of certain 
chromosomes are known to arise from sections created by numerous 
segmental duplications. 
d. Copy number variants (CNVs) are a special form of repeat 
sequences, which have become important in recent years as new 
platforms are capable of interrogating all common large-scale CNVs in a 
given genome. Through copy number variation, an individual can have 
multiple copies of a gene or region, because the length of the repeated 
sequence is long (commonly defined as > 1kb in length) and the copy 




number typically ranges from zero to six. There is considerable variation 
in the possible size of copy number variations, which can extend up to 
several megabases long (Feuk et al., 2006). Homo- or heterozygous 
deletions (i.e. having a CNV with zero and one copies, respectively) are 
more easily interpreted in a biological context (Stefansson et al., 2008), 
because the loss of sequence at this scale frequently leads to severe 
phenotypes, such as mental retardation (Webber et al., 2009). However, 
the relevance of having excess copies of a CNV is not as well 
understood. Most CNVs have been found to be tagged by one or more 
common SNPs. Therefore, their roles in common diseases have largely 
been covered by SNP studies, which have not uncovered variants with 
high effect sizes, suggesting that the roles of common CNVs in common 
diseases is minor (Wellcome Trust Case-Control Consortium, 2010). 
However, much hope is currently placed on rare and/or large-scale 
CNVs (Walters et al., 2010) that are not yet sufficiently tagged by 
existing SNP studies. 
4. Chromosomal abnormalities are major changes in the chromosome 
structure, often involving millions of bases at a time. There are five different 
classes of such changes. Deletions and duplications act as their counterparts in 
CNVs and both usually have severe consequences on the survivability of the 
organism, but certain whole-chromosome duplications can lead to non-lethal 
phenotypes such Down syndrome (Roizen and Patterson, 2003) and 
Klinefelter’s syndrome (Klinefelter, 1986). Inversions involve the rotation of a 
segment of DNA from end to end, and if the inversion is not associated with 
an additional change in sequence length, the inversion does not lead to any 
pathology. In fact, an inversion on chromosome 8 is highly common among 
European populations (McEvoy et al., 2009)). Insertions and translocations 
involve pieces of a chromosome added or exchanged between chromosomes, 
which can be asymptomatic, but are more frequently observed in various 
cancers.  
 
The sequence of any two full human genomes differs from one another by 0.1%, or 
one change per approximately 1,000 bases (The International HapMap Consortium, 
2005). As a practical example of genetic differences between individuals, Levy et al. 
calculated the difference between two individuals from the same population (the HGP 
reference sequence, and the Venter genome) to be 12.3 Mb, divided into 3.2 Mb in 
SNPs (of which 1.3 Mb were novel), and 300,000 heterozygous and 560,000 
homozygous indels. The non-SNP variation (i.e. variation due to CNVs, segmental 
duplications, inversions) was estimated to account for 74% of variant bases, or 4% of 
the genome (Levy et al., 2007). Further, 17% of the known genes (4,107/23,224) were 
found to contain a non-synonymous mutation, and a full 44% of known genes were 
found to have mutations in the UTR or coding regions. A 2003 paper estimated that 
segmental duplications alone account for 3.5% of total variation (Cheung et al., 2003).  
 
The various elements of the genome have specific mechanisms that cause their 
occurrence. Concentrating on the elements forming the basis of this thesis, SNPs and 
microsatellites, the former occur due to de novo mutations caused by radiation and 
chemicals, as well as mistakes made by the enzymes copying DNA. Microsatellite 
length changes occur at roughly once every 1,000 generations (Weber and Wong, 
1993), by slippage of the DNA replication machinery which occurs every now and 




then when copying repeated sequence (Kruglyak et al., 1998). The most important 
part of the genome in terms of human survival is the coding sequence, comprising a 
few percent of the total sequence. The human genome contains an estimated 20,000 to 
26,000 genes, with additional variation provided by differential processing through 
alternative splicing and transcriptional control, which allows a coding sequence to be 
transcribed in different ways. Unlike repeated sequence, the coding sequence is highly 
conserved (Sorek et al., 2004), since most random changes to the coding sequence are 
likely to have a major effect on the resulting protein. 
 
While the changing nature of the genomic landscape is a tradeoff paid for 
evolutionary flexibility, it also results in the existence of genetic conditions. While 
evolutionary pressure keeps truly severe mutations in check, a number of additional 
factors can partially subvert the process causing particular diseases to become more 
prevalent. One such subversion is the so-called genetic bottleneck: a situation where a 
small subsection of the general population is the founder population for a new 
population, which remains isolated from outside genetic influences. A genetic 
bottleneck causes unusually high population frequencies of certain genetic markers, 
and thus using a population that has undergone a genetic bottleneck increases the 
power of genetic studies (de la Chapelle, 1993). Such bottlenecks usually occur for 
social or political reasons – for example, in the case of a small tribe that is cast out of 
a major population group for religious, political, or language reasons – like the 
Hutterites (Ober et al., 2000) in Canada and Eastern United States, and the Ashkenazi 
Jews in Israel (Hammer et al., 2000). Another classic example is the extensive use of 
the population isolate of Northern Finland, and especially the Kuusamo region (Varilo 
et al., 2000), to map complex diseases, such as asthma (Laitinen et al., 2001). The 
details of the Finnish genealogical history have been extensively debated elsewhere 
(Peltonen et al., 1999, Norio, 2003b), and will not be discussed here beyond the fact 
that the special features of the Finnish population isolates make them useful in disease 
gene mapping. 
 
Another factor preserving harmful genetic mutations through evolution is the 
existence of recessive mutations: mutations that need to be present on the haplotype 
inherited from both parents in order for the corresponding phenotype to manifest. 
Given a sufficiently rare frequency of recessive mutations in the population, as was 
shown by G.H. Hardy in 1908 (Hardy, 1908), the frequency of the rare mutation stays 
largely unchanged in a population since the occurrence of its phenotype is very rare. 
As a result, the recessive mutation will likely remain in the population forever. The 
situation is complicated further when the mutation has a beneficial effect in addition 
to the negative effect; the classical example is the mutation underlying sickle cell 
anemia, where having a single copy of the mutation is beneficial as it provides 
resistance for malaria while having two copies results in the manifestation of disease 
(Kwiatkowski, 2005).  
 
Methods of studying the genetics of human diseases 
 
Twin studies 
Twin studies are the classical starting point to finding genetic causes for diseases. 
Given that monozygotic (MZ) twins share 100% of their genome, dizygotic (DZ) 
twins 50% and both share the same environmental background, by comparing the 




incidence difference of a given condition or trait between the MZ and DZ groups 
gives a direct estimate of half (100%-50% = 50%) of the genetic load for that 
phenotype. Through further calculations it is possible to estimate the environmental 
component (roughly equal to total risk minus genetic risk). From these calculations 
the amount of heritability associated with a particular phenotype can be determined, a 
key metric in determining whether genetic studies are warranted. Heritability is a 
measure of the proportion of phenotypic variation that is attributable to genetic 
variation, and is equal to the genotype variance divided by the phenotypic variance 
(H2, reflecting all possible genetic variance) or the additive variance divided by the 
phenotypic variance (h2, reflecting only the additive variance). The latter is used more 
commonly, as h2 can be readily estimated from twin studies as twice the difference in 
correlation between MZ and DZ twins.  
 
Linkage studies in families 
The traditional next step in trying to find genetic risk factors is a family-based linkage 
study. In a linkage study, the segregation of genetic markers located across the 
genome is compared to the segregation of the study phenotype in the pedigree. The fit 
of a marker inherited along a phenotype is calculated as a the LOD score (the primary 
outcome measure in Studies I and II), defined as the base 10 logarithm of the 
likelihood of the given marker inheritance pattern divided by the random likelihood of 
the pattern. The chance to detect the haplotype that co-segregates with the disease 
status (if any) increases by collecting as large families as possible with multiple 
affected individuals. In practical terms it is observed that every additional informative 
meiosis increases the attainable LOD score by 0.3. In practice, a linkage analysis tests 
haplotypes defined by microsatellite markers in order to find single markers (two-
point analysis) or multiple markers (multipoint analysis) that associate with the 
disease status. A limiting step in the success of linkage studies is the “conversion 
step”, which is the transformation of long-range haplotype segregation information 
(assumed to tag rare, possibly family-specific mutations) to the identification of the 
underlying mutations. However, rather than being a problem with the linkage study 
design, this difficulty is more due to the fact that information on the polymorphisms at 
a detected locus is only available for the most common polymorphisms, and therefore 
rare haplotypes causing disease are left unnoticed.  
 
Candidate gene association studies 
In the candidate gene approach, a hypothesis-based selection of a limited number of 
interesting genes is made based on positional information from linkage studies, 
functional information from pre-existing hypotheses or a combination of the two 
(Hirschhorn et al., 2002). Subsequently, a selection of genetic markers located in or 
near the selected genes is genotyped, typically in a case-control design of obtaining a 
sample of patients and another of healthy controls as identical to the patient sample in 
every way (except the phenotype studied) as possible. The frequencies of genetic 
markers in the two groups compared, and markers with clear frequency differences 
are considered to be associated with the phenotype to a degree of confidence given by 
the statistical significance of the frequency difference. A clear drawback to this 
approach is that it requires a priori knowledge of how the pathways or systems work 
in order to make a valid selection of genes. As a result, this inference is usually made 
on very limited information (Buckland, 2001). A second problem is that unlike in 
linkage and genome-wide association studies, only a narrow area covering the gene 
and its immediate surroundings is genotyped, because it is rarely feasible to cover 




much of the intergenic area due to technological constraints. The distribution of 
eQTLs’ (changes to the sequence that affect the expression of a gene) (Nica and 
Dermitzakis, 2008) distances from the alleles they affects is relatively even until a 
distance of around 1 Mb (Stranger et al., 2007), so that even if the studied gene is 
chosen correctly, its contribution to disease susceptibility may be via a long-range 
modifier or other distant mechanism that fall far outside the studied area. 
 
Genome-wide association studies 
The latest addition to the geneticists’ arsenal has been the GWA study. In a GWA 
study, the testing is similar to the candidate gene study in that a pool of affected and 
control individuals is college, but instead of having to pre-determine the (usually 
narrow) regions of interest, a large number of markers with roughly equal distribution 
across the genome are genotyped at once. The GWA approach has some major 
advantages over others; unlike a candidate gene study it is relatively hypothesis-free 
with regard to disease mechanisms as every gene in the genome is tested in roughly 
the same manner. One drawback is that a number of assumptions regarding the 
frequency of alleles and the underlying LD structure have dictated the array design. In 
contrast to a linkage study, it directly studies the SNP variation instead of the 
haplotype structure, so the problematic conversion step required in linkage studies is 
avoided. However, GWA studies only test common markers as the genotyping 
platforms and calling algorithms are typically only capable of handling SNPs with a 
frequency >1%. There is relatively low power to detect rare SNPs that fall between 
genotyped markers. 
 
Targeted and whole genome/exome resequencing 
Traditionally, once a sufficiently narrow area within a linkage region, candidate gene 
or around a common variant has been identified, previously unknown variants 
(generally novel rare variants or incompletely tagged common ones) in the area are 
studied by resequencing the region. However, due to the prohibitive cost of 
resequencing large areas and performing the analysis in many samples, the confidence 
in both sample and location selection has to be very high in order to avoid the same 
problems that limit candidate gene analysis. Recently, whole-exome (ie. targeting the 
sequence of all protein-coding regions) and whole-genome resequencing have become 
viable alternatives being of reasonable cost for small sample sizes. Capturing rare 
exome sequence variants is a promising approach to detect rare variants with higher 
effect sizes explaining a larger portion of the missing heritability in common diseases, 
as demonstrated by a recent paper (Ng et al., 2009). Future improvements in 
sequencing technology promise a substantial decrease in the cost of sequencing full 
genomes, so it is likely that full-genome sequencing – which captures practically all 
sequence variation and not just common variation - will relatively soon take 
precedence over GWA studies. 
 
Simple and complex diseases and models of inheritance 
 
Genetic diseases and their studies are divided into several classes based on the 
estimated complexity of the disease inheritance and the mathematical implications of 
the inheritance pattern. If a disease directly follows Mendel’s laws of segregation in 
an extended family, the implication is that a single causative gene or locus exists 
(though the implication is not conclusive). These diseases are therefore referred to as 




simple or Mendelian diseases. Due to the rarity of such diseases (usually <1/10,000), 
in almost every case there will only be one gene that segregates with the disease, as 
the likelihood of carrying two such mutations is vanishingly small. However, different 
genes may cause the same disease even though the model of inheritance is simple, and 
different variations within the same genes can exist. For example, three different 
genes for familial hemiplegic migraine (FHM) are known; CACNA1A (Ophoff et al., 
1996), ATP1A2 (De Fusco et al., 2003), and SCN1A (Dichgans et al., 2005), and over 
twenty mutations in CACNA1A and over thirty mutations of ATP1A2 have been 
reported (de Vries et al., 2009a), with variable migraine phenotypes (Ducros et al., 
2001).  
 
In practice, having only one target to study makes the analysis relatively 
straightforward, with only few confounding factors (such as incomplete penetrance – 
i.e. that not all individuals with the mutation necessarily exhibit the trait, phenotype or 
clinical symptoms in question). Examples of such diseases are Marfan’s syndrome 
(Faivre et al., 2007), sickle cell anemia (Kwiatkowski, 2005) and Huntington’s 
disease (The Huntington's Disease Collaborative Research Group, 1993). Perhaps the 
best known example are the two variants conferring lactose persistence, where the 
presence of a single SNP is sufficient to confer the phenotype of being able to break 
down lactose, one in northern Europeans (Enattah et al., 2002) and another in pastoral 
groups of eastern Africans (Ingram et al., 2007).  
 
However, in most cases the severity of these disease phenotypes results in negative 
evolutionary pressure (i.e. since offspring carrying a mutation causing a severe 
disease will have less – or indeed none at all – offspring of its own, the mutation stays 
rare), these kinds of mutations are rare in the general population. This also means the 
effect of these conditions on public health even taken together is low, though of 
course potentially devastating for anyone directly or indirectly affected by them. For 
common heritable diseases, such as diabetes and depression, the implication is that 
since evolution keeps mutations with a large contribution to a disease rare, the 
heritability either represents a sum of a multitude of rare mutations, interplay between 
common genetic variants with small individual effects, or a combination of the two. 
In any case, when no easily discernible pattern of inheritance can be observed, the 
disease is classified as a complex disease. For these diseases, detecting an underlying 
variant or mutation is much more difficult, and generally requires sample sizes in the 
multiple thousands, due to the inability to tell apart the minute differences between 
clinical phenotypes caused by the different mutations. For this reason, various studies 
have explored better phenotyping methods, such as latent classes (Nyholt et al., 2004) 
(see Chapter 4) and endophenotypes (Paunio et al., 2004). Additional role in these 
diseases may be played by some unknown and/or poorly understood mechanisms, 
such as methylation or some other epigenetic mechanism (lit. “above genetics”, 
referring to a hereditary mechanism that is independent of the DNA code, e.g. DNA 
methylation or chromatin remodeling). In a Swedish study, where the hunger status of 
grandparents was found to associate with metabolic syndrome phenotype presentation 
in the grandchildren (Kaati et al., 2002). 
 
How the presence of a mutation or variant affects the phenotype, whether for a simple 
or complex disease, is determined by the model of inheritance. The first difference is 
whether the mutation behaves in a dominant (the effect of the mutation is strong 
enough to cause disease when carrying only a single damaged allele) or recessive 




(when the mutated allele has to be inherited from both parents). Second, the mutation 
can be autosomal (reside in the gender-independent chromosomes), or be either X- or 
Y- or mitochondrially linked. In X-linked diseases, such as hemophilia A (Rosendaal 
et al., 1990), a recessive form of a disease will be rare in females, but more common 
in males – and only women can transfer affected alleles to male children. In Y-linked 
diseases, only males can be affected. Mitochondrial diseases (such as the MELAS 
syndrome (Goto et al., 1990)) are inherited from the mother, but as only a proportion 
of the inherited mitochondria may be affected (and thus the effects may be limited to 





The phenotypes used to compare frequencies of any genetic variant are divided into 
two groups; dichotomous traits and quantitative traits. For a dichotomic trait, the 
phenotype is binary in nature – affected vs healthy, presence vs absence of an event 
such as myocardial infarction, or a biomarker that is within vs outside normal 
parameters. Dichotomous traits are more commonly used in genetic studies, as they 
can be readily used to estimate odds ratios (OR) in a case-control design (Pearce, 
1993). To a certain extent, making such a division is always arbitrary in nature: for 
example, the migraine diagnostic criterion for pain considers moderate, severe, or 
unbearable intensity as “intense pain”, and mild pain as “no intense pain”. Not only is 
this definition highly subjective, but it also assumes a major difference to exist 
between the border categories (mild and moderate) (Donner and Eliasziw, 1994). 
Further discussion on the matter can be found in Chapter 4. 
 
Normally distributed phenotypes where a numerical value can be assigned to samples 
in the analysis (e.g. height, LDL cholesterol level, concentration of an enzyme) are 
called quantitative traits. This kind of phenotype is in general terms more suitable for 
general features and measures, such as the examples mentioned above. However, the 
analysis of quantitative traits has been adapted to disease studies through use of 
endophenotypes such as C-reactive protein concentration (Elliott et al., 2009), the 
carotid artery wall thickness in cardiovascular disease (Duggirala et al., 1996, Gerdes 
et al., 2002) and the timing of the cognitive decline in Alzheimer’s disease (Martins et 
al., 2005). Quantitative phenotypes also contain larger amounts of information in 
comparison to a dichotomous trait, and thus the statistical analysis tools are somewhat 
more sophisticated for this kind of analysis. The challenges for a quantitative trait are 
mostly related to measurement accuracy, representativeness of a measurement (e.g. 
for hormone levels that vary by the time of day), and the underlying model of 
inheritance. The first two of these challenges can, to a certain extent, be addressed by 
having multiple measurements available. However, the question of the underlying 
model of inheritance is a more complex problem; genetics of stature are a good 
example of a highly heritable and easily measurable trait, where success in 
determining the genetic background has long eluded researchers (Visscher, 2008), as 
discussed in the previous chapter. 
 




Figure 2. The concept of extreme phenotypes: 
considering only the values in the black areas converts 
a quantitative measure to an extreme dichotomous one. 
 
One approach to address this problem has been the concept of extreme phenotypes 
(Allison et al., 1998). In this type of analysis (see Figure 2), only the far ends of the 
phenotype distribution are considered, effectively turning a quantitative trait into a 
dichotomous trait (in the sense that now a major, non-linear difference between the 
two groups exist). However, the quantitative measurements available for all samples 
allows for the use of more powerful statistical methods. Another assumption in this 
approach is that by using the extremes, the genotype distribution is more akin to that 
found in a Mendelian disease. For example, this approach has been used to study 
people with extreme HDL cholesterol levels in plasma (Cohen et al., 2004). The 
underlying assumption is that an individual with measurement value in the top 
percentiles for a given trait would likely carry many of the “cholesterol-increasing” 
variants, and that a person in the bottom percentiles would lack many or most of 
them.  
 
Methods of correction 
 
Methodical error correction is paramount given the large amounts of data involved in 
a typical genetic association study and the issues involved in measuring any biological 
data. Standard correction methods for genome-wide data include testing for Hardy-
Weinberg equilibrium (Hardy, 1908) (the frequencies of genotypes are within the 
ranges that can occur in nature), minor allele frequency, genotyping success rates, 
heterozygosity and gender as well as accounting for population stratification. 
 
The vast amount of genetic information available in the current GWA chip technology 
(up to 1 million markers per chip at the time of writing) allows a robust correction for 
geographic stratification, unknown relatedness between samples and genetic outliers. 
This is a considerable strength of the GWA approach, and while it is possible to 
achieve the same effect with an extremely strict study design, such a study design is 
very difficult to implement in practice. 
 
The vast amount of genetic information available in the current GWA chip technology 
(of up to 1 million markers per chip at the time of writing) allows a robust correction 
for (in practice, almost the elimination of the confounding term due to) geographic 
stratification, unknown relatedness between samples and genetic outliers. This is a 
considerable strength of 
the GWA approach, and 
while it is possible to 
achieve the same effect 
with an extremely strict 
study design, in practical 
terms reaching the same 
level of certainty as with 
the various genome-wide 
approaches would require 
immense efforts. 
 
One of the major 
contributions from the 
HapMap project was the 




Figure 3. Comparison of a) the region of origin of individuals from 
Lapland in northern Finland with b) their multidimensional scaling 
(MDS) analysis results. The results clearly indicate the correlation 
between geographic and genetic identity, down to a county level. From 
Sabatti et al. (2009), used with permission. 
identification of how population stratification affects the distribution of common 
variants in the genome sequence. Based on pattern analysis (such as multidimensional 
scaling), the amount of available SNP information from a GWA array can be used to 
distinguish the genetic origin of an individual (or, more correctly, the identity of the 
haplotypes that an individual has inherited), down to a scale of a few hundred 
kilometers in Europe (Lao et al., 2008), or down to the level of individual counties 
(see Figure 3) within countries (Sabatti et al., 2009). In GWA studies, this information 
is used to exclude population outliers from the study sample, which for its part 
increases the power of the study as non-representative samples are removed. 
Similarly, the SNP information is used to accurately determine cryptic relatedness 
(unexpected long distance relatedness between the samples). For non-GWA data, 
detecting these types of errors is next to impossible; the minimum amount of 
information considered sufficient for a population stratification analysis, for example, 
is around 10,000 markers located across the genome (Purcell et al., 2007). 
 
The Human Genome Project 
 
The basis for the modern genetic studies was laid in the study of the first haploid 
genome by the Human Genome Project (HGP), which compiled a single consensus 
sequence of DNA by studying the DNA of two anonymous males and two anonymous 
females - though most of the information came from one of the males due to quality 
considerations (Osoegawa et al., 2001). The first working draft was released in 
2001(Lander, Linton et al. 2001; Venter, Adams et al. 2001) and the main project was 
completed in 2004 (International Human Genome Sequencing Consortium, 2004). 
The project established a number of genetic measurements for the first time, such as 




the number of genes in the human genome and allowed standardized approaches to 
mapping the genome, forming the basis for the whole-genome approaches. This was 
the first project to provide a near-complete sequence for a vertebrate genome. The 
HGP also provided the first comprehensive look at the make-up of the genome. The 
amount of coding sequence (genetic code which can be translated into working 
proteins) was measured at less than 1-2%, while various repeat sequences account for 
more than 50%, the meaning of which will be discussed in Chapter 2. Key to this 
thesis, the HGP laid the basis for a structured approach to genome-wide analysis 
beyond the resolution of linkage studies that rely on the comprehensive genetic maps 
created in the earlier phases of HGP and allowed for the standardized mapping of 
sequence variants directly. 
 
The International HapMap Project 
 
To continue the work of the HGP, the HapMap project sought to develop a haplotype 
map of the human genome by sampling a small number of individuals from distinct 
population groups from different parts of the world. In order to construct a haplotype 
map, a combination of existing SNP data from the dbSNP database 
(www.ncbi.nih.gov/projects/SNP/), validated ancestral alleles found by comparison of 
HGP information and that of the Chimpanzee Genome Sequencing Project (The 
Chimpanzee Sequencing and Analysis Consortium, 2005) and previously identified 
SNPs from commercial sources (Matsuzaki et al., 2004) were used to identify variants 
across the genome every 5 kb apart. A haplotype map reveals which markers are 
inherited together and was considered as a useful tool in interpreting the data from the 
Human Genome Project, because it would show how sequences differ between 
individuals and populations. The map gave the first glimpse of how evolutionary 
selection works on a genomic level. The HapMap project also mapped the positions of 
common single nucleotide polymorphisms (SNPs) and provided a publicly available 
resource for data verification, interpretation and imputation for future projects. Given 
the prohibitive cost of full genome sequencing, assaying common variants was meant 
to provide a shortcut to uncovering variants with effects on common diseases.  
 
Three populations (CEU – Central Europeans in Utah, representing a Caucasian 
population; CHB+JPT – Han Chinese in Beijing and Japanese in Tokyo, as an Asian 
population; YRI – Yorubans in Ibadan, Nigeria, as an African population) were 
selected for study. 30 full trios (parents and single offspring, a total of 90 individuals) 
were selected from the CEU and YRI populations, and 45 and 44 unrelated 
individuals from the CHB and JPT populations, respectively. The project was 
executed in different phases. In Phase I, a single SNP with minor allele frequency 
greater than five percent was genotyped at every 5 kilobases for a total of 1,007,329 
SNPs (The International HapMap Consortium, 2005). In Phase II, the amount of 
SNPs was increased to 3.1 million (Frazer et al., 2007). In Phase III (in press at the 
time of writing), the number of individuals has been increased to 1,184 and the 
number of populations to 11 (The International HapMap 3 Consortium, 2010). 
Through the extensive analysis of these individuals, the HapMap project created vast 
amounts of information on common human SNP variation, just as the HGP did for 
linkage information. The HapMap data paved the way for the creation of genome-
wide association (GWA) arrays that concurrently genotype a portion of the common 
SNP variation in the genome. 




The genome-wide association era 
 
The genetic map made available by the Human Genome Project combined with the 
information on common genetic variation from the HapMap project made it possible 
to design and mass produce chip arrays that simultaneously genotype a large number 
of common variants across the human genome. The candidate gene approach, 
preceding the GWA era, was burdened by the need to correctly guess the targets, the 
lack of a true way to assess stratification and case/control-matching among other 
things (Hirschhorn et al., 2002). The GWA study is limited in its targeting of a 
particular variant frequency spectrum and, as practice has shown, a particular effect 
size range (see Figure 4; (Manolio et al., 2009). The first such study was conducted on 
age-related macular degeneration (AMD), and a variant of rs11200638 was detected 
to confer risk for AMD by affecting the promoter of gene HTRA1, a serine protease 
(Dewan et al., 2006, (Yang et al., 2006). The first large-scale study on a common 
disease was on type II diabetes, which confirmed the previously known association to 
the TCF7L2 gene and detected three other associating SNPs (Sladek et al., 2007). A 
key study, published in 2007, was the Wellcome Trust Case-Control Consortium 
(WTCCC) study (Wellcome Trust Case-Control Consortium, 2007). For this paper, 
14,000 patient samples representing seven diseases (bipolar disorder, coronary artery 
disease, Crohn’s disease, hypertension, rheumatoid arthritis, type I and II diabetes) 
were analyzed separately against 3,000 shared controls. Genes were identified for 
every one of the studied disorders except hypertension, and several were identified for 
most diseases including nine for Crohn’s disease. The WTCCC study addressing 
bipolar disorder was the first GWA study of a neuropsychiatric disorder, and resulted 
in the identification of a single significant SNP. Since then, over 500 GWA studies 
have been conducted in human diseases (see Figure 5). 
 
However, the detected variants have all had small effect sizes and thus account for 
only a small proportion of the estimated heritability. For Crohn’s disease, one of the 
early success stories of GWA studies, the 32 known loci account for roughly 20% of 
the total heritability (Barrett et al., 2008). For height, one of most genetically 
determined human features (80-90% estimated heritability), 40 known loci explain 
only 5% of the variance (Visscher, 2008). Possible causes for this lack of explained 
heritability have been a heated topic of discussion of late, and a recent review outlined 
the possible culprits (Maher, 2008). First, the inherent limitations of the GWA 
approach may be to blame: only common variation for a given sample is studied, 
which may dilute signals from indirectly tagged variants; future resequencing efforts 
should be able to solve this problem. Second, low penetration might be to blame; an 
association test expects every allele to be similar, and if the effect of the variant is 
modified by some unknown factor, the association will be considerably reduced; this 
problem will be difficult to solve, and likely involves massively greater sample sizes. 
Third, previously undetected copy number variation may be to blame, for which 
resequencing and improved CNV detection techniques should help. Fourth, the 
problem might not be in the detection techniques but rather in inadequate 
understanding of either the true phenotypes (an idea that plays a major role in this 
thesis) or the causative biological networks. In both of these cases, the needed 
improvements and solutions require a better understanding of the biology behind the 
phenotypes. Finally, the least favorable possibility is that the heritability estimates for 
common diseases are strongly inflated, and that no large effects have been found 
simply because they do not exist.  





Figure 4. Setting the stage: the different categories of genetic variation 
based on the frequency and effect size of a variant. For rare variants with 
high effect sizes, the traditional approaches of linkage scans and 
candidate gene studies were relatively successful (see Hirschhorn et al. 
2002), and variants of this category involved in migraine are studied in 
Study I and II. Currently these variants are beginning to be tackled with 
whole-genome sequencing approaches (discussed later in this Chapter). 
For the low-hanging fruits, evolution has effectively removed these from 
the gene pool, and only isolated examples remain (such as the lactase 
gene mutation, as discussed earlier). Rare variants of small effects are 
currently outside of reach, and will require considerable additional 
whole-genome resequencing efforts to be found – and without new 
understanding of biological networks etc. these will likely have little 
meaning. The middle group of low frequency variants will be the 
interesting territory for the next few years, as data from the 1000 
Genomes project and the various re-sequencing efforts becomes 
available. Considerable inroads into the common variant category have 
been made with GWA studies in the recent years, and the study of 
variants in this category form the basis of Studies III and IV. Adapted 
from Manolio et al., 2009.





Figure 5. Published Genome-wide Associations as of September 2009 (Hindorff et 
al., 2009).  
 




Table 1. Disability-adjusted life years lost to the 
major disease groups per 100,000 inhabitants in 
Finland and in the EU in 2004 among 15-59-year-
olds, according to WHO Global Burden of Disease. 
2  HEADACHE DISORDERS AND CHANNELOPATHIES 
 
Neuropsychiatric disorders and relevant diagnostic divisions  
 
Disorders of the brain are among the leading cases of disease and disability. 
“Neuropsychiatric disorders” is a WHO term for the group of disorders covering all of 
these disorders, covering ICD-10 code groups F and G. These groups contain both 
severe, often eventually fatal diseases like amyotrophic lateral sclerosis and 
Huntington’s disease, and quality-of-life conditions like depression, Alzheimer’s 
disease and migraine. Diseases from either group can have a serious effect on the 
quality of life of any sufferer. In terms of disability-adjusted life years (DALY), a 
measurement which takes into account not only years of life lost due to deaths caused 
by the disease but also the amount of disability caused and the number of years lived 
with the disability (YLD), diseases of this group are by far the most severe burden 
among the working age (15-59 years; see Table 1) (Murray et al., 2002). In this range, 
neuropsychiatric disorders account for 35% of the total disease burden in Europe, 
although they account for only 11% of estimated mortality (V. Anttila, unpublished 
data based on WHO measures).  
Condition Finland EU average 
Neuropsychiatric conditions 4 336 3721 
Unintentional injuries 1 444 959 
Cardiovascular diseases 1 432 1105 
Malignant neoplasms 1 075 1334 
Sense organ diseases 873 854 
Digestive diseases 804 529 
Intentional injuries 737 441 
Musculoskeletal diseases 492 493 
Respiratory diseases 452 625 
Diabetes mellitus 244 225 
Infectious and parasitic diseases 113 230 
Maternal conditions 104 74 
Endocrine disorders 79 157 
Nutritional deficiencies 74 73 
Oral conditions 72 74 
Respiratory infections 59 62 
Congenital anomalies 53 33 
Genitourinary diseases 38 57 
Other neoplasms 12 18 
Skin diseases 9 13 
Perinatal conditions 2 2 




A 2004 epidemiological study places the number of people in Europe (28 countries; 
EU member countries after May 1st 2004 plus Iceland, Norway and Switzerland) 
affected with a neurological disorder at 127 million (out of 466 million; 27.3%) 
(Andlin-Sobocki et al., 2005). Within the spectrum of neurological disorders, various 
forms of headache, formally headache disorders, are one of the most common disease 
classes affecting population worldwide, affecting 46% of the adult population 
(Stovner et al., 2007). Large-scale epidemiological studies confirm relatively stable 
prevalence on all continents (see Figure 6), across ethnic groups and living conditions. 
Headache disorders affect both sexes, and all ranges of age and socio-economic 
conditions (Lipton et al., 2001); and detailed reports of their presence exists from 
2,000 years ago (Sacks, 1995). 
 
In approaching headache disorders, a number of further divisions can be made. 
Traditionally neuropsychiatric disorders have been divided according to medical 
specialties into neurology, neurosurgery and psychiatry (Price et al., 2000). Of these 
categories, headache disorders fall under the first, though a psychological component 
has long been suspected and should not be discounted. In neurology, diseases of the 
nervous system are primarily divided into those affecting the central nervous system 
(CNS; the parts of the nervous system enclosed in meninges; the brain and the spinal 
cord) and the peripheral nervous system (the rest of the nervous system). The central 
nervous system is isolated from the rest of body by the blood-brain barrier, which 
separates the blood in the circulatory system from the cerebrospinal fluid. 
Maintenance of this barrier is a crucial for brain function, and failure to uphold the 
barrier has been implicated as a mechanism in epilepsy (Oby and Janigro, 2006, Uva 
et al., 2008, van Vliet et al., 2007) and suspected to play a part in migraine as well. 
Most headache disorders are thought to happen within the CNS, though improper 
modulation of signals from the peripheries is an important feature. Within CNS 
disorders, headache disorders are categorized as episodic and paroxysmal disorders. 
This last category includes, in addition to headache disorders, epilepsy, 
cerebrovascular disorders, sleep disorders and certain movement disorders. 
Figure 6. Current headache (A) and current migraine (B) prevalence of 
headache, globally and divided by continent. Data from Stovner et al. 2007. Data 
for total and male migraine prevalence for Australia is not available. Please note 
that for current headache prevalence in North America, the authors note that the 
the gender-specific rates are based on a single study, whereas the total 
prevalence is based on a meta-analysis, and is therefore likely to be more 
accurate. Am. – America. 




Figure 7. Total number of cases of the major 
neurological disorders in Europe. The two major 
diseases where channelopathies are thought to play a 
major role (migraine and epilepsy) in the list are 
denoted by a star. Adapted from Andlin-Sobocki et al., 
2005, used with permission. 
 
Episodic diseases of the brain and their comorbidity 
 
The diseases making up the group of episodic and paroxysmal disorders fall 
essentially into two categories; headache disorders are a group where relatively little 
is known of the underlying pathophysiology (outside of a few specific examples, such 
as FHM, discussed further below). Within the headache disorders, only broad, 
descriptive distinctions can be made, such as the difference between tension-type 
headache and migraine, and which can be largely theoretical, such as the difference 
between MA (migraine with aura) and MO (migraine without aura). The second 
category, covering cerebrovascular and sleep disorders, as well as epilepsy, consists 
of a large group of disorders where the mechanisms are much more understood, with 
many known causes (for example, dozens of causes for insomnia are known, from 
fluoroquinolone to fatal familial insomnia). A large number of similarities exist 
between the two categories. Perhaps the best known overlap is between two of the 
more common representatives of the two categories, migraine and epilepsy (see 
Figure 7). For example, the diagnostic criteria for migraine recognize class 1.5.5. 
Migraine-triggered seizure, defined as an epileptic seizure triggered by migraine aura, 
as well as coining the term migralepsy for the pathognomonic overlap (International 
Headache Society, 2004). Significant comorbidity exists as well; a 1994 study found 
that the frequency of migraine in patients suffering from epilepsy was 24%, compared 
to 12% in non-epileptic relatives (Ottman and Lipton, 1994). An Icelandic study 
reported an 8.1-fold increase in the risk of developing epilepsy for children with 




migraine with aura (Ludvigsson et al., 2006), and an Italian study in a pediatric 
headache center reported that children with migraine have a 3.2 times higher risk of 
developing epilepsy compared to patients with tension-type headache, and children 
with epilepsy having a 4.5-fold increased risk of developing migraine (Toldo et al., 
2010). In a Finnish study it was found that for males with MA, having a family 
member with migraine significantly increased the risk of epilepsy (Artto et al., 2006). 
Epileptic attacks are at least occasionally accompanied by migraine-like headache, 
and certain medications (such as valproate and topiramate (Goadsby et al., 2002), and 
certain other antiepileptics currently in development (Bialer and White, 2010)) work 
for both conditions. The characteristic Jacksonian march of symptoms in certain 
forms of epilepsy (i.e. the progression of motor symptoms through different parts of 
the body in order of the representation of those symptoms on the motor cortex as the 
seizure progresses) is very similar to cortical spreading depression passing through 
the visual cortex in migraine aura. Further, a number of rare disorders, including 
mutations in the NaV1.7 ion channel (SCN9A) which cause primary erythromelalgia 
(Yang et al., 2004), NaV1.1 ion channel (SCN1A) which causes familial hemiplegic 
migraine and epilepsy (Castro et al., 2009), and EAAT1 glutamate transporter 
(SLC1A3) causing episodic ataxia and hemiplegia (de Vries et al., 2009b) have 
clinical presentations characterized with both epileptic seizures and migraine-like 
pain. Most mutations known in episodic disorders are of the former type, that is, 
mutations in ion channel genes (with the last being in a gene encoding a protein that is 
part of the same synaptic space, as discussed in the discussion). Hence genetically 
many of the diseases of the second category are classified as channelopathies, and 
based on the clinical overlap it is hoped that lessons learned from this group could 




Channelopathies are a group of diseases where a defect in an ion channel protein is 
causative (see Table 2 (Graves and Hanna, 2005)). Ion channels play a critically 
important role in maintaining homeostasis as well as cellular and neuronal signaling, 
and are found in virtually all human cells, as well as being highly conserved 
throughout evolution (Graves et al., 2005). Ion channels consist of an alpha subunit, a 
pore-forming structure that allows the movement of ions between the two sides of the 
cell’s plasma membrane. This structure is typically not open in “resting state”, but is 
induced into the open form by a change in voltage on the plasma membrane, or the 
binding of a specific ligand. In addition, most channels contain additional subunits, 
which modulate the alpha unit. Most channelopathies are congenital Mendelian 
diseases, while a few are acquired (usually as a result of an autoimmune reaction). 
These diseases affect mostly the brain and the muscles (including the heart), as the 
basic function of these tissues (muscle contraction, transmitting neuronal signals) is 
highly dependent on ion channel function, though anumber of autoimmune diseases, 
such as myasthenia gravis (Vincent, 2002) and the Lambert-Eaton myasthenic 
syndrome (Takamori et al., 2000) also possess an ion channel component, due to an 
autoimmune response against an ion channel. 




Table 2. CNS and muscle channelopathies according to the affected channel. Adapted 







Phenotype CNS MuscleSodium channel SCN1A Familial hemiplegic migraine x   SCN1A Generalised epilepsy with febrile seizures plus syndrome (GEFS+) x   SCN1B x   SCN2A Severe myoclonic epilepsy of infancy x   SCN4A Hypokalemic periodic paralysis  x  SCN4A Hyperkalemic periodic paralysis  x  SCN4A Paramyotonia congenita  x  SCN4A Potassium aggravated myotonia  x      Chloride channel CLCN1 Myotonia congenita (Thomsen's, Becker's)  x      Calcium channel  CACNA1A Familial hemiplegic migraine x   CACNA1A Episodic ataxia type 2 x   CACNA1H Childhood absence epilepsy x   CACNA1S Hypokalemic periodic paralysis  x  CACNA1S Malignant hyperthermia  x  CACNL2A Malignant hyperthermia  x      Potassium channel KCNA1 Episodic ataxia type 1  x   KCNE3  Hypokalemic periodic paralysis  x  KCNE3  Hyperkalemic periodic paralysis  x  KCNJ2 Andersen’s syndrome  x  KCNQ2 Benign familial neonatal convulsions x   KCNQ3 Benign familial neonatal convulsions x  




Table 3. Primary and secondary headaches, adapted from International Classification 
of Headache Disorders, second edition, 2004. 
 
Primary and secondary headaches 
 
As headache is a natural response to various noxious stimuli, headache disorders are 
divided into two main groups in the International Classification of Headache 
Disorders (International Headache Society, 2004) (see next Chapter) based on the 
cause of the pain. The first and more common group, primary headaches, consists of 
conditions where some unknown cause is affecting the cranial pain pathways 
themselves (see Table 3). In this group, the cause and mechanisms are poorly 
understood, in contrast to the secondary headaches, where a definite cause can be 
identified. The cause is generally some other condition and headache is part of the 
typical pathophysiology of that disease, or a direct response to it (e.g. pain caused by 
release of markers of cell damage from the brain tissue, due to damage by physical 
force, or chemical damage). A third group, neuralgias and other headaches, are a 
small group of conditions where a secondary reason (such as neural inflammation in 
post-herpetic neuralgia) is affecting some part of the cranial pain pathways, making it 
in theory both a primary and secondary headache.  
Secondary headaches Headache attributed to: 5. … head and/or neck trauma 6. … cranial or cervical vascular disorder 7. … non-vascular intracranial disorder 8. … a substance or its withdrawal 9. … infection 10. … disorder of homeostasis 11. … disorder of cranium, neck, eyes, ears, nose, sinuses, teeth, mouth or other facial or cranial structures 12. … to a psychiatric disorder 
Primary headaches 1. Migraine 2. Tension-type headache 3. Cluster headache 4. Other primary headaches 
Neuralgias and other headaches 13. Cranial neuralgias, central and primary facial pain and other headaches 14. Other headache, cranial neuralgia, central or primary facial pain 





3  MIGRAINE 
Introduction 
 
Migraine is a complex neurological syndrome, with two main forms (migraine 
without aura, MO, and migraine with aura, MA). It is typically characterised by 
severe, neurogenic pain and neurological symptoms varying from mild tiredness to 
paralysis, lasting from days to weeks. Migraine has been a recognized disease since 
ancient Greece, where Hippocrates and Aretaeus wrote extensively about hemicrania, 
a condition of the nerves (Sacks, 1995), with the latter also describing aura and 
recognizing its connection to some but not all migraine. As detailed in the previous 
chapter, migraine has a roughly equal prevalence across the globe, and thus as far as 
can be determined, a similar presentation across both time and place. Despite its 
common nature and the extent to which it burdens the healthcare system, the 
importance of migraine as a disease entity was realized late, with the first specialist 
institution founded in 1970 (Sacks, 1995) and the first specific clinical criteria set in 
1988 (International Headache Society, 1988). Considerable underreporting and lack 
of awareness of migraine has been widely reported (as reviewed by Buse et al. (Buse 
et al., 2009)) as well as under-treatment - a US study in 2007 found that 43% of 
migraine patients had never used migraine preventative medication (Lipton et al., 
2007). A study on headache specialists (though positive selection may play a role) 
estimated the lifetime prevalence of migraine to be as high as 71.9% for men and 
81.5% for women (Evans et al., 2003). 
 
Prevalence, incidence and effect on public health 
Migraine is roughly three times more common among women than in men. A clear 
majority of the difference between migraine incidence between the sexes occurs at the 
time of puberty, and is virtually removed after menopause (as seen in Figure 8 
(Stewart et al., 1991)), suggesting a link between hormonal balance and migraine. 
 
The overall prevalence of migraine and the incidence peak during working age makes 
migraine a somewhat unusual neurological disease. Estimates of the one-year 
prevalence range from 10% (Rasmussen et al., 1991) to 15% (O'Brien et al., 1994), 
Figure 8. Sex-specific incidence rates of migraine with and without aura for 
A) females and B) males per 1000 person-years based on 10,131 survey 
respondents in Washington County, Maryland, USA. Adapted from Stewart et 
al., 1991. 




with the largest study of 51,383 subjects reporting 12% (Hagen et al., 2000). Lifetime 
prevalence estimates between 13-18% in Europe (Stovner et al., 2006), it is by far the 
most common neurological condition in this age group. Lifetime prevalence of MA 
alone has been estimated to be 7% (Ulrich et al., 1999). According to WHO statistics, 
migraine ranks as the 19th most severe disease according to years lived with disability 
(YLD) in the global population, and the 9th among women (Leonardi and Mathers, 
2003). 
 
In terms of disability-adjusted life years (DALY), the WHO 2004 estimate (World 
Health Organization, 2008) of loss due to migraine is 177 years per 100,000 Finns 
(2004 average for EU member states: 176), making it the 4th most severe 
neuropsychiatric condition overall (after unipolar depressive disorders, alcohol use 
disorders and dementias including Alzheimer’s disease; V. Anttila, unpublished data 
based on WHO measures; see Figure 9 (Lokal_profil, 2009)). Among the 15-59 age 
group, migraine is the third most severe, with dementia understandably much rarer in 
this age group. A 1991 study in the US estimated the number of people suffering 
moderate to severe disability to be 11.3 million (8.7 million females, 2.6 million 
males), with 4.5 million people (3.4 million females, 1.1 million males) suffering 
from such attacks monthly (Stewart et al., 1992). The same study found that in the US 
migraine correlates strongly with economic status, with a 60% higher prevalence of 
migraine in the poorest income group when compared to the highest income groups. 
The effects on quality of life are considerable (Solomon et al., 1993).  
 
In Europe, a 2004 study estimated the total cost of migraine to be €27 billion in the 
EU, accounting for roughly a third of all costs due to neurological diseases – most in 
indirect costs (Andlin-Sobocki et al., 2005) (see Table 4). A US study in 2008 found 
the average direct cost of migraine to be $2,571 per patient (significantly higher than 
a matched migraine-free cohort) (Hawkins et al., 2008), with most of the costs arising 
from out-patient care and prescriptions; in-patient and emergency department care, 
though common in this group, accounted for only $1.25 billion (or ~10%) of direct 
costs as procedures or advanced interventions are rarely needed. An epidemiological 
study in 1999 calculated the average number of bed rest days due to migraine in the 
US to be 3.8 for men and 5.6 for women per year, for a total of 112 million bedridden 
days (Hu et al., 1999) – or approx. 1.8% of total workdays lost due to migraine. 
Figure 9. Disease-adjusted life years lost due to migraine in 2002 per 100,000 
inhabitants, according to WHO data. For reference, see text. No data was 
available for Morocco. 




Table 4. Costs due to brain disorders in Europe in 2004, organized by disease 
category. All costs in millions of euros, adjusted for purchasing power parity. From 
Andlin-Sobocki et al., 2005. Used with permission. 
 
€ million in costs Healthcare Direct non-medical Indirect Total
Neurosurgical diseases 4 099 269 3155 7523Brain tumour 1 162 269 3155 4586Trauma 2 937   2937
Neurological diseases 21 286 20259 42389 83934Epilepsy 2 752 4240 8554 15546Migraine and other headaches 1 495  25507 27002Multiple sclerosis 2 194 3977 2598 8769Parkinson’s disease 4 582 6140  10722Stroke 10 263 5901 5730 21895
Neurological/mental disorders 12 840 42337  55176Dementia 12 840 42337  55176
Mental disorders 97 221 9336 132985 239542Addiction 16 655 3962 36657 57274Affective disorders 28 639  77027 105666Anxiety disorders 22 072  19301 41373Psychotic disorders 29 855 5374  35229
All brain disorders 135 445 72200 178530 386175
 
Migraine attack  
 
A migraine attack typically consists of four phases, any of which may be absent from 
an attack. These phases are the premonitory phase, the aura phase, the headache 
phase, and the postdromal phase (see Figure 10). The first (premonitory) and last 
(postdromal) phases are characterized by either positive or negative symptoms. The 
positive symptoms are roughly similar to an episode of hypomania, including 
hyperactivity, cravings and elevated and optimistic mood. More common are the 
Figure 10. The typical procession of a migraine attack. Considerable variation 
exists – for example, the pain can immediately progress into the severe phase, 
or alternate between mild and severe pain.




Figure 11. Time series of fMRI imaging results 
showing a wave of cortical spreading depression, 
as it begins to spread from the occipital lobe of the 
brain of a patient having a migraine attack. 
Different measurement points along the cortex 
reveal that the depolarization wave is spreading 
across the visual cortex. Adapted from Hadjikhani 
et al., 2001. Used with permission. 
negative symptoms, similar to a depressive episode, including sadness, hopelessness, 
hypoactivity, excessive sleep and lack of motivation (International Headache Society, 
2004). 
 
The aura phase, present in MA patients and absent in MO patients, is detailed below. 
The headache phase of a migraine attack typically lasts 4-72 hours. The pain has a 
number of typical features, which include a combination of some of the following: 1) 
a pulsating nature, that is, the intensity of the pain intensifies and de-intensifies with 
the heartbeat, 2) it is aggravated by physical activity, both suggesting a vascular link, 
3) unilateral location, suggesting a central origin and the involvement of only one 
brain hemisphere, 4) to be of moderate or severe intensity, and 5) to be associated 
with nausea and/or vomiting and/or sensitivity to light or sounds, characterizing a 
general oversensitivity of the sensory system. Osmophobia (the fear of smells or in 
this case oversensitivity to smells) is, although not an official part of the criteria, 
considered a part of the clinical picture as well (International Headache Society, 
2004). 
 
Migraine aura and the cortical spreading depression 
 
The migraine aura, presence of which differentiates the two main forms of common 
migraine, refers to gradually developing neurological symptoms (ranging from 
auditory hallucinations to full paralysis, and covering most neurological symptoms 
possible), lasting at least several minutes and less than one hour, although in reality 
the variation is greater and 
aura may, in rare cases, last 
even for several weeks. The 
symptoms are fully 
reversible, though they may 
be followed by a post-ictal 
phase after the attack, and 
the symptoms are typically 
only one-sided 
(International Headache 
Society, 2004).  
 
The aura is thought to be 
the outcome of a slowly 
spreading wave of 
depolarization in the brain, 
called cortical spreading 
depression (CSD), first 
detected in 1944 by Leao et 
al. (Leao, 1944). It is a 
wave of increased neuronal 
activity and cerebral blood 
flow, which moves at 2-3 
mm / minute (Pietrobon, 
2005). After the wave has 
passed, a recovery period 




occurs within the neurons and cerebral blood flow is reduced. In imaging studies (see 
Figure 11), the spread of the CSD correlates with symptoms on the affected cortical 
region – for example, as the wave spreads across the visual cortex, the patient can 
observe a corresponding pattern in the visual field (Hadjikhani et al., 2001). 
Typically, the migraine aura includes a combination of visual, sensory, and speech 
disturbances. These are divided into positive and negative symptoms, depending on 
whether the disturbance is adding sensory (non-existing) information or removing it. 
Examples of positive symptoms include scintillating scotoma (visual cortex), where 
objects “gain” jagged edges, or the sensory symptom of “pins and needles”, a pain 
sensation without an external cause (sensory cortex). Negative symptoms can include 
partial blindness (visual cortex) or numbness (sensory cortex).  
 
International Classification of Headache Disorders 
 
The first version of the headache classification, ICHD-I (Headache Classification 
Committee of the International Headache Society, 1988), was published in 1988 by 
the International Headache Society (see Table 5). It was the first time a hierarchical 
classification of all headache-related disorders was published, and represented a major 
step in reproducibility for both research and clinical practice for disorders which are, 
after all, largely description-based. It is part of the WHO International Classification 
of Diseases (ICD-10). It was last updated in 2004 with the introduction of the 2nd 
edition (see Table 6), ICHD-II (International Headache Society, 2004).  
 
Table 5. Diagnostic criteria for Migraine without Aura, 1988 (Headache 
Classification Committee of the International Headache Society, 1988) and 2004 
(International Headache Society, 2004). Criteria have remained unchanged between 
the editions. 
1.1 Migraine without aura A. At least five attacks fulfilling criteria B–D B. Headache attacks lasting 4–72 h (untreated or unsuccessfully treated) C. Headache has at least two of the following characteristics: 1. Unilateral location 2. Pulsating quality 3. Moderate or severe intensity (inhibits or prohibits daily activities) 4. Aggravation by walking stairs or similar routine physical activity D. During headache, at least one of the following: 1. Nausea and/or vomiting 2. Photophobia and phonophobia E. At least one of the following: 1. History, physical - and neurological examinations do not suggest secondary cause of headache 2. History, physical - and neurological examinations do suggest such disorder, but it is ruled out by appropriate investigations 3. Such disorder is present, but migraine attacks do not occur for the first time in close temporal relation to the disorder 





Table 6. Diagnostic criteria for migraine with aura, according to the 1988 IHS 
classification (1.2 Migraine with Aura) (Headache Classification Committee of the 
International Headache Society, 1988) and the 2004 classification (1.2.1 Typical 
Aura with Migraine Headache) (International Headache Society, 2004). 
 
1.2 Migraine with aura (1988) A. At least two attacks fulfilling criterion B B. At least three of the following four characteristics: 1. One or more fully reversible aura symptoms indicating focal cerebral cortical and/or brain stem dysfunction 2. At least one aura symptom develops gradually over >4 min, or >= 2 symptoms occur in succession 3. No aura symptom lasts >60 min. If more than one aura symptom is present, accepted duration is proportionally increased 4. Headache follows aura with a free interval of >60 min (it may also begin before or simultaneously with the aura) C. At least one of the following: 1. History, physical - and neurological examinations do not suggest secondary cause of headache 2. History, physical - and neurological examinations do suggest such disorder, but it is ruled out by appropriate investigations 3. Such disorder is present, but migraine attacks do not occur for the first time in close temporal relation to the disorder 
1.2.1 Typical aura with migraine headache (2004) A. At least two attacks fulfilling criteria B–D B. Aura consisting of at least one of the following, but no motor weakness: 1. Fully reversible visual symptoms including positive features (e.g., flickering lights, spots, or lines) and/or negative features (i.e., loss of vision) 2. Fully reversible sensory symptoms including positive features (i.e., pins and needles) and/or negative features (i.e., numbness) 3. Fully reversible dysphasic speech disturbance C. At least two of the following: 1. Homonymous visual symptoms (note: additional loss or blurring of central vision may occur) and/or unilateral sensory symptoms 2. At least one aura symptom develops gradually over >=5 min, and/or different aura symptoms occur in succession over >= 5 min 3. Each symptom lasts >= 5 and <= 60 min D. Headache fulfilling criteria B–D for 1.1 Migraine without aura begins during the aura or follows aura within 60 min E. Not attributed to another disorder (note: history and physical - and neurological examinations do not suggest any of the disorders listed in groups 5–12 [see Table 3], or history and/or physical and/or neurological examinations do suggest such disorder but it is ruled out by appropriate investigations, or such disorder is present but attacks do not occur for the first time in close temporal relation to the disorder) 




Figure 12. Illustration of the relevant anatomical structures involved in migraine 
pathophysiology, from Goadsby et al, 2002. Copyright © [2002] Massachusetts 
Medical Society. All rights reserved. (reprinted with a permission from New England 
Journal of Medicine). 
 
Migraine pathophysiology: neuronal versus vascular theory 
 
Relatively little is known of the pathophysiology of migraine and discussion has been 
dominated by two theories: the neuronal and the vascular theories of migraine. The 
former is currently favored (Dodick and Silberstein, 2006). The consensus is that 
some triggering event, with or without genetic or environmental predisposing factors, 
sets up a state of cortical neuronal hyperexcitability (Pietrobon and Striessnig, 2003). 
This puts the brain in a state that allows the propagation of a strong polarizing 
wavefront. Various mechanisms have been implicated to explain why the brain is 
susceptible to such waveforms, like excess glutamate in the brain, but no consensus 
on the matter exists yet. In contrast, the propagation of brain waves is more strictly 
controlled in the normal state brain (Lopes da Silva, 1991). CSD and its progression 
across different regions of the cortex are considered to be responsible for the various 
aura symptoms. The intense neuronal activity associated with the passing wave and 
the reduced blood flow following it are thought to trigger the pain sensation of 
migraine. The likely mechanism for the pain is thought to be a combination of 
neurogenic sterile inflammation and central sensitization (i.e. incorrect pain handling). 
This central sensitization is believed to arise from brainstem dysfunction causing 
impaired nociception, especially in the region of periaqueductal grey (PAG), various 




brainstem nuclei and the trigeminal ganglion (see Figure 12). A generalized decreased 
inhibition in this region is thought to underlie both the pain perception, the sensitivity 
to sensory stimuli (Pietrobon et al., 2003), and the response to stress (Domingues et 
al., 2009), which is one of the key triggers of migraine. Other observations supporting 
the role of a neuronal mechanism in migraine include a recent imaging study that 
pointed to the role of hypothalamic activation in migraine (Denuelle et al., 2007) and 
several studies that have pointed to abnormal response to stimuli and signal 
processing in migraineurs between attacks. Abnormal habituation is seen to 
characterize the response to both visual and auditory signals in MA patients (Afra et 
al., 2000) and both MA and MO patients (Wang et al., 1996), suggesting a migraine 
brain potentiates certain types of abnormal repeated stimuli. Abnormal habituation 
suggests an ongoing interictal habituation dysfunction among migraineurs. A number 
of studies have linked such habituation defects to glutamate in Aplysia (Ezzeddine and 
Glanzman, 2003) and mice (Bespalov et al., 2007). In rats, blockage of metabotropic 
glutamate receptors were found to influence short-term habituation to olfactory 
stimuli (Best et al., 2005, (Yadon and Wilson, 2005). In summary, the neuronal theory 
of migraine postulates that this neurogenic activity is sufficient to cause migraine, and 
that the vascular aspects of migraine are caused by CSD or other neuronal phenomena 
(Dodick et al., 2006).  
 
The vascular theory of migraine is based largely on the observation that a number of 
vasodilatory substances can induce migraine in humans (Schytz et al., 2009) and that 
migraine medications, like ergotamine (Tunis and Wolff, 1953) and triptans 
(Humphrey and Goadsby, 1994), produced strong vasoconstriction. Vascular smooth 
muscle dysfunction is also often suggested to play a role in migraine pathophysiology 
(Tietjen, 2009). The vascular theory is also supported by a number of findings in 
monogenic syndromes, as discussed in chapter 5. However, current understanding 
heavily favors the neuronal hypothesis, which accounts for the vascular effects as 
incidental or unrelated (Goadsby, 2009). For instance, a recent imaging study showed 
the lack of cerebral vasodilation during migraine attacks (Schoonman et al., 2008). 
 
Regardless of the underlying theory, a number of observations point to a potentially 
pivotal role of enhanced brain glutamate levels behind the hyperexcitability of a 
migrainous brain, as well as in the triggering of migraine attacks (Goadsby et al., 
2006). The main findings supporting a key role for glutamate in migraine 
pathophysiology include: (i) glutamate receptor antagonists may have acute anti-
migraine activity (Andreou and Goadsby, 2009); (ii) the great majority of preventive 
migraine agents, despite belonging to widely different pharmacological classes, share 
the ability to block CSD in experimental animal models (Ayata et al., 2006) and may 
modify the glutamate-mediated trigeminal pain pathway (Shields and Goadsby, 2005, 
(Storer and Goadsby, 1999); (iii) the increased cortical release of glutamate fully 
explains the dramatically increased susceptibility to CSD seen in transgenic mouse 
models of FHM1 (Tottene et al., 2009, (van den Maagdenberg et al., 2010); (iv) 
noxious dural stimulation, as an experimental animal model for acute migraine, 
increases glutamate release from trigeminal ganglion neurons (Goadsby and Classey, 
2000); (v) plasma (Ferrari et al., 1990) and cerebrospinal fluid (Martinez et al., 1993) 
levels of glutamate are increased in migraineurs with and without aura in between 
attacks, further rising during attacks; (vi) a recent magnetic resonance spectroscopy 
study suggested that migraineurs have different glutamate-to-glutamine ratios when 
compared to controls, suggesting malfunction of excitatory amino acid transporters in 
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deep brain structures of migraineurs (Prescot et al., 2009); (vii) in a patient with a 
severe phenotype of migraine-like headaches and additional neurological episodic 
features, a missense mutation in the EAAT1 glutamate transporter gene was 
associated with severely reduced glial uptake of glutamate (Jen et al., 2005); and (viii) 
glutamate-mediated thalamocortical transmission is crucial for head pain (Storer et al., 
1999). A recent study suggested that in trigeminal neurons, glutamate release (as well 
as the release of calcitonin-gene related peptide, another neurotransmitter intricately 
linked with migraine) is controlled by calcium channels (Xiao et al., 2008), providing 
a possible link between glutamate and the known familial hemiplegic migraine genes 
(see Chapter 5). 
Arecommonformsofmigrainedistinctorpartofthesamespectrum?
One of the key open questions in migraine research is whether the two main types of 
common migraine are separate entities or simply slightly weaker/stronger versions of 
the same condition. The main arguments in favor of the “distinct disorders” 
hypothesis are that: the affected-sibling risk ratios are considerably different: 1.9 for 
MO, 3.8 for MA (Russell and Olesen, 1995); a majority of patients never suffer from 
attacks with aura; the existence of a form of migraine where aura is present without 
headache (equivalent migraine); and that these forms are traditionally clearly 
dichotomized in diagnostic criteria ( (International Headache Society, 1988)). The 
“distinct disorders” hypothesis is also supported by several population-based surveys 
(Russell et al., 1995, Russell et al., 1996, Russell et al., 2002) and it should be noted 
that a majority of the comorbidity studies in migraine (see below) have found positive 
correlations specifically with MA and not migraine in general. One example of this is 
a recent study which showed that the risk of developing epilepsy was considerably 
increased in MA patients, but not in MO patients (Ludvigsson et al., 2006). 
Furthermore, the study by Kruit et al., 2004 showed that the increased risk for brain 
lesions was only found among MA patients.
Counterarguments in favor of the “variations on a spectrum” hypothesis also exist 
(e.g. Kallela et al., 2001b) and are supported by genetic studies and a latent class 
analysis of migraine (Ligthart et al., 2006, Nyholt et al., 2004). Arguments in favor of 
this view include that most MA patients suffer from both types of attacks with varying 
frequencies and that patients suffering attacks where solely aura is present being a 
rarity, as well as that affected-sibling risk ratios are higher across the diseases - that is, 
the likelihood for a second sibling to develop MA when the first sibling has MO is 
greater than the general risk (Ulrich et al., 1999), and vice versa. Indeed, most MA 
patients suffer from attacks with and without aura, and thus fall on a frequency (or 
severity, depending on the viewpoint) gradient between pure MA and pure MO. Pure 
MA, referring to only having attacks that are associated with aura, is very rare. The 
gradient can be viewed as a frequency/severity continuum where position depends on 
the proportion of attacks aura is present. This view is reflected on our interpretation of 
the results of Study IV, where our findings seem to support the “variations on a 
spectrum” hypothesis (see Study IV discussion for further details). The continuum is 
dichotomized for clinical purposes into one extreme, where no aura is ever present 
(MO) and everyone else (MA) regardless of the ratio of MA and MO attacks. It could 
be argued that the second edition of the diagnostic criteria has moved from the earlier 
complete dichotomy towards a more flexible view. The introduction of new 




subcategories for MA (1.2.1 Typical aura with migraine headache and 1.2.2 Typical 
aura with non-migraine headache) separates the aura and headache parts and the new 
1.5.1 Chronic migraine category introduced a formal frequency cut-off for the number 
of migraine attacks per month. It is therefore quite possible that a future version of the 
criteria will more finely assess the headache and aura aspects of migraine. Thus far, 
there is not much robust genetic or biological evidence to conclusively support either 
the “variations on spectrum” or the “distinct disease” hypothesis apart from a few 
interesting twin studies (Ligthart et al., 2006, Nyholt et al., 2004) and Study IV.  
Major comorbid disorders 
 
Migraine is comorbid with a large number of other neuropsychiatric and 
immunological conditions, suggesting that migraine itself is a common reaction to a 
broad array of disturbances in the brain. It is present more frequently than expected in 
patients with depression, anxiety disorders, various pain disorders and clinical and 
sub-clinical brain lesions. The classical comorbid disorder is tension-type headache, 
though several epidemiological studies have found no comorbidity between it and 
migraine (Rasmussen et al., 1992, Ulrich et al., 1996); however, it has been shown 
that in migraine triggering factors (such as alcohol and chocolate) may worsen 
tension-type headache as well (Ulrich et al., 1996). Migraine has been reported to be 
associated with increased lower back pain with an OR 2.1 in patients with less than 30 
pain days per year and 3.4 in patients having more than 30 days with back pain 
(Hestbaek et al., 2004). A Norwegian study found that migraine patients were almost 
twice as likely to report musculoskeletal symptoms (OR 1.9), with headache 
frequency being a strong predictor (OR 5.3 for female chronic headache patients, 3.6 
for males) (Hagen et al., 2002). For psychiatric comorbidity, the connection between 
depression and migraine has been reported in both directions; depression increases the 
risk of migraine (RR 3.4), while migraine increases the risk of depression (RR 5.8) 
(Breslau et al., 2003). Another large Norwegian study found that migraine patients 
were more likely to suffer from depression (OR 2.7) as well as anxiety disorders (OR 
3.2) (Zwart et al., 2003). Bipolar disorder (BPD) is another psychiatric phenotype that 
has been extensively linked to migraine: a 2003 study found migraine to be twice as 
common among BPD patients as controls (Hirschfeld et al., 2003), and a 2006 study 
estimated the increase in prevalence to be 2.5-fold (McIntyre et al., 2006). A range of 
sleep disorders, from obstructive sleep apnea to hypersomnia, have been reported to 
be comorbid with migraine (Rains and Poceta, 2006). Finally, a Finnish study which 
included samples also used in this thesis, reported an increased risk for psychiatric 
disorders (OR 4.09), as well as allergies (1.83) and hypotension (1.43), as well as for 
stroke and epilepsy (Artto et al., 2006) (comorbidity with latter is discussed in 
previous chapter).  
 
Interesting aspect of the clinical background of migraine are the links between patent 
foramen ovale (PFO), a congenital weakness in the atrial heart wall, stroke and 
migraine with aura. PFO is a relatively symptomless condition present in 15-25% of 
the population (Di Tullio et al., 2007), and is thought to provoke migraine aura 
through an unknown mechanism. A 2005 study found PFO to be much more common 
in migraine patients than migraine-free controls (47% vs. 17%) (Schwerzmann et al., 
2005), and presence of more than small right-to-left shunt increased the risk of 
migraine 7.78-fold. PFO has been found to mostly associate with MA, while the risk 
for MO patients was much closer to the controls (29% for MA, 4% for MO, 2% for 




migraine-free controls) (Carerj et al., 2003). PFO closure trials for migraine relief 
have largely provided inconclusive results (Schwedt et al., 2008), though a number of 
anecdotal positive studies exist (Post et al., 2004). Only one large, randomly 
controlled trial has been reported so far (Dowson et al., 2008), in which no significant 
benefit from closure could be demonstrated, although the high prevalence of PFOs in 
MA patients was confirmed.  
 
Both PFO and migraine with aura increase the risk for cryptogenic strokes (Lamy et 
al., 2002). A number of reasons have been suggested involving blood flow through 
the right-to-left shunt and passage of small emboli through PFO (Anzola et al., 1999) 
to serotonin-activated platelets (Buzzi and Moskowitz, 2005). Our group has also 
reported a case study of a young female patient with a large shunt who suffered a 
stroke at a young age (Artto et al., 2008). MA is strongly linked with an increased risk 
of ischemic stroke. Interest was sparked by the CAMERA study, a large-scale 
imaging project on migraine patients (Kruit et al., 2004), that suggested that patients 
with migraine with aura in particular have a high risk of subclinical white matter brain 
lesions with an OR of 13.7 for posterior circulation territory lesions. A recent meta-
analysis estimated the risk of ischemic stroke to be roughly two-fold (Schurks et al., 
2009a). 
 





4  THE SEARCH FOR VARIANTS PREDISPOSING TO 
MIGRAINE 
 
Heritability of migraine 
 
The heritability estimates For migraine are fairly high. A 1995 Finnish study 
estimated the heritability to be between 34% and 51% (Honkasalo et al., 1995), 
depending on the type of migraine. Interestingly, the this study also calculated the 
heritabilities for the various migraine symptoms; the highest estimate was for 
unilaterality (56%) and the lowest for nausea and vomiting (45%). A large-scale 2003 
study placed the range of migraine heritability in six countries between 34% to 57% 
(Mulder et al., 2003). A Danish study estimated that the difference in migraine rates 
between monozygotic (MZ) and dizygotic (DZ) twins is significantly higher in MA 
(concordance rate 34% for MZ vs. 12% for DZ twins) (Ulrich et al., 1999). For MO, 
the difference in concordance rates was also significant but not as large, 43% for MZ 
vs. 31% for DZ (Gervil et al., 1999).  
 
Having a first-degree relative with migraine has been shown to increase risk for any 
migraine (Russell and Olesen, 1993). Compared with the general population, first-
degree relatives of MO patients have 1.9 times higher risk for MO, and 1.4 times 
higher risk for MA (Russell et al., 1995). However, for relatives of MA patients, the 
risk of MA was four-fold, while risk of MO did not differ from the general 
population, suggesting genetic distinctness of these forms of migraine. Further, 
affected-sibling risk ratios were found to differ, 1.9 for MO and 3.8 for MA.  
 
Familial hemiplegic migraine and other monogenic syndromes 
 
The first genetic clues on what causes CSD in humans were obtained from familial 
hemiplegic migraine (FHM), a very severe Mendelian form of migraine with aura. 
FHM is considered a useful analog of migraine with aura, as the aura in FHM is very 
similar to that of MA apart from the hemiplegia (Thomsen et al., 2002). For this 
reason, FHM is considered an extreme form of MA. It is characterized by aura attacks 
where, at least occasionally, unilateral motor weakness is present, which suggests the 
involvement of the motor cortex. The unilateral motor weakness is fully reversible 
and is associated with positive or negative symptoms of the visual or sensory cortex.  
 




Figure 13. Known genes in familial hemiplegic 
migraine (FHM) and their proposed effects on 
susceptibility to cortical spreading depression. Glu – 
glutamate, K+ - potassium. Gain or loss of function 
refers to the effect of the causative mutations on the 
function of the channel named. Adapted from 
Sanchez del-Rio et al., 2006. 
In 1993, a French study in 
two families revealed a 
locus on chromosome 19 
for FHM (Joutel et al., 
1993). This was followed 
by a number of studies, 
including one in Finland 
(Hovatta et al., 1994). 
Finally, in 1996 the first 
gene for FHM (CACNA1A) 
was identified (Ophoff et 
al., 1996). FHM is an 
autosomal dominant 
disorder, and today three 
known mutations in ion 
channel genes are known 
(FHM1: CACNA1A (Ophoff 
et al., 1996), FHM2: 
ATP1A2 (De Fusco et al., 
2003), FHM3: SCN1A 
(Dichgans et al., 2005)). 
Due to the autosomal 
dominant nature, FHM diagnosis requires at least one first- or second-degree relative 
with the same kind of attacks; without an affected relative, the diagnosis is sporadic 
hemiplegic migraine (SHM). CACNA1A encodes a subunit of a neuronal P/Q-type 
CaV2.1 channel, mutations in which have also been reported to be associated with 
episodic ataxia type 2 and spinocerebellar ataxia type 6 (Jodice et al., 1997) as well as 
epilepsy (Chioza et al., 2001). So far, more than 20 mutations in CACNA1A have been 
reported, and interestingly they result in a range of different neurological phenotypes. 
ATP1A2 encodes an α2-subunit of a sodium / potassium pump, in which mutations 
have also been associated with mental retardation and epilepsy (Jurkat-Rott et al., 
2004), cerebellar problems (Spadaro et al., 2004), and benign childhood convulsions 
(Vanmolkot et al., 2003). SCN1A encodes a sodium channel which has a well known 
role in epilepsy (Graves et al., 2005, (Meisler and Kearney, 2005). Figure 13 shows 
the proposed biological effects of these mutations (Sanchez-Del-Rio et al., 2006), and 
detailed review of these mutations can be found in a recent review (de Vries et al., 
2009a). A sporadic form of hemiplegic migraine (SHM) also exists (Thomsen et al., 
2003a), which has been shown to confer increased familial risk to MA but not MO 
(Thomsen et al., 2003b). 
 
Migraine headache also presents as a symptom in a number of monogenic conditions, 
including cerebral autosomal dominant arteriopathy with subcortical infarcts and 
leukoencephalopathy (CADASIL). CADASIL is a disease caused by mutations in the 
NOTCH3 gene, which plays a role in smooth muscle function in the brain vasculature 
(Joutel et al., 1996). Another example of a mutation related to the vascular system is 
the TREX1 gene mutationthat causes retinal vasculopathy with cerebral 
leukodystrophy (RVCL), a progressive condition involving blindness due to vascular 
retinopathy, brain infarcts and vascular dementia (Richards et al., 2007). RVCL and 
its comorbidities with migraine and stroke have led to suggestions of the significance 




of vascular dysfunction in migraine, (Tietjen, 2009, Vanmolkot et al., 2008), and 
recently support by a small Italian empirical study (Napoli et al., 2009). 
 
Genetic studies in common migraine 
 
Several candidate genes have been tested for association with the risk of migraine in 
case-control studies, with the most cited example being the C677T variant of the 
methylenetetrahydrofolate reductase (MTHFR) gene (Kowa et al., 2000). This 
mutation is quite interesting as it has been reported to be associated with, in addition 
to migraine, acute lymphoblastoid leukemia (Wang et al., 2010), abdominal aortic 
aneurysms (McColgan et al., 2009), ischemic stroke (Bentley et al., 2010), breast 
cancer susceptibility (Zhang et al., 2010), reduction in the risk for colorectal cancer 
(Taioli et al., 2009), and a large number of other phenotypes. This variant has been 
thoroughly studied in migraine, including several studies with sufficient sample sizes 
(Lea et al., 2004, Scher et al., 2006, Todt et al., 2006b, Kaunisto et al., 2006, Schurks 
et al., 2008 and Rubino et al., 2009a). Two recent meta-analyses have reported very 
slight association between the C677T variant and migraine with aura (e.g. p=0.03 for 
association to migraine in Schurks et al.) (Rubino et al., 2009a, Schurks et al., 2009b), 
mainly due to the two largest studies to date showing negative results (Todt et al., 
2006b) and (Kaunisto et al., 2006). A recent meta-analysis suggested that the 
association can only be detected in non-Caucasian samples (Schurks et al., 2009b). If 
this kind of stratification truly exists in the data, it could explain the large number of 
associations to this variant in candidate gene studies, where stratification is hard or 
impossible to detect (see Chapter 2).  
 
Other genes with reported association to migraine include the dopamine beta-
hydroxylase gene (DBH), for which two protective variants have been reported 
(rs1611115 (Fernandez et al., 2009) and rs2097629 (Todt et al., 2009)), the insulin 
receptor (INSR) (McCarthy et al., 2001, (Netzer et al., 2008), estrogen receptor 1 
(ESR1) (Colson et al., 2004, (Oterino et al., 2008) and tumor necrosis factor alpha 
(TNF-alpha) (Yilmaz et al., 2010). However, the same problem as for MTHFR exists 
for these studies as well; sample sizes have generally been relatively small, and larger 
follow-ups, e.g. for MTHFR and ESR1 (Kaunisto et al., 2006), have failed to replicate 
the findings. In addition, considerable publication bias is likely to be involved 
(personal communication with multiple groups) and would skew the meta-analysis 
results. 
 
A number of targeted linkage scans in samples of one or few families preceded the 
genome-wide linkage scans. A targeted Australian study detected significant linkage 
to the 19p13 locus (Nyholt et al., 1998b). Another locus on 19p13, distinct from the 
FHM1 locus was reported in 2001 in a North American family (Jones et al., 2001). 
Two further Australian studies concentrated on the X chromosome, finding a locus 
(Nyholt et al., 1998a) and detecting significant association to a locus on Xq24-




Study Nationality Families Significant loci Ref Wessman et al., 2002 Finnish 50 4q24 1 Cader et al., 2003 Canadian 42 11q24 2 Björnsson et al., 2003 Icelandic 103 4q21 3 Nyholt et al., 2005 Australian * 5q21 4 Russo et al., 2005 Italian 10 15q11-q13 5 Lea et al., 2005 Australian 92  6 Anttila et al., 2006 Finnish 50 4q24, 17p13 7 Anttila et al., 2008 Finnish, Australian 210 10q22-q23 8 Ligthart et al., 2008 Dutch 105 - 9 Tikka-Kleemola et al., 2010 Finnish 36 9q31 10 Oedegaard et al., 2010 American 31 - 11 
 
Table 7. Reported genome-wide linkage scans in large migraine family samples, and 
significant loci reported according to the Lander-Kruglyak significance definition 
(Lander and Kruglyak, 1995).  
 
Footnote: References are 1 (Wessman et al., 2002), 2 (Cader et al., 2003), 3 
(Björnsson et al., 2003), 4 (Nyholt et al., 2005), 5 (Russo et al., 2005), 6 (Lea et al., 
2005), 7 (Anttila et al., 2006), 8 (Anttila et al., 2008), 9 (Ligthart et al., 2008), 10 
(Tikka-Kleemola et al., 2010), 11 (Oedegaard et al., 2010). Study 4 marked with an 
asterisk used 790 sib pairs instead of families. 
 
 
q28 (Nyholt et al., 2000). A 2002 Swedish genome-wide scan reported a locus on 
6p12-p21 (Carlsson et al., 2002), as did an Italian study for a locus on 14q21-q22 
(Soragna et al., 2003). The first genome-wide linkage scan in a large family sample 
was conducted in 2002 (Wessman et al., 2002). Table 7 lists the genome-wide linkage 
scans published in migraine so far.  
 
A number of loci with genome-wide significant evidence of linkage have been 
reported, but despite a number of studies replications have been sparse (with notable 
exceptions 4q24, 10q23 and 18q12). More importantly, the linkage loci have not 
yielded any genetic variants for migraine, though a number of candidate genes within 
the best linkage regions have been studied for association. Examples of candidate 
gene studies based on the linkage information include the promising candidate genes 
such as the GABA gene cluster on 15q12 (Oswell et al., 2008) and AQP4 on 18q12 
(Rubino et al., 2009b). This dearth of results in a highly heritable disorder suggests 
possible heterogeneity in the phenotypes, which has served as an impetus to develop 
alternative phenotyping methods. 
 




Alternate migraine phenotyping methods 
 
The standard approach to migraine phenotyping involves the end diagnosis, formed 
on symptom traits based on a patient’s description of attacks. In order for a headache 
to be considered migraine, it has to fulfill a number of symptom criteria, listed in the 
ICHD-II (International Headache Society, 2004). While this works well in clinical 
practice, given that many kinds of headache can fulfill the criteria it is likely that for 
research purposes this introduces heterogeneity to the end diagnosis. A related issue is 
the nature of the MA and MO diagnoses. An MA attack also needs to fulfill MO 
criteria for pain, which suggests it would make sense to analyze both groups together. 
The first genome-wide linkage screen (Wessman et al., 2002) attempted to combine 
MA and MO groups into a “general migraine” group, but all of the detected linkage 
signals were reduced. However, if the theory regarding the interrelatedness of MA 
and MO (as discussed in Chapter 4) is correct, the ability to combine samples from 
both groups could increase statistical power for future samples. 
 
Another potential source of heterogeneity is the aura outlier group. When looking at 
the patient information in the Finnish pedigrees in detail, there is a clear outlier group 
which we refer to as “unclassified migraine with aura”. These patients are in reality 
most likely aura patients, but their aura presents in a form not be recognized by the 
current IHS criteria. Examples of nonconforming aura are atypical visual symptoms, 
motor symptoms without accompanying sensory symptoms and aura of atypical 
length. This phenomenon has been noticed at the other International Headache 
Genetics Consortium sites as well (G. Terwindt, personal communication, U. Todt, 
personal communication, and T. Freilinger, personal communication). Given that this 
group does present with pain fulfilling the MO criteria, this group likely represents a 
source of heterogeneity within the MO diagnosis group.  
 
For these reasons, alternate phenotyping methods in migraine have been proposed. 
The first of these was the latent class analysis by Nyholt et al. (Nyholt et al., 2004). 
The latent class analysis is a subset of structural equation modeling. It is used to find 
subtypes of related cases (i.e. latent classes) from multivariate categorical data in the 
absence of direct knowledge of class membership (Goodman, 1974). Is has been 
widely employed in disease epidemiology (Kaldor and Clayton, 1985) for diseases 
such as multiple sclerosis (Zwemmer et al., 2006) and rheumatoid arthritis 
(Schumacher and Kraft, 2007). The analysis provides a maximum likelihood estimate 
of the classes that fulfill the observed symptom distribution. Nyholt et al. (2004) 
estimated the number of latent classes in migraine to be four, with the first class 
lacking migraine (the healthy individuals in families), the second with mostly mild 
headache, and the two migraine groups denoted as CL2 and CL3 that roughly 
correspond to MO and MA, respectively. The use of these latent classes instead end 
diagnoses has repeatedly shown to improve migraine linkage signals (Anttila et al., 
2008, Goodman, 1974, Nyholt et al., 2005). 
 
Another alternate method, the trait component analysis, is discussed under Study I and 
II in the Results part of this thesis. 
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AIMSOFTHESTUDY
The purpose of this thesis was to identify genetic loci and variants influencing the 
susceptibility to migraine, first within the larger context of the Finnish Migraine 
Genetics Project, which aims to study the clinical characteristics of migraine patients 
and identify migraine predisposing genes in the Finnish population. In later parts of 
the thesis, our scope was expanded to cover data from collaborators in the 
International Headache Genetics Consortium, a joint venture of migraine research 
groups from a number of countries. The main approaches used in this thesis were 
demonstrating linkage through a genome-wide linkage study and demonstrating SNP 
association through either a candidate gene or a genome-wide association study.  
The specific aims of this thesis were:  
1. To develop an alternative migraine phenotyping method to improve the 
statistical power for genetic studies 
2. To apply the method developed in Aim 1 to identify genetic factors 
influencing susceptibility to migraine, specifically by studying the 
contribution of 
a. rare variants by means of genome-wide linkage scans 
b. common variants by a candidate gene approach and a genome-wide 
association study 




To address Aim 1, each of the studies in this thesis employed a new phenotyping 
method, the trait component analysis, to the various datasets. For Aim 2a, Studies 
I-II used microsatellite marker data from three independent genome-wide linkage 
scans (two Finnish and one Australian) to investigate rare haplotypes affecting 
migraine susceptibility. For Aim 2b, Studies III-IV used SNP data from a number 
of multinational samples to investigate the role of common variants in migraine 
susceptibility. In addition, to satisfy Aim 1, in each study alternate phenotyping 
methods were used to further dissect the genetic background of migraine. 
In Study I, we re-examined data genotyped for an earlier study (Wessman et al., 
2002) of 438 Finnish subjects (296 with migraine) from 50 independent, 
multigenerational families (see Table 8) using the novel phenotyping approach of 
trait component analysis (TCA). Additional genotyping for finemapping was 
performed on the same set of subjects based on the initial results. The subjects 
were selected from a clinic-based patient collection of roughly 7,000 individuals 
and 1,400 families, based on the severity of their migraine symptoms. Selection 
favored the most disabling cases. In Study II, 454 Finnish migraine patients and 
241 unaffected family members from 31 independent, multigenerational families 
were selected from the same collection. In addition, 269 Australian migraine 
patients and 387 unaffected family members within 152 independent nuclear 
families selected from two Australian twin cohorts were studied. Microsatellite 
markers were genotyped, and additional finemapping performed on the same 
samples based on initial results. To serve as a replication sample, an additional set 
of 192 migraine patients and 132 unaffected family members from 27 
independent, multigenerational Finnish families were studied.  
In Study III, a candidate gene hypothesis based on the channelopathy aspect of 
rare forms of migraine was used as the basis of a SNP association study, 
conducted in a Finnish study sample of 841 unrelated MA cases and 884 unrelated 
migraine-free controls were used for a candidate gene study of 155 ion transporter 
genes. In Study IV, the genome-wide association study approach was used to 
address the role of common genetic variants in migraine, through a genome-wide 
association analysis on 2,748 migraine with aura cases and 10,747 controls, 
followed by a replication in four populations with MA or MO patients. 
Table 8. The numbers of families and samples genotyped in each study. 
Numbers in parentheses indicate the corresponding numbers in the replication 
set of the study.
 Families Familymembers Familymembers Unrelatedindividuals Controlindividuals
withmigraine withoutmigraine withmigraine
I 50 296 142  
II 183(27) 723(192) 628(132) 256 230
III    841(2,835) 884(2,740)
IV    2,748(3,202) 10,747(40,062)
V. Anttila - Identification of genetic susceptibility loci for migraine 
52 
Studysubjects
The study designs of Study I and the parts of Studies II-IV relating to Finnish 
patients were approved by the Helsinki University Central Hospital Ethics 
Committee (approval #622/E0/02). The Queensland Institute for Medical 
Research Human Research Ethics Committee and the Australian Twin Registry 
approved the parts relating to Australian patients. Studies III and IVwere approved 
by (in addition to the previous) by the ethics committees of the University of Kiel, 
Univeristy of Cologne, Ludwig-Maximilians-Universität in Munich, Leiden 
University Medical Centre and the Danish Research Ethics Committee. Informed 
consent was obtained from all subjects.
i. Finland
Since 1992, a group of neurologists under Mikko Kallela and Markus Färkkilä 
(major participants of the group include Ville Artto, Hanna Harno, Hannele 
Havanka, Matti Ilmavirta, Salli Vepsäläinen, Markku Nissilä, Erkki Säkö and 
Marja-Liisa Sumelahti) have been collecting a Finnish migraine family database 
from headache clinics around Finland. Primary collection points were headache 
clinics in Helsinki, Turku, Jyväskylä, Tampere and Kemi. All participants were 
asked to fulfill the validated Finnish Migraine Specific Questionnaire for Family 
Studies (FMSQFS (Kallela et al., 2001a)) and to provide a blood sample. The 
criterion for inclusion in the database was that at least three members of the family 
(defined as grandparents, parents, parents’ siblings siblings and own children) 
have migraine. Based on the questionnaire responses, over 200 variables were 
recorded that included information on the IHS symptoms, typical attack features, 
age of onset, other diseases, place of birth, etc. Mikko Kallela diagnosed all 
patients based on the questionnaire data. A neurologist (Mikko Kallela, Markus 
Färkkilä or Ville Artto for the majority of patients) performed a physical 
examination of the index patient in each family and sometimes other family 
members as well. At the time of writing, the collection consists of over 7,000 
blood samples and questionnaire responses from roughly 1,400 families.  
ii. Australia
Subjects from two Australian twin cohorts were used in Study II: one of twins 
born 1902-1964 (Heath et al., 1997) and another of twins born 1964-1971 (Heath 
et al., 2001). IHS symptom data (Headache Classification Committee of the 
International Headache Society, 1988) was gathered using an extensive semi-
structured telephone interview that included diagnostic questions for migraine.  
iii. Germany 
For studies III and IV, two sets of German migraine with aura subjects were 
studied. Patients in the first set were recruited at a headache center in Kiel for a 
patient collection maintained at the University of Cologne. All patients were 
diagnosed as having MA by experienced neurologists with a specialization in 
headache disorders, from either a face-to-face interview or a detailed telephone 
interview. Interviews were standardized by using a comprehensive migraine 
questionnaire (Todt et al., 2006a). The second set was recruited at the Department 
of Neurology at the Klinikum Großhadern of the Ludwig-Maximilians-Universität 
in Munich. All were diagnosed as MA patients in a face-to-face interview by an 




experienced headache specialist, using a German translation of the Finnish 
FMSQFS questionnaire (Kallela et al., 2001a), accompanied by a follow-up 
telephone interview when necessary.  
 
iv. The Netherlands 
The Dutch sample consisted of MA patients recruited through a web page or at an 
outpatient clinic at the Leiden University Medical Centre, and selected to take part 
in the clinic-based Leiden University Migraine Neuro Analysis (LUMINA) study. 
For the patients recruited through the web page, diagnoses were assigned based on 
data from an extended questionnaire, followed by a telephone interview. For the 
patients recruited through the outpatient clinic, diagnoses were assigned directly 
by a physician experienced in diagnosing migraine patients.  
 
v. Iceland 
The majority of individuals suffering from migraine headache were recruited 
based on responses to a screening questionnaire mailed to a random sample of 
20,000 residents of the Reykjavik area aged 18–50 years. Additional patients were 
recruited through a list of patients provided by two neurologists or through 
responses to an advertisement in the Icelandic Migraine Society newsletter. All 
recruits were asked to answer the DMQ2 or DMQ3 questionnaires (Kirchmann et 
al., 2006). A validation follow-up was conducted by an experienced physician. 
 
vi. Denmark 
A computer search of the Danish National Patient Register of all hospitalized 
patients in Denmark was used as the basis for recruiting MA patients with a 
family history of MA. A screening telephone interview was conducted for all 
eligible patients. If a patient was confirmed to suffer from MA in the screening 
interview, any relatives with migraine-like headache were also diagnosed 
according IHS criteria (International Headache Society, 2004) in an extensive 
validated semi-structured telephone interview, performed by trained physicians. 
Control samples 
For Studies I and II, unaffected individuals (coded as having “unknown” phenotype 
due to the chosen linkage analysis approach; see below) from each family were used 
to estimate founder haplotype frequencies. For the discovery cohort of Study III, 884 
unrelated control samples with no personal or family history of migraine were 
obtained from the Finnish Twin Cohort, based on age- and sex-matching to the cases 
in that study. For the replication phase of Study III, matched controls were obtained at 
each study site from individuals participating in other studies who screened negative 
for migraine. For the initial phase of Study IV, population-matched controls were 
obtained from the Finnish Health2000 study, the Finnish Helsinki Birth Cohort study 
(Barker et al., 2005), the German KORA S4/F4 study (Wichmann et al., 2005), the 
German Heinz-Nixdorf Recall study (Schmermund et al., 2002) , the German PopGen 
cohort (Krawczak et al., 2006), the Illumina iControlDB database (consisting of 
caucasians matched to the other German controls), and the Dutch Rotterdam Study I 
(Hofman et al., 2007). For the replication phase, additional controls were obtained 
from deCODE Genetics to represent Icelandic and Danish controls, and from the Max 
Planck Institute study (Heck et al., 2009) and the GlaxoSmithKline study (Muglia et 
al., 2008) for German controls. For an overview of the control samples used for each 
population, see Table 9. 





Table 9. Methods used to obtain diagnostic information in each study sample of Studies I-
IV. Asterisk indicates that for the German study samples, Munich and Cologne samples 








































































































































































In each study sample, diagnostic questions regarding various headache features were 
asked based on ICHD-I (International Headache Society, 1988) or ICHD-II 
(International Headache Society, 2004) as detailed in Table 9. Answers to these 
questions and a number of additional questions were used to determine MA or MO 
diagnosis in accordance to the IHS criteria (see Chapter 3). In the case of the 
Australian questionnaire, a single question regarding the presence of visual aura was 
used to determine the difference between MA and MO. In cases where the diagnosis 
assignment was ambivalent due to insufficient or conflicting information, telephone 
follow-ups were conducted to ascertain the correct diagnosis. For linkage analysis in 
Studies I and II, the direct answers to the diagnostic questions were used as additional 
phenotypes in TCA and for Study II statistically estimated latent classes (based on 
previous empirical estimation for models of symptom profiles) were used in LCA. 
 
Genotyping methods 
a. DNA extraction 
DNA was extracted from peripheral blood lymphocytes from patient blood 
samples using standard methods. 
 
b. Microsatellite genotyping 
For Study I, we analyzed microsatellite data generated previously at UCLA 
(Wessman et al., 2002). In that study, 350 polymorphic microsatellite markers 
covering the autosomes and the X chromosome from the Human MapPairs 
Genome-Wide Screening Set (Broman et al., 1998) were genotyped. Extracted 
DNA was amplified by multiplex PCR assays with fluorescent primers designed 
to detect the microsatellite loci. Pipetting of the reactions was performed by a 
Hydra Microdispenser (Robbins Scientific). The amplification reactions were run 
in microtiter 96-well plates, by Tetrad thermal cyclers (MJ Research). The 
resulting PCR fragments, along with a size-standard ladder and fragments from 
known control individuals from Fondation Jean Dausset CEPH, were separated on 
6% acrylamide gels by electrophoresis using a LI-COR DNA 4200 Genetic 
Analyzer (LI-COR). The bands on the gels were automatically interpreted into 
genotypes by the Saga1.0 software package (University of Washington and LI-
COR). Allele sizes were standardized to those of CEPH control individuals. 
Markers that failed genotyping were replaced by microsatellite markers from the 
Genome Database and from the Marshfield genome database. All genotypes were 
verified by human inspection. In the finemapping phase, 14 additional 
finemapping markers were genotyped. Capillary electrophoresis, as employed by 
the MegaBACE 1000 DNA Sequencing System (GE Healthcare Bio-Sciences), 
was used to separate DNA fragments. Alleles were called by the MegaBACE 
Genetic Profiler 1.5 software (GE Healthcare Bio-Sciences). 
 
For Study II, 387 markers were genotyped at the Finnish Genome Center, using 
standard methods either on the ABI or the MegaBACE genotyping systems. 
Genotyping was based on the LMS-MD10 microsatellite marker set (Applied 
Biosystems, Foster City, CA, USA). For the ABI system, genotyping was 
performed with the ABI 3730 capillary sequencing instrument, and PCR products 
were resolved with the ABI 3730 data collection software and sized with the 




Genemapper software package from Applied Biosystems. For the MegaBACE 
system, capillary electrophoresis employed by the MegaBACE 1000 DNA 
Sequencing System (GE Healthcare Bio-Sciences, Piscataway, NJ, USA), was 
used for separating DNA fragments. Alleles for this system were called by the 
MegaBACE Genetic Profiler 1.5 software.  
 
c. Illumina Golden Gate assay 
In Study II, a custom-made Illumina Golden Gate assay (Illumina, San Diego, 
CA, USA) was used to genotype 1,536 SNPs at the Broad Institute in Boston, 
MA, USA. SNPS were chosen from within the region identified in the previous 
parts of the study (chr10, 78.233–88.884 Mb, NCBI build 35). The tagSNPs on 
chromosome 10 were selected using Haploview’s Tagger option with the CEU 
population in the HapMap SNP set as the reference population. (v21). All 
tagSNPs had minor allele frequencies >10% and r2 thresholds of >0.8. The 
Illumina BeadStudio software version 3.1.0.0 (Illumina) was used for calling SNP 
genotypes. Quality control cut-offs were >97% for sample-specific call rates and 
>95% for SNP-specific call rates. In total, 1,323 SNPs passed quality control. 
 
d. Perlegen SNP genotyping 
In Study III, a custom-made ion-transport SNP array was designed by Perlegen 
Sciences Inc. (Mountain View, CA, USA) based on a SNP list provided by us. 
Our list contained 5,975 tagSNPs with MAF >10% that targeted 155 ion channel 
genes. The array was manufactured by Affymetrix Inc. (Santa Clara, CA, USA) 
and quality control was performed by Perlegen.  
 
e. Illumina HumanHap GWA assays 
Genome-wide association (GWA) genotyping for Study IV was performed at the 
Wellcome Trust Sanger Institute using either the Illumina HumanHap 610k or 
550k SNP microarrays following the manufacturer’s Infinium II protocol 
(Illumina Inc.). Automated genotype calling was performed using the Illuminus 
software (Teo et al., 2007), which was followed by manual inspection of cluster 
quality for any SNP with a p-value <1x10-4. Strict quality control criteria (>95% 
for sample-specific call rate, >97% for SNP-specific call rate, Hardy-Weinberg 
equilibrium p-value >10-6 and >1% MAF) were applied. To identify 
contaminations and other error sources, overall sample heterozygosity proportions 
were calculated and outliers eliminated. To exclude related individuals a strict pi-
hat (measure of IBD proportion, defined as [proportion of SNPs at IBD=2] + 
[proportion of SNPs at IBD=1]/2) cut-off of 12.5% was used. Due to the 
combined analysis in three populations, each SNP was required to have been 
successfully genotyped in each of the three study samples. In total, 429,912 
markers passed all quality control criteria. 
 
f. eQTL study 
For Study IV, an eQTL study was performed on 75 samples of umbilical tissue 
(primary fibroblasts, lymphoblastoid cell lines and primary T-cells) obtained from 
the GenCord resource. Umbilical cord was chosen because it is readily available 
and allows the acquisition of multiple cell types for each individual. Sample 
collection was performed systematically on full term or near full term pregnancies 
to ensure homogeneity for sample age. Umbilical cords were collected from 75 
newborns of Western European origin born at the maternity ward of the 




University of Geneva Hospital and from each umbilical cord three cell types were 
derived: 1) primary fibroblasts, 2) LCLs and 3) primary T-cells (for detailed 
Methods see Dimas et al. 2009). Total RNA was extracted from these three cell 
types and 1.5 μg of cRNA was hybridized to Illumina’s WG-6 v3 Expression 
BeadChip array to quantify transcript abundance. Intensity values were log2 
transformed and normalized independently for each cell type using quantile 
normalization for sample replicates, and median normalization across all 
individuals. Each cell type was renormalized using the mean of the medians of 
each cell type expression values. For the genotypes of the expression study, DNA 
samples were extracted from umbilical cord tissue LCLs with the Puregene cell kit 
(Gentra-Qiagen, Venlo, the Netherlands) and genotyping was performed using the 
Illumina 550K SNP array (Illumina Inc., San Diego, USA). 
 
Statistical methods 
a. Two-point linkage analysis of microsatellite 
In Study I, two-point linkage analysis of microsatellite markers were employed 
using an affecteds-only strategy (i.e., all individuals not classified as affected were 
considered to have an ‘‘unknown’’ phenotype) to allow for reduced penetrance, 
lack of environmental exposure, etc. In Study I, parametric and nonparametric 
LOD scores were calculated for the 350 markers genotyped both under locus 
homogeneity and under locus heterogeneity using the AUTOGSCAN 
(Hiekkalinna et al., 2005) program, which employs the LINKAGE (Lathrop and 
Lalouel, 1984) and HOMOG (Ott, 1983) analysis softwares. In parametric 
analysis a dominant mode of inheritance and locus heterogeneity was assumed. 
Each of the IHS traits and trait groups were analyzed, in turn, as the phenotype. 
All analyses were performed with the disease-gene frequency set at 0.001 under 
the assumption of autosomal dominant inheritance and a phenocopy proportion of 
2.4%, which reflects the frequency of MA in the population. The strategy is in 
accordance with Göring and Terwilliger (Goring and Terwilliger, 2000) and in 
line with our previous research (Wessman et al., 2002).  
 
b. Multi-point linkage analysis for microsatellite markers 
For Study I, Multipoint parametric and nonparametric analyses were performed 
for regions showing evidence of linkage in the parametric two-point analysis by 
use of the program GeneHunter, version 2.1_r5beta (Kruglyak et al., 1996a). 
Parametric linkage analysis was performed using the model presented under two-
point linkage analysis, while allowing for locus heterogeneity. For Study II, we 
used the nonparametric MERLIN NPLpairs Z-score statistic (Weeks and Lange, 
1988) to test for increased allele sharing among affected individuals (Kruglyak et 
al., 1996a). To avoid biasing our results on possible overrepresented rare variants 
in a few large families, we also analyzed the Finnish genome-wide sample as a set 
of nuclear families. For consistency with the previous Australian genome-wide 
linkage scan and in order to use the information from unaffected individuals, we 
used a nonparametric quantitative trait linkage (NPLqtl Z-score) statistic for the 
analyses of the Australian families in order to obtain additional linkage 
information from unaffected individuals. In this analysis, affected individuals 
were coded as “1”, unaffected individuals were coded as “0”, and those with 
missing phenotypes were coded as “x”. Multipoint nonparametric linkage analysis 
was performed with the MERLIN computer program. The MERLIN NPLpairs and 




Figure 14. The limits of statistical power for the SNP 
association analyses in Studies II-IV. The black arrow 
indicates the position of the variant identified in Study 
IV. 
NPLqtl Z-score statistics were implemented in the general Whittemore and 
Halpern framework (Whittemore and Halpern, 1994). Based on the Z-scores, a 
likelihood ratio test for linkage performed by MERLIN was used to estimate the 
LOD score statistic using the exponential modeling procedure of Kong and Cox 
(Kong and Cox, 1997). 
 
c. SNP association analyses  
In Study III, single marker basic allelic association tests were performed using 
PLINK v1.00 (Purcell et al., 2007). Significance of the test results was evaluated 
through the max(T) permutation procedure in PLINK.  
 
In Study IV, the primary analysis method was the assessment of genotype 
differences for genome-wide SNP data between cases and controls using two-
tailed Cochran-Mantel-Haenszel (CMH) test for 2x2xK stratified data (K = 3), as 
implemented in PLINK software version 1.06 (Purcell et al., 2007), with a 
nominal variable 
used to code for 
population identity. 
For population-
specific results, the 
CMH test was used 
with K=1. For the 
meta-analysis of 
the top marker, 
CMH test with K=7 
was implemented 
in manner similar 
to the primary 
analysis, but for a 
single marker. 
Significance of the 
test results was 
evaluated by 
comparing them to 
the generally 
accepted 5 x 10-8 (Altshuler et al., 2008), and a genomic inflation factor 
(estimated from median of all χ2 values) was calculated to verify correct case-
control set matching. To evaluate statistical power of the SNP association 
analyses, the limiting minor allele frequencies necessary for 80% and 50% 
statistical power for various odds ratios (OR) can be seen from Figure 14. For 
these calculations, a multiplicative model and a disease prevalence of 15% were 
assumed. For each study, the study-specific significance limit was used (3.8 x 10-5 
for Study II, 1.9 x 10-5 for Study III, and 5.0 x 10-8 for Study IV).  
 
d. Additional quality control measures for GWA data 
i. Elimination of population stratification 
To eliminate population outlier samples based on SNP data pattern 
analysis, IBS distances for each sample pair in the same population 
were estimated using the “genome” option of PLINK software version 
1.06 (Purcell et al., 2007). The resulting IBS distance matrix data was 




subjected to multidimensional scaling analysis, which identifies the 
eigenvectors within the data in decreasing order of magnitude. In 
accordance with standard practice, the first 20 eigenvector dimensions 
were examined for each population sample, and outlier samples based 
on a visual examination were excluded from the analysis.  
ii. Verification of case-control matching 
To ascertain that the control sets properly matched the case sets and to 
check that the population stratification analysis had worked properly, 
genomic inflation factors were estimated from the association analysis 
results. The inflation factor was calculated by finding the median χ2 
value from a 1-d.f. allelic χ2 test. For each of the study populations, the 
median value was less than 1.1, generally accepted as sufficient 
matching. 
 
e. eQTL study  
The expression level values from the Illumina expression array for each individual 
were analysed for correlation with the common variant genotypes of the same 
individual using the Spearman rank correlation test. The same method was used in 
a previous study in 2007 by Stranger et al., which identified around 1,500 genes 
with either trans- or cis-acting association with a common sequence variant 
(Stranger et al., 2007). 
 
f. Transcription binding site analysis 
Known human transcription factor binding site motifs (456 in total) were 
extracted from the TRANSFAC 12.2 database (Matys et al., 2006). Sequence 
region +/- 1400 bases from rs1835740 was retrieved from the human NCBI37 
genome assembly using the Ensembl API (Hubbard et al., 2009). The positions 
retrieved were chr8:98,165,513-98,168,313. Transcription factor motif hits within 
the retrieved sequence were computed using Nmscan software, distributed as part 
of the NestedMICA suite (Down and Hubbard, 2005). The sequence background 
model required for significance cut-off calculation was trained on 1,000 randomly 
chosen human intergenic sequences (protein coding sequence was excluded). A 
bootstrapping procedure was used to assess the significance of the maximum bit 
scores of the motifs within the region of interest: the nucleotide sequence was 
shuffled 10,000 times retaining the nucleotide content, and scored against the 
same binding site motifs, each time recording the maximum bit score hit, and 
matches that were found to be below expectation of 0.01 were retained. After 
scanning the genomic region close to rs1835740, we retrieved the 31-way 
Eutherian mammal multiple alignment from 98,166,803 bp to 98,166,938 bp 
using Ensembl Compara to display the nearest statistically significant matches 
found for the motif scanning. 




RESULTS AND DISCUSSION 
 
1. Introduction of an Alternative Phenotyping Method, the Trait 
Component Analysis, for Family-based Linkage Studies in Migraine 
 
The key motivation for the studies in this thesis was to find a better method of 
studying the genetics of migraine, which would improve the understanding of the 
condition’s causative pathophysiology – largely unknown at the start of the thesis. 
Factors, such as only having a descriptive diagnosis instead of quantifiable laboratory 
markers create innate difficulties for the study of neuropsychiatric conditions. 
Migraine is not exempt of these difficulties. Due to the lack of biomarkers, the 
migraine diagnosis is based on particular diagnostic questions (the IHS diagnostic 
criteria; see Chapter 3 for more details), which represent the current idea of the 
condition’s underlying pathophysiology. However, given our limited knowledge, the 
diagnostic method is not necessarily a refrelction of the true biology, which is an 
additional confounding factor for downstream analyses.  
 
To try to address some of this phenotypic heterogeneity, more quantifiable 
phenotypes were explored. A new phenotyping approach called the trait component 
analysis (TCA) was developed in a bid to increase the statistical power of genetic 
studies. This approach was made possible by the introduction of the 2nd edition of the 
criteria in 2004 (International Headache Society, 2004), which for the first time 
outlines the attack symptoms of both migraine with (MA) and without aura (MO) in a 
similar manner. This consistency allowed us to consider a better way of dealing with 
the common situation among Finnish migraine family pedigrees of having both MA 
and MO cases. Finnish migraine families were gathered following the ascertainment 
of a MA index case and MO is often seen in the same pedigrees. Furthermore, we 
often observed situations where the parents of the index case both had MO or where a 
grandparent’s MA would manifest itself again in a grandchild while the parent 
between the two suffers from MO. Initial attempts to consider both MA and MO as 
affected at the same time led to a loss of known linkage signals (Wessman et al., 
2002), suggesting that some stratification was necessary.  
 
In practice, TCA forms multiple phenotypes directly from the diagnostic questions of 
migraine. TCA studies aim to study the diagnostic questions’ biological relevance in 
addition to finding new genetic loci relating to migraine. Instead of the traditional 
diagnosis approach, TCA directly uses patient responses as phenotypes. In this way 
the usual process of combining questions’ answers to determine a migraine diagnosis 
is bypassed.Instead of considering, for instance, the presence of two vascular 
symptoms (pulsation, pain intensity, unilaterality and aggravation by physical 
exercise or prevention of normal activity) as “migraine”, patients with any given 
vascular symptom, like pulsating pain, are considered to be a group by themselves. 
According to the IHS criteria, any combination of two or more of those four 
symptoms leads the same outcome, which leads to considerable heterogeneity in the 
group. For example, diffuse pain of moderate intensity covering the whole head that 
prevents working is considered the same as unbearably intense pulsating pain on one 
temple that does not prevent one from working. In TCA, each person gets one 




phenotype value for each symptom, and is analysed several times (once per 
phenotype). The extra burden of proof due to the increased number of tests is 
corrected for by having a higher significance limit that is determined by the number of 
tests. Another important feature of TCA is that it allows the study of the two main 
forms of migraine, MA and MO, in the same phenotypic context. In addition to the 
reported co-segregation of the two diseases discussed in Chapter 3, we have also 
made the empirical observation in the families we have studied that a parent with 
either migraine diagnosis often has a child with the other type of migraine (i.e. if a 
parent has MA, the offspring has MO, or vice versa). A diagnosis-based linkage 
analysis would consider such case as negative transmission, and thus the offspring’s 
diagnosis as a sporadic occurrence. However, if the parent and child share similar 
symptoms, such as pulsating pain, TCA would acknowledge the successful 
transmission. Being able to account for these situations increases the number of 
relevant meioses considered in the analysis, which results in higher detection power. 
 
In Study I, we re-analyzed data from a 2002 genome-wide linkage scan of 50 
migraine with aura families (Wessman et al., 2002) using the trait component 
approach. In a two-point linkage analysis assuming locus heterogeneity, significant 
evidence of linkage was found with two loci: D17S945 (17p13, HLOD score 4.65) 
and D4S1647 (4q24, HLOD score 4.53). The locus on 4q24 had been previously 
identified in 2002 (Wessman et al., 2002), but the locus on 17p13 had previoulsy only 
shown nominal evidence of linkage in the same study. A further six markers showed 
suggestive evidence of linkage (HLOD score > 2.60, the limit of suggestive evidence 
after correction for the number of phenotypes tested): D4S2380 (4q22), D4S2394 
(4q28), D4S1520 (4q31), D18S877 (18q12), D18S862 (18q21), D18S1364 (18q22). 
The suggestive markers defines two new loci: 4q28-q31 and 18q12. Ther latter, 
18q12, replicates a loci previously identified in the Icelandic population (Björnsson et 
al., 2003).  




Figure 16. Two-point linkage analysis 
results from chromosome 4 data in Study I, 
comparing the results from the MA 
diagnosis, phonophobia trait phenotype, and 
the age of onset <20. Dotted lines between 
points are for illustration purposes. V. 
Anttila, unpublished data. 
Figure 15. Two-point linkage analysis 
results from chromosome 4 data in Study I 
using MA and MO diagnoses. Dotted lines 
connecting the points are for illustration 
purposes. V. Anttila, unpublished data. 
 
1.a. Improved linkage to the previously detected locus on 4q24 
 
The first point of comparison between 
the diagnosis-based and TCA 
approaches is the primary finding of the 
original 2002 study, the locus on 4q24. 
The original study used the presence of 
migraine aura as the main phenotype. 
Comparing the linkage results (Figure 
15) based on migraine aura (the MA 
diagnosis) and migraine pain (the MO 
diagnosis) shows that the 4q24 locus is 
linked to the former, which suggests 
that the IHS symptom combination 
does not have sufficient resolution at 
this locus in these samples. However, 
comparison to the results of the TCA 
analysis (Figure 16) suggests that the 
inheritance may be more complicated 
than this; the main peak at 105 cM is 
identified by most of the traits and is 
improved by some. The LOD score for 
marker D4S1647 using TCA was 4.53 
(p-value 2.47 x 10-6) and was 
previously at 4.20 (p-value 5.46 x 10-6 
for MA). More importantly, clearer 
results are observed in the areas 
surrounding the peak. For example, 
TCA shows a much stronger signal at 
the previously nominal peak at 141 cM 
(4q28-q31), the LOD score increased 
from 1.55 to 2.99.  
 
The consistency in detecting this locus 
was considered a good indicator for the 
reliability of TCA and of the locus 
itself. The linkage of many of the 
migraine traits to this locus suggests a 
robust link between this locus and migraine susceptibility. This locus was the first 
locus to show significant evidence of linkage to migraine in a large multigenerational 
family sample (Wessman et al., 2002) and was also the first one to be replicated 
(Björnsson et al., 2003). A 2004 study in schizophrenia (Paunio et al., 2004) used a 
similar endophenotype-based approach. The study utilized diagnostic features as 
quantitative traits (such as measures scoring verbal memory and visual working 
memory) and showed improved linkage scores and new loci in comparison to the end 
diagnosis approach. Interestingly, several traits (such as measures of executive 
function, delayed memory and verbal learning) showed evidence of linkage to a locus 
on 4q24 that overlapped and encompassed the migraine peak. Recently, a study in 




families with both bipolar disorder and migraine (Oedegaard et al., 2010) (comorbid 
disorders, as discussed in Chapter 4) showed suggestive evidence of linkage to 4q24 
that even centred on the same marker found in the 2002 Wessman et al. study and 
Study I. Given that this signal is stronger when concentrating on the migraine 
diagnosis only, limited conclusions regarding the role of this locus in the 
pathophysiology of bipolar disorder can be drawn. However, the presence of a 
moderately strong signal in families where migraine and bipolar disorder are 
comorbid, combined with the close phenotypic relationship between schizophrenia 
and bipolar disorder, suggests that this locus may indeed play a key role in processes 
behind the pathogenesis of several brain disorders. 
1.b. A new locus on 17p13 
The primary finding in Study I was the identification of the new 17p13 locus (though 
this locus has shown nominal evidence in a previous Australian scan (Lea et al., 
2005)). This locus had shown nominal evidence of linkage in the original 2002 study 
(see Figure 17). Significant evidence of linkage was found to marker D17S945 (LOD 
score under locus homogeneity 4.65, p-value = 1.85 x 10-6, LOD score under locus 
heterogeneity 4.65, p-value = 1.1 x 10-5, multipoint LOD score 3.94 at 22.0 cM), with 
an ASP LOD score of only 0.82 (p-value 0.026), suggesting a dominant effect at this 
locus. A number of adjacent markers also showed evidence of linkage, though the 
signal was clearly concentrated around marker D17S945. Multipoint analysis placed 
the top signals at 19.4 cM (GeneHunter parametric analysis (Kruglyak et al., 1996a)) 
and 22.0 cM (GeneHunter nonparametric analysis). 
 
It is quite intriguing that the use of a trait that still correlates with the diagnosis itself 
illuminates a new locus. Using the MA diagnosis as phenotype finds only a relatively 
Figure 17. Chromosome 17 linkage results, showing the multipoint 
linkage analysis results using the pulsation phenotype, and the two-point 
linkage results from Wessman et al. 2002 using MA end diagnosis for 
comparison. Dotted line connecting MA results is for illustration 
purposes. NPL – non-parametric linkage. 




low evidence of linkage (LOD score 1.01, p-value 0.016). There is a considerable 
difference between the individuals in each group: 51 (out of 252) of the individuals 
considered as affected in the original 2002 study were now coded as unknown (i.e. 
they are MA patients without the pulsating pain phenotype), and 66 (out of 235) 
individuals previously considered unknown were now coded as affected (i.e. they are 
MO patients with the pulsating pain phenotype). In total, these two groups together 
represent almost 50% of the affected individuals in the study sample, so the 
considerable change in LOD score (from nominal to significant) is plausible in that 
sense. A family-specific analysis showed that roughly a third of the families in the 
study showed a high degree of linkage to this locus, suggesting that this signal may be 
due to a relatively high-impact variant of either lower penetrance or lower allele 
frequency. Another possible explanation is that pulsation is a useful measure in 
distinguishing and separating some underlying subtype of migraine out of the whole 
spectrum of the disorder. For example, if sporadic forms of migraine were to have a 
lower incidence of pulsating pain due to missing or having some pathophysiological 
component associated with the pulsating sensation, this could explain the behavior of 
the linkage signal at the 17p13 locus.  
1.c. Additional new loci detected 
In addition to the 17p13 locus, two loci with suggestive evidence of linkage were 
detected. On 18q12, a previously identified locus in the 2002 scan as well as in the 
Icelandic population (Björnsson et al., 2003) was detected with nearly every analyzed 
trait. The traits showing linkage to this locus are those more clearly associated with 
the headache component of migraine, especially since the top associating traits is, 
with the highest score found with the strict application of the IHS criteria for MO, and 
especially the “vascular” criteria of pain (pain intensity, unilaterality, aggravation, and 
pulsation). Considering the phenotypes as well as the high ASP scores at this locus 
that suggest a recessive effect, it is not surprising that this locus displayed only 
nominal evidence of linkage in the original 2002 MA scan. However, if the 
underlying genetic locus is recessive in effect, the sample size needed to better 
describe it is probably considerably higher.  
 
On 4q28-q31 a third new locus was detected by various traits, with the age of onset 
under 20 years showing the strongest evidence of linkage. We believed that limiting 
the age of onset of migraine might allow us to concentrate on the most severe 
migraine cases by biasing the case distribution in favor of the genetic cases and away 
from the sporadic cases that make up the migraine spectrum. Our success in doing so 
is a matter for debate, but the strong increase in linkage signal observed at this locus 
suggests that this approach would be useful in future studies. However, more work is 
required to validate this method of alternate migraine phenotyping. 
 
1.d. Conclusions 
The somewhat unexpected results of this study, such as the large significance gains 
for the 17p13 locus, suggest that the trait component analysis is useful in uncovering 
previously hidden factors determining migraine susceptibility. While the approach in 
this study was used in a largely hypothesis-generating fashion, the results raise several 
intriguing possibilities: (1) the presence of subgroups with the two diagnosis groups 
that are genetically considerably more homogeneous, or conversely a more 
heterogeneous group with unusual symptom groupings; (2) a potentially useful role 




for pulsation as a key trait in distinguishing cases with a higher genetic load; and (3) 
the existence of several new loci affecting migraine susceptibility. 
 
The trait component analysis (TCA) is based on the idea that individual clinical 
symptoms might provide a better stratification method than latent classes or end 
diagnoses. It is important to note that all three of the main loci detected by TCA are 
also clearly present in the diagnosis-based results. However, only nominal evidence of 
linkage is observed using the diagnoses and the considerable improvement of the 
detected signals strongly suggests two possible explanations: (1) the existence of 
some confounding subgroup present in the diagnosis phenotype analyses and not in 
TCA; or (2) the individual traits better reflect the underlying biology of these loci. 
Therefore, based on these successful results the approach was applied as the primary 
analysis method in Study II, the subsequent Finnish migraine scan.  





2. Genome-wide Linkage Scan Using Multiple Populations 
 
In Study II, we collaborated with a migraine research group from the Queensland 
Institute for Medical Research in Brisbane, Australia to analyze 210 families 
consisting of 1,675 individuals suffering from MA and MO. The primary study 
sample consisted of two independent scans from Finland (58 multigenerational 
families) and Australia (125 nuclear families). The replication set came from Finland 
(27 multigenerational families that were not related to the primary Finnish study 
sample). The purpose of this study was to expand our efforts in alternate migraine 
phenotyping and to attempt the replication of a locus in a population different from 
that of the initial discovery sample. Replication of a locus in two populations as 
genetically diverse as the Finns and Australians would provide strong evidence for a 
shared migraine pathway or mechanism. In this study, we applied the three different 
migraine phenotyping methods used at the time: the end diagnosis, LCA, and TCA. 
The high number of families and individuals in this study gave us the opportunity to 
make a good comparison of the different phenotyping methods. Significant evidence 
of linkage was observed at a locus on chromosome 10q22-q23 (LOD score 5.50 in 
Finns, 3.50 in Australians, 2.41 in an independent Finnish replication study). In 
addition, four previously reported loci - 8q21 from (Nyholt et al., 2005), 14q21 
(Soragna et al., 2003) as well as 18q12 and Xp21 (Wessman et al., 2002) were 
replicated successfully.  
 
2.a. Robust detection of a new locus on 10q22-q23 
The primary finding in this study was the identification and replication of the 10q22-
q23 locus in all three study samples using multiple markers. In both the Finnish and 
Australian primary scans, significant evidence of linkage was observed with markers 
around 100 cM on chromosome 10. The 95% confidence intervals placed the top of 
the peaks between 99-114 cM among Finns and 94-115 cM among Australians with 
the highest multipoint LOD scores of 4.91 and 3.42, respectively. An overlapping 
signal was also observed in the replication sample, which had only been genotyped 
for markers finemapping the 10q22-q23 locus by applying the Lander-Kruglyak 
replication threshold of 1.8 from (Lander et al., 1995). A combined analysis of the 
Finnish and Australian scans using the pulsation phenotype resulted in a multipoint 
LOD score of 5.24 at 102 cM. A comparison between the different phenotyping 
methods in the combined study sample showed that TCA performed consistently 
better at detecting this locus than either of the other methods (the highest LOD score 
was 5.24 with TCA, 3.37 with LCA and 1.89 with diagnosis-based analysis). The 
difference was especially apparent in the Australian sample, in which only nominal 
evidence of linkage was observed using the other phenotyping methods. Interestingly, 
comparison with the results from the previous Finnish and Australian scans showed 
that this locus has been previously observed. However,only by using TCA has this 
locus been revealed in the Finns of the 2002 study by Wessman et al. (see Figure 18); 
not even nominal evidence of linkage was observed using the MA diagnosis-based 
analysis. At the time, this was the first locus in migraine for which multiple 
replications had been observed, including the replication of a locus in the same 
population as the original finding.  





Figure 18. Linkage analysis results at the 10q22-q23 locus. A. Non-parametric 
multipoint linkage analysis results across chromosome 10 from Study II, 
combined with results from a previous study by Nyholt et al. (2005), and two-
point results from Study I. B. Close-up of the 10q22-q23 peak, between 80 cM 
and 130 cM. C. Comparison of the localization of the top linkage signal from 
each study. The horizontal line in each case indicates the location of the 
highest linkage signal in that study sample, and the vertical line indicates its 
95% confidence interval. Final category shows the overlap between the 
studies. 




Further improvement on the linkage signal was observed in a female-only analysis, 
which had been employed in a previous study (Björnsson et al., 2003). In the Finnish 
sample, highly significant evidence of linkage was observed this way (HLOD score 
7.68, p-value 1.68 x 10-9). This finding suggests either that there is a higher degree of 
heterogeneity among males at this locus, or that some female-specific (for example, a 
hormone-related) mechanism underlies the signal at this locus.  
 
2.b. No association to common SNPs targeting 10q22-q23 
Given the significance of the linkage signal at this locus, a SNP-based follow-up 
study was conducted in order to detect any common variants underlying the linkage 
signal. Even though the area of maximal allele sharing in the linkage analysis was 
fairly narrow (just a few megabases in size), due to the ideas proposed by Kruglyak 
and Lander (Kruglyak and Lander, 1996b), we decided to expand the area for a SNP 
association follow-up study to between 78.3 Mb and 88.8 Mb, so as to cover 
functionally interesting genes at both ends. This region was then genotyped using an 
Illumina Golden Gate assay, covering 1,537 SNPs within this interval, targeting 40 
trios and 324 cases and 214 unrelated controls from the linked families optimized 
based on the haplotype information. However, none of the SNPs tested showed 
significant association to the migraine or TCA phenotypes. Given the relatively low 
number of cases and controls tested, and that only common variants were 
interrogated, the result is perhaps not surprising. 
 
2.c. Reproducibility of trait component analysis and detected loci 
In both Study I and Study II TCA clearly improves the linkage results more than 
would be expected by random chance – that is, the increase in linkage scores 
overcomes the increased significance limits calculated by taking into account the 
extra testing. This extra burden was estimated to correspond to testing five (Study I 
sample) or six (Study II sample) independent phenotypes (the equivalent independent 
number of traits, after the correlation between them has been accounted for using the 
matSpD software (Nyholt, 2004)), consequently resulting in LOD score significance 
limits of 4.00 (Study I; increase of 0.7) and 3.83 (Study II, increase of 0.78). It should 
be noted that though the latter used a larger number of effective tests (hence the larger 
increase), the uncorrected estimate for the original significant limit was less 
conservative in Study II. This difference was due to a new method of estimating that 
limit; in Study I, we applied Lander and Kruglyak’s approach (Lander et al., 1995) 
which estimates the significance limit using limit theory for the absolute significance 
limit for a linkage study with infinite markers, while in Study II we applied a 
correction which takes into account the lack of complete inheritance information in a 
linkage study, as described previously (Nyholt et al., 2005). 
 
Prior to these studies, two loci had been replicated in migraine; 4q21-4q24 and 18q12, 
both reported in Finns (Wessman et al., 2002) and Icelanders (Björnsson et al., 2003). 
In this study, the improvement in existing peaks and the appearance of new ones 
happens in a consistent and reproducible manner (i.e. the new loci show a high degree 
of replication; see Table 10). 
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Footnote: Study references are 1 (Wessman et al., 2002), 2 (Carlsson et al., 2002), 3 
(Cader et al., 2003), 4 (Soragna et al., 2003), 5 (Björnsson et al., 2003), 6 (Lea et al., 
2005), 7 (Nyholt et al., 2005), 8 (Anttila et al., 2006), 9 (Anttila et al., 2008), 10 
(Ligthart et al., 2006), 11 (Oedegaard et al., 2010). The notes in the last column refer 
to: a Single family study, b Study used a relaxed definition of migraine diagnosis, c
Study used endophenotypes, d Study concentrated on a special subtype of migraine 
with aura. Asterisks indicate studies that are a part of this thesis. Repl - replication.
Out of the 27 loci reported in migraine, 15 have been replicated, and most of them 
multiple times; the top loci based on the current evidence are 10q22-q23 (six scans – 
Anttila et al. 2008 reported three, with all showing linkage to this locus), 4q21-q24 
(five scans), 18q12 and 13q14-q33 (four scans), 5q13-5q21, 14q21-q22 and 1q23-q31 
(three scans). Out of the two trait component studies, out of ten reported loci, eight 
have been replicated since or have themselves replicated previous studies. Compared 
to bipolar disorder, for example, where reproducibility has been a long-standing 
problem (Segurado et al., 2003) and schizophrenia, where similar problems have been 
observed (Badner and Gershon, 2002), the results in migraine are fairly consistent – 
even though a formal linkage scan meta-analysis has not been performed. However, it 
is interesting that a number of the best linkage regions in migraine show considerable 
overlap with the top regions in schizophrenia (1q22, 13q32-34) and bipolar disorder 
(4q24, 10q22, 14q24-q32, 18q12) (Craddock et al., 2005, Segurado et al., 2003), 
especially in the light of a recent linkage scan of co-occurring migraine and bipolar 
disorder (Oedegaard et al., 2010). 
The consistency of migraine findings is demonstrated by the locus on 17p13, which 
was undetectable with the end diagnosis (Wessman et al., 2002). However, a follow-
up finemapping study conducted after significant evidence of linkage was detected 
with the pulsation trait in Study I showed linkage of a number of SNPs genotyped at 
this locus with the MA end-diagnosis. This suggests that TCA had greater sensitivity 
to detect this signal. Furthermore, the follow-up of this finding in Study IV provides 
support to the usefulness of the TCA approach, because the association to this locus 
seen with end diagnosis is improved by TCA (V. Anttila, unpublished data). 
Similarly, the 10q22-q23 locus detected in Study II showed consistent and robust 
linkage signals across studies only when TCA phenotypes were applied. Since 




publication, this has been observed in an additional scan (Ligthart et al., 2006). It 
remains to be seen what genetic variants can be discovered at this locus. 
 
2.d. Comparison of the different phenotyping approaches 
The reproducibility of TCA results raises the possibility of two intriguing 
explanations; first, while finding a genetic cause to a symptom-related mechanism 
does not necessarily reveal the causes for the onset of a migraine attack, it would in 
all likelihood allow new insights into the biological processes of a migraine attack. 
For example, identifying the particular features of migraine showing strongest linkage 
to the 4q24 locus could reveal additional information involved in what happens on the 
visual and auditory cortices during photo- and phonophobia (possibly even outside 
migraine), and could possess application in e.g. epistatic approaches. This highlights a 
crucial difference in the relationship to the “clinical background” of migraine between 
the different phenotyping approaches: LCA creates fixed combinations of clinical 
features, in effect creating a new diagnostic classification, based on symptom 
structure typical to each class based on heritability estimates, while trait component 
analysis is based on the hypothesis that the information contained in each response 
itself is closer to the underlying biology. Based on the traditional assumptions in 
genetics, where estimates of heritability and affected-sibling risk ratios from twin 
studies are used as the guideline for all subsequent work, LCA as a methodology 
should in theory generate superior results. The observations from these two linkage 
scans indicate that this may not be the case in migraine (see Figure 19), suggesting 
that some additional confounding factor or factors may be involved. There are at least 
two possible explanations to the observed results: 1) the existence of a confounding 
Figure 19. Comparison of the linkage results on chromosome 10 
produced by the different phenotyping approaches in the joint Finnish-
Australian study sample in Study II. 




subgroup (e.g. sporadic migraine due to non-genetic factors), which increases 
diagnostic heterogeneity, thus influencing both the end diagnosis and the original 
LCA profile estimation; 2) that the underlying assumption of both LCA and TCA is 
true – that the symptom questions can be used to distinguish “real” (or “genetic”) 
migraine from something else mimicking itself as migraine (likely some condition 
related to altered pain processing, possibly with a strong psychological component). 
This latter possibility has the implication that some combination of traits or traits and 
heredity profiles (likely with the vascular criteria, especially pulsation, playing a 
major role) could be used to improve homogeneity in treatment trials, epidemiological 
studies etc. 
 
One important feature of Study II is the ability to compare a highly enriched family 
sample (i.e. the Finns) with a typical population-based sample (the Australians), and 
to show that the method applies in both contexts. In Study I, a possible explanation to 
the new peaks would have been the presence of very rare variants and haplotypes, 
with large effect sizes, now present in detectable amounts due to the extreme 
enriching, but with little relevance on the population level or for practical neurology. 
However, the pattern of improved linkage signals persists in the Australian 





The detection and replication of the 10q22-q23 locus is the first time when a single 
locus has been linked to migraine susceptibility in multiple populations within a 
single paper, and was the first study in which the same markers showed significant 
evidence of linkage to migraine. The considerably high LOD score in the female 
group especially provides strong evidence that some key part of the susceptibility 
resides at this locus. Furthermore, the results of this study confirm the usefulness of 
trait component analysis in migraine genetics. In comparison between the different 
phenotyping approaches, it performed consistently better than latent class analysis, 
and considerably better than the diagnosis-based approach. Encouragingly, the trait 
component analysis was better or at least equally good at detecting every locus in both 
Study I and II, suggesting that the gain in power through traits is consistent across 
different underlying inheritance models and haplotype frequencies. 
 
In these first two studies, we were able to address Aim 1 (the development of a new 
migraine phenotyping method) quite well with the application of TCA to several 
clinic-based samples and one population-based sample (the Australian linkage scan). 
As a result, we provided valuable new insights into the practice of migraine linkage 
scans. For Aim 2a (studying rare variants through linkage scans), we succeeded 
reasonably well by identifying and replicating of a number of new loci, including the 
strongly linked locus on 10q22-q23. However, we have been unable to find the 
responsible genes at the locus. So Aim 2a has not been an unqualified success and 
work on the 10q22-q23 locus continues. 




3. Candidate Gene Study of 155 Ion Transport Genes 
 
In Study III, we employed a custom-made Perlegen genotyping assay covering 5,257 
SNPs targeting 155 ion transport genes. These genes were selected from publicly 
available databases based on function as ion channels, following on the channelopathy 
hypothesis (see Figure 20). An initial scan of 841 unrelated migraine samples and 884 
unrelated controls failed to detect any significant associations. However, given the 
relatively low power to detect common variants with this sample size, we selected all 
SNPs with an allelic p-value < 0.005 (n=66) for follow-up study. No SNPs showed 
significant association to migraine, and thus we conclude that common variants of 
moderate effect size in ion transport genes do not play a major role in susceptibility to 
common migraine within these European populations. Similarly, the three known 
FHM genes showed no association in the screen, which is in line with previous 
research by our group (Kaunisto et al., 2005). 
 
3.a. Target selection 
The “common variant – common disease” hypothesis proposes that common diseases 
rise from the genetic effects of variants of relatively high frequency in the general 
population, which explains why certain diseases are common. From an evolutionary 
point of view, these common variants would possess only minimal effect on 
reproductive capability, involving largely diseases appearing after fertility period 
(neurodegenerative diseases, metabolic syndrome etc.), and thus escape evolutionary 
pressures.  
 
Before it was possible to use GWA data, which at the time was prohibitively 
expensive, educated guesses had to be made in the selection of target genes in order to 
study the role of common variants in ion channel genes. Based on the fact that FHM 
studies successfully identified causative genes that are all ion channels, we targeted 
all available ion channel genes (including the three FHM genes) based on the data-
mining of the available biological databases (such as the Kyoto Encyclopedia of  
 
Figure 20. The research plan for Study III. SNP – single nucleotide 
polymorphism. 













Genes and Genomes [KEGG] at genome.jp/kegg) for known ion channel genes. An 
initial list of 768 partially overlapping genes from the various databases was 
eventually reduced to 155 based on the reliability of their detection and the quality of 
available data (see Table 11). Regions covering the genes with an additional 20 kb at 
the 5’ end and 10 kb at the 3’ end of each gene were included the study. TagSNPs 
were then selected to cover all common variants with MAF ≥ 10% in the study 
regions with an r2 ≥ 0.8. The resulting total was 5,269 SNPs. These markers were first 
studied in a Finnish sample of 841 unrelated migraine cases and 884 population-based 
controls with SNPs showing p-values <0.005 selected for replication in multinational 
samples from Germany, the Netherlands and Australia. 
 
3.b. No association to common variants either with diagnosis or trait 
component analysis 
In the initial Finnish study sample, no significant association to migraine was 
observed. The SNP with the lowest p-value was rs13276133 (p-value 0.00041); 
however, after multiple testing correction through permutation, the empirical p-value 
was only 0.7713. A total of 66 SNPs in nine genes (ATP2C2, CACNA1E, CACNB2, 
KCNE2, KCNK12, KCNK2, KCNS3, SCN5A and SCN9A) were selected for 
replication.  
 
In the replication analysis, none of the 66 SNPs chosen for replication showed 
consistent evidence of association between cohorts. Given that the estimated power to 
replicate an association at a p<0.05 level from the initial study was over 70% for each 
of the top SNPs, we can be relatively confident that the original associations were 
spurious in nature, especially as even the lowest replication p-value was relatively 
high (rs400922 on chromosome 16; empirical p-value 0.15). The use of TCA did not 
considerably improve results (highest TCA signal was seen with marker rs12996816 
on chromosome 2, which had an allelic p-value of 0.001 using the MA diagnosis, and 
6.32 x 10-5 using the pulsation trait; Bonferroni-corrected significance limit for the 
study was 1.9 x 10-5). For the trait component analysis part of the study, we used the 
traits photo- and phonophobia in addition to pulsation, as they were considered to be 
the best traits based on the 2006 study (Anttila et al., 2006). The top results for the 
other traits were with markers rs13276133 (chr 8q21.11; p-value 0.00021, 
photophobia) and rs12054449 (chr 3p21.1; p-value 0.00031; phonophobia). 
Category Genes on array Voltage-gated calcium channels 26 Voltage-gated potassium channels 74 Voltage-gated sodium channels 14 Chloride channels 21 ATPase ion transporters 20 Total 155 
Table 11. Categories of ion channels and pumps represented in the array. 




3.c. Possible signs of epistasis between ion channel genes 
As many of the ion channels are hetero- or multidimers and thus act together in cells, 
a SNP x SNP epistasis analysis was conducted among the studied SNPs using the 
epistasis analysis option in PLINK (Purcell et al., 2007). Given the large number of 
SNPs available, we followed the recommendation by Blangero et al. (Blangero et al., 
2000) to restrict the analysis to those SNPs that have been chosen for replication for 
showing nominal association (p < 0.005) to migraine. In this analysis, uncorrelated (r2 
= 0.0009) SNPs in genes KCNB2 (rs1431656) and CACNB2 (rs7076100) were found 
to have an interaction p-value (pointwise p-value 1.99 x 10-5, 0.022 after correction) 
that remained significant after Bonferroni correction adjusted for independence of 
tests using SNPSpD (Nyholt, 2004). The interaction estimated from the SNP data 
would confer an OR of 1.64 for migraine. These genes are located on two different 
chromosomes (KCNB2 on 8q13 and CACNB2 on 10p12). However, it should be noted 
that the interaction was only found in the Finnish cohort. It almost replicated in the 
Australian cohort (p=0.057), but no interaction was present in the Leiden cohort (both 
SNPs were successfully genotyped in these three populations only). The CACNB2 
SNP is unfortunately not included in the GWA platform used in Study IV, and so we 
could not replicate the interaction in the larger study. No previously reported 
connection was found between the two by a PubMed search or in any of the relevant 
databases (such as the Kyoto Encyclopedia of Genes and Genomes).  
 
3.d. Conclusions 
The results of this study were fairly straightforwardly negative, both with the 
diagnosis-based approach and the TCA approach. Given that the most likely reason 
for this, not tagging enough of the variation surrounding these genes, was mostly 
excluded as a cause in Study IV, and therefore we concluded that common variants of 
moderate to high effect sizes in these genes do not play a role in migraine 
susceptibility. Untagged rare variants may of course still play a role in these genes, 
and given the known FHM pathology, this may even be likely. However, the answer 
to the role of rare variants in ion channel genes can only be sufficiently answered 
through resequencing. 
 





4. Genome-wide Association Study in Migraine 
 
In Study IV, we performed a genome-wide association study on 2,748 Finnish, 
German and Dutch migraine with aura patients and 10,747 population-matched 
controls. The discovery sample was recruited on the basis of the presence of migraine 
aura at four sites: two German sites, Cologne and Munich, in addition to the Finnish 
and Dutch sites – Helsinki and Leiden, respectively. Genotyping was performed using 
the Illumina HumanHap 610k and 550k arrays at the Sanger Institute with controls 
obtained from existing studies. Initial analysis in this sample set was followed by a 
replication study in four populations (Icelandic, Danish, German and Dutch) and a 
meta-analysis. 
 
4.a. Significant association to marker rs1835740 on 8q22.1 
 
In the genome-wide association analysis, we detected a single marker with association 
to migraine that surpasses the threshold for genome-wide significance, 5 x 10-8. The  
Figure 21. Cochran-Mantel-Haenszel test results for SNP association to 
migraine phenotype around rs1835740 in Study IV. Red line indicates 
level of genome-wide significance (5 x 10-8). Black arrows denote 
recombination hotspots surrounding the identified marker. Asterisk 
indicates the association result of the marker in meta-analysis. 




marker, rs1835740, is located at 98.2 Mb on chromosome 8q22.1 and showed an 
association p-value of 5.12 x 10-9 to the minor allele using the Cochran-Mantel-
Haenszel test (see Figure 21). This SNP has a roughly 21% minor allele frequency in 
the general population, with a considerable geographic gradient towards Asia (where 
the reported risk allele frequency can be as high as 65%). No association was 
observed to any of the previously detected FHM genes or any of the candidate genes 
listed in Chapter 4 of the Review of the literature. Haplotype and conditional analyses 
failed to increase the association signal and no long-range LD was detected, most 
likely due to two recombination hotspots which surround the associating marker 
(denoted by black arrows in Figure 21), suggesting that the causative variant 
underlying the signal is likely to be in close proximity to the detected marker itself. A 
replication study in Danish, Icelandic and German migraine study samples (overall 
2,853 cases and 37,980 controls) replicated the signal on rs1835740. Interestingly, the 
replication was successful not only in migraine with aura samples, as in the primary 
analysis, but also in migraine without aura samples (see Figure 22) although the 
relatively low number of cases in this diagnosis group limits the ability to make 
definitive conclusions for this group, and in a population-based study set (Icelandic 
set) as well as clinic-based sets (German and Danish set).  
 
Given the rarity of migraine patients whose attacks are accompanied by aura in 100% 
of attacks (“MA only”), only 589 were found even with this concerted effort; the 
remaining 2,142 patients suffer from attacks with and without aura (“Both MA, MO), 
with varying proportions of attacks with aura. Interestingly, the MA only group 
showed a fairly uniformly higher association and effect sizes than the Both MA, MO 
group. In the initial GWA, the effect is less marked (OR 1.33 vs. 1.21), suggesting a 
Figure 22. Odds ratios for rs1835740 in each study sample in 
Study IV organized by diagnosis. Asterisk indicates German study 
sample where an outlier control group has been excluded.




Figure 23. Illustration of the theoretical view 
of the migraine diagnoses and symptoms 
underlying the trait component analysis. Black 
arrow denotes the “Both MA, MO” group in 
Study IV, grey arrow denotes the “MA only” 
group. Adapted from Anttila et al. 2006. Used 
with permission. 
possible explanation could be found in the small sizes of the replication sets in this 
group (n=293 for Denmark, n=196 for Iceland). However, an ever smaller sample of 
MA only samples in Iceland (n=137) is still showing an effect size in line with the 
larger MA only samples.  
 
One thing which cannot be clearly stated from this study, however, is whether this 
SNP would be associated with aura or pain, since even though the MO only samples 
show some association (albeit with the small sample sizes in this group, it has to be 
admitted that only limited amount of the conclusions can be drawn for this group), it 
may be argued that this group would contain a number of patients with either lower 
penetrance of the full phenotype (thus limiting the clinical presentation to only 
migraine without aura) or patients where the aura is yet to manifest itself for some 
reason (admittedly an unusual progression, given that aura typically manifests itself 
early in life). However, given that though the sample size of 1,744 MO only patients 
may be relatively small in the normal GWA context, it is still a relatively decent size 
for sub-class analysis. Another possible explanation to the difference in OR between 
the groups - is that because of the differences in the severity of the phenotype, one 
could speculate that the most severe phenotype, MA only, contains the smallest 
proportion of sporadic cases, 
typically considered more likely 
to have a severe phenotype. In 
this sense, the results for the SNP 
rs1835740 conform nicely with 
the view of migraine presented in 
Study I. In Study I (see Figure 
23), we illustrated the 
relationships between the 
diagnosis groups with partially 
overlapping concentric circles, 
reflecting the overlapping nature 
of the migraine diagnoses. The 
arrows indicate the patients 
groups corresponding to the aura 
groups in Study IV. When 
comparing this with Figure 24, 
one can see how the effect size of 
the identified variant increase 
towards the more severe end of 
the spectrum (towards the left 
edge in Figure 23, towards the 
right edge in Figure 24). The 
approach in Study I, where the 
trait component approach was 
used to try to identify more 
severe cases of migraine, in the 
sense that cases with more 
symptoms will be more 
represented in the trait 
phenotypes, and the “severity of 
aura” scale reflected in the results 




Figure 24. Migraine severity spectrum plotted 
against the rs1835740 effect size. MO – 
migraine without aura; MA – migraine with 
aura; FHM – familial hemiplegic migraine. 
of Study IV, show that this kind 
of stratification can be used to 
add power in migraine studies. 
This approach could, after a 
fashion, be considered an analog 
to the extremes-only analysis 
(discussed in Chapter 1) in 
migraine. However, a more 
elegant approach, perhaps by 
using the traits in a principal 
components or a multivariate adaptive regression analysis could yield further 
increases in power. 
 
4.b. An eQTL Study of rs1835740 
 
The associating marker rs1835740 is located between several functionally interesting 
genes on chromosome 8q22.1, and therefore an eQTL study (an analysis of transcript 
expression levels of each gene in a tissue sample compared to common sequence 
variants) was conducted. Umbilical cord cells from the GenCord resource were 
Figure 25. Expression level of the probe targeting MTDH/AEG-1 in 
lymphoblastoid cell lines, partitioned by rs1835740 genotype of the 
individual. Expression level scale is arbitrary and conditional on the 
normalization of the entire dataset. Black pyramids indicate average 
value in each genotype group, and the solid line indicates the linear 
trend line for the group average. Box plot of the same data can be 
seen in Study IV. 




Figure 26. Results of the TRANSFAC binding site analysis (M.Piipari, 
unpublished data) showing a) the conservation of the sequence around rs1835740 
between 98,166,853-98,166,938 bp across 14 species. Bases in grey highlight the 
nkx3-1 binding motif in the sequence; the base in black is variant rs1835740. b) 
the nkx3-1 binding motif itself. 
genotyped using a GWA study platform and their expression levels were quantified 
using the Illumina WG-6 array using previously described methods (Stranger et al., 
2007). Of the three types of cells tested, only lymphoblastoid cell lines showed that 
the genotype of this marker strongly correlates with the transcript levels of a nearby 
downstream gene, MTDH/AEG-1 (metadherin/astrocyte-elevated gene 1; see Figure 
25).  
 
The eQTL link between the detected variant and MTDH/AEG-1 provides an 
interesting potential functional effect for the detected association. However, there are 
a number of potential weaknesses to consider in the eQTL approach, requiring further 
study. First, even though the detected eQTL is the only significant one present in 
LCLs for SNP rs1835740, this does not mean the same eQTL is present (or the only 
one) in neural tissue. The two other analyzed tissues, fibroblasts and primary T-cells, 
did not show a significant eQTL effect for this SNP with any genes in the region. A 
genome-wide analysis of eQTLs in these three tissues showed that on average, only 
30% of detected significant signals in one tissue were present in another tissue and 
that most eQTLs are specific to a single tissue (Stranger et al., 2007).  
 
Second, even though the significant correlation between rs1835740 and the transcript 
levels is promising, it does not necessarily mean rs1835740 is the causative variant. It 
is possible (perhaps even likely, given the current opinion on effects of rare and 
common variants) that the common SNP is reflecting the effect of a nearby rare 
variant which is also present in the individuals of the eQTL study. Suggestion of this 
type of effect was present in a binding site analysis we conducted (M. Piipari, 
unpublished data, see Figure 26,), where a potential nkx3-1 factor binding site was 
located only 44 base pairs from the SNP (see Figure 26). However, recent studies 
have suggested this kind of modulation through eQTL variants may underlie most 
GWA findings, and perhaps goes a way towards explaining the missing heritability 
(Nica et al., 2010). 
 




Figure 27. Signal pathway involving MTDH/AEG-1 proposed in Sarkar et al. 2009. Ha-
ras – retrovirus-associated DNA sequence, Harvey type, c-Myc – general transcription 
factor, LSF – Late SV40 transcription factor, DPYD – dihydropyrimidine 
dehydrogenase, ALDH3A1 – aldehyde dehydrogenase 3 family member A1, Met – 
hepatocyte growth factor receptor, NF-kB – nuclear factor-kappaB, PI3K/Akt – 
intracellular signal pathway, ERK and p38 MAPK – MAP kinase pathways, Wnt – 
signaling pathway. Used with permission. 
4.c. Role of MTDH/AEG-1 in neurological diseases 
 
The role and function of MTDH/AEG-1 has generally been studied more in cancer 
(Sarkar et al., 2009), where the gene has been shown to play a role in tumor cell 
proliferation (Li et al., 2009) and angiogenesis (Emdad et al., 2009). MTDH/AEG-1) 
has been shown to be involved in a number of biological pathways, such as the TNF-
alpha (Boycott et al., 2008)/NF-kB (Sarkar et al., 2008) pathway (tumor necrosis 
factor alpha/nuclear factor kappa beta) which is involved in various responses to 
stress and hypoxia (see Figure 27) in brain cells (Dallas et al., 2007).  
 
With clearer links to known migraine physiology, a number of the studied functions 
of MTDH/AEG-1 relate to neuropsychological phenotypes; 1) the FOXO1 
transcriptional factor (Li et al., 2009), and its effect on the PI3K/Akt pathway (Sarkar 
et al., 2009), has been shown to play a direct role in regulating epileptiform activity 
(Shanley et al., 2002) and neuroprotection after epileptic seizures (Shinoda et al., 
2004), and a paper implicating the pathway in autism spectrum disorders (Kwon et al., 
2006) showed that abnormal activation of the pathway results in exaggerated 
responses to sensory stimuli reminiscent of migraine. On a more fundamental level, 
activation of this pathway in Drosophila melanogaster by the analog of the FOXO1 
transcriptional factor, which is regulated by MTDH/AEG-1, has been shown to play a 
role in modulation of neuronal excitability and survival via the PI3K kinase (Al-
Mubarak et al., 2009); 2) MTDH/AEG-1 directly participates in the regulation of 
EAAT2/GLT1 levels (excitatory amino acid transporter 2/glutamate transporter 1). 
EAAT2/GLT1 is the primary glutamate transporter in the brain (Kang et al., 2005) - 
see Figure 28 (Machado-Vieira et al., 2009). The transporter is responsible for 
clearing glutamate from the synaptic cleft. The down-regulation of this transporter is 




Figure 28. Therapeutic targets for pharmacological 
compounds targeting glutaminergic neurotransmission 
(indicated by roman numerals). Numeral VII indicates 
the glial transporters EAAT1 and EAAT2. From 
Machado-Vieira et al., 2009. Used with permission. 
hypothesized to cause increased ambient glutamate levels. Even though Study III 
showed there is no association of common variants in ion channel genes with 
migraine, glutamate homeostasis is indirectly related to ion channel function via the 
complex interplay between ion channels and glutamate. Glutamate receptors directly 
influence ion channel activity via regulation of the intracellular concentration of Ca2+ 
in neurons (Fagni et al., 2000). Furthermore, PI3K influences the levels of ion 
channels that are trafficked into the cell surface (Hou et al., 2008, (Viard et al., 2004). 
In mice brains, the deletion of the FHM gene CACNA1A has a direct effect on 
glutamate release (Lonchamp et al., 2009) and the regulation of glutamate-dependent 
NMDA receptor signalling (Mela et al., 2006). Glutamate receptors are targets for 
anti-epileptic medications (Alexander and Godwin, 2006), anxiety and stress 
disorders (Swanson et al., 2005) and schizophrenia (Patil et al., 2007). In summary, 
there is a considerable amount of evidence showing that the functions of MTDH/AEG-
1 (see Figure 27) extend beyond cancer, and that through regulation of EAAT2/GLT1 
it is a strong candidate for migraine. 
 
4.d. Population-based results show considerable overlap with linkage 
findings 
 
Interestingly, in Study IV the genome-wide association analysis show several 
promising association peaks in the previously identified linkage regions. For example, 
in the Finnish study sample, the highest association result (SNP rs16940918; p-value 
6.9 x 10-8, roughly comparable to LOD score of 6.34 based on the formulae by Nyholt 
et al. (Nyholt, 2000); V. Anttila, unpublished data) is located close to the marker 
D17S945 (LOD score 4.65) reported in Study I (see Figure 29). In the linkage study, 
this peak was observed primarily with the pulsation trait, and in the GWA study the 
best trait was aggravation by physical exercise. Interestingly, these two traits are 
considered to best reflect the peripheral sensitization component of migraine, which 




Figure 29. Plot showing linkage scan results from Study I (solid 
and dashed lines show parametric (PL) and non-parametric 
(NPL) multipoint linkage results. Individual dots show SNP 
marker association results from the Finnish study sample in Study 
IV. Note: the two y-axes are not directly comparable; see text. 
Figure 30. Results of the Finnish GWA association study 
sample, using a) migraine diagnosis and b) aggravation 
trait component. 
drives the central sensitization and contributes to the neurogenic inflammation 
(Pietrobon et al., 2003). Using trait component analysis, the top p-value rises to 2.6 x 
10-9 (see Figure 30). The combination of these results suggests that this locus could 
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can be inferred from them. One interesting finding is the two associations to 18q12 in 
the region immediately surrounding the DCC gene (deleted in colorectal carcinoma), 
which encodes the netrin 1 receptor that guides axonal growth cones of neurons and is 
a promising functional candidate gene. 
4.e. Conclusions 
In Study IV, we were able to detect and convincingly replicate the first SNP 
association in migraine. The identification of this variant, along with the eQTL link to 
a potentially interesting biological mechanism, is a promising finding. Given that the 
identification was made in migraine patients that are very strongly ascertained for 
severe migraine at headache clinics, and that the signal is strongest in the pure MA 
group, which is quite rare – perhaps 0.5% in the population, raises the possibility that 
this variant will only be useful in the specialist clinic setting and not on the population 
level. Initial results from the Health2000 control population used in the study, where 
we were able to gain self-reported headache phenotypes, the variant frequency did not 
differ between those reporting headache (for any cause) and those without; 
frequencies were 22.14% and 21.96%, respectively, compared to around 25% in the 
pure MA cases.  
 
An interesting future study will be to see whether the trait component analysis can be 
used to increase the detection resolution further in GWA studies as well. If this turns 
out to be the case, the increase in power due to being able to stratify MO patients into 
more and less severe cases should be of special significance in GWA studies of MO, 
where a clear diagnostic marker like aura is not present to help in distinguishing 
correct phenotypes. 
 
With the current sample size, we are largely able to exclude the role of common high-
impact variants in migraine. Further, the lack of results to any of the previously 
reported candidate genes in any of the study populations suggests that the 
considerable heterogeneity in migraine may at least partially explain those reports. 
Upcoming migraine GWA scans will be able to answer this question more 
thoroughly, especially regarding MO. In the meantime, the MO association observed 
in this study is not significant enough to draw strong conclusions, as the numbers of 
samples are fairly low. However, the MAF excess of 3% between the MO only cases 
(23.2%; n = 1,744) and controls (20.3%; n = 37,980) represents some 55 extra 
individuals carrying the risk allele, which is a fairly large number of samples to 
attribute to low penetrance or unusual symptom progression. The results thus suggest 
that the most likely explanation for the variable amount of association in the Both 
MA, MO group is the small individual replication sample size, given that the meta-
analysis results are in line with the current migraine spectrum theory (see Chapter 3). 
 
For Aim 2b (studying the role of common variants in migraine through a GWA 
study), we report success. We identified the first SNP, rs1835740, with genome-wide 
significant association with migraine. We were also able to propose a functional 
mechanism for it, which brings forward the study of migraine genetics. The trait 
component analysis of GWA data is still ongoing, but it appears to be useful in 
improving association signals. 




CONCLUDING REMARKS AND FUTURE PROSPECTS 
 
Despite the monumental efforts of the last several years, understanding the genetic 
basis of common diseases remains an elusive goal. A large number of positive 
associations have been reported, but the small effect sizes across the board suggest 
either that the detection is incomplete (Maher, 2008). Possible explanations for this 
may be that the common markers detected are tagging still unknown rare variants, in 
which case the estimates for effect size as well as the proportion of genetic variance 
explained are incorrect, or that some unknown mechanism (such as genotype-
dependent alternate splicing) is acting between the variants and biology (Nica et al., 
2010), or that we simply do not understand genetics to a sufficient depth. How to 
uncover the hidden heritability remains one of the most important open questions in 
the field. However, promise of a better understanding of common variants was 
provided by a recent study in schizophrenia and bipolar disorder reporting strong 
evidence that the heritability in those disorders is due to at least hundreds of common 
variants (Purcell et al., 2009). 
 
As discussed in Chapter 4, the findings of published linkage studies in migraine 
heavily suggest that at least ten loci may play a role in migraine. The first GWA 
results suggest that the story of migraine genetics is likely similar to those of 
schizophrenia and bipolar disorder. Even though the results of the candidate gene 
approach in migraine have been mixed at best and some of our existing data not yet 
published (e.g. an upcoming Norwegian MO study, V. Anttila, unpublished data) 
show little or no role of the previously identified candidate genes, the linkage scan 
results in migraine are encouraging. Published linkage scans in migraine, including 
those in this thesis, show a considerable amount of overlap with each other, which is 
to an even larger degree than the findings in bipolar disorder or schizophrenia 
(Oedegaard et al., 2010). The overlap suggests that there might be common mutation 
targets in elements of the migraine pathogenesis. Even though overlapping linkage 
findings do not necessarily indicate the existence of the same causative variant or 
mutation, they do support the idea that migraine-related mutations concentrate in the 
same genes. Therefore loci like 4q24, 10q22-q23 and 18q12 provide promising targets 
for future resequencing and epistasis studies. 
 
One important problem in the studies of the genetic background of migraine is the 
dynamic nature of the disease. We aimed to address this issue in our data collection. 
The questionnaire asks about the presence of symptoms at any time and for a self-
reported estimation of the number of lifetime migraine attacks (the number of both all 
attacks and severe attacks). However, current collection methods may be inadequate 
to reflect the difference between, for example, constant rates of attacks over several 
decades versus brief but active attack periods. Brief but active attack periods may 
result from a combination of unusual psychological and environmental exposures 
rather than genetic predisposition. The nature of migraine is a challenge for the 
practice of strict diagnostic dichotomy. Many patients develop and lose symptoms of 
migraine over time. Therefore, the inclusion of longitudinal information would be an 
interesting approach for genetic studies, which has not been studied thus far. It will be 
very interesting to see what advances in expression studies and proteomics will offer 
for migraine diagnostics in the future.  





It is entirely possible that the susceptibility to particular symptoms has a distinct 
biological background and that their appearance and disappearance over time is 
modulated by other unknown factors (including normal physiological changes, like 
those in the hormone balance). Even though finding the genetic cause of a particular 
symptom does not necessarily reveal the causes for the onset of a migraine attack, it 
provides new insights into the processes that shape the course of a migraine attack. 
For example, the finding that more linkage information is captured by considering 
only individuals with sensory symptoms (photo- and phonophobia) and not all MA 
patients suggests that variations within the locus on 4q24 may reveal something of the 
pathophysiological processes involved in the triggering of visual and auditory 
symptoms specific to the corresponding cortices (or their modulation by other regions 
of the brain). Due to the nature of complex disorders, pathways and mechanisms 
found in this way would probably not be specific to migraine, but to overall brain 
function. However, proper understanding of complex network effects of this type calls 
for a new kind of integration of proteomic, genomic and systems biology approaches.  
 
Regardless of these limitations, sufficiently large sample sets have yielded a number 
of interesting insights into the underlying pathophysiology of a number of common 
diseases. The insights show promise for future personalized medicine and basic 
research. The main achievement of this study is the several new targets identified for 
future studies in migraine, which remains a relatively poorly understood disorder both 
in terms of genetics and pathophysiology. The complexity of the comorbidities, 
difficulty of the phenotype and genetic heterogeneity of such a common disorder 
remain major challenges and perhaps explain the relative dearth of migraine research 
groups. However, the first GWA will likely be a good stepping-stone to encourage 
further interest in the disease. The potential of the glutamate hypothesis will hopefully 
stimulate further research. Several genome-wide studies of the genetics of an 
increasing number of migraine patients are being conducte as well as first large-scale 
migraine meta-analysis. The improved imputation prospects arising from the 1000 
Genomes project along with the huge amount of genetic information on migraine 
patients should make the next few years very exciting for migraine research. 
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ARTICLE
Trait Components Provide Tools to Dissect the Genetic
Susceptibility of Migraine
V. Anttila, M. Kallela, G. Oswell, M. A. Kaunisto, D. R. Nyholt, E. Hämäläinen, H. Havanka,
M. Ilmavirta, J. Terwilliger, E. Sobel, L. Peltonen, J. Kaprio, M. Färkkilä, M. Wessman, and A. Palotie
The commonly used “end diagnosis” phenotype that is adopted in linkage and association studies of complex traits is
likely to represent an oversimplified model of the genetic background of a disease. This is also likely to be the case for
common types of migraine, for which no convincingly associated genetic variants have been reported. In headache
disorders, most genetic studies have used end diagnoses of the International Headache Society (IHS) classification as
phenotypes. Here, we introduce an alternative strategy; we use trait components—individual clinical symptoms of mi-
graine—to determine affection status in genomewide linkage analyses of migraine-affected families. We identified linkage
between several traits and markers on chromosome 4q24 (highest LOD score under locus heterogeneity [HLOD] 4.52),
a locus we previously reported to be linked to the end diagnosis migraine with aura. The pulsation trait identified a
novel locus on 17p13 (HLOD 4.65). Additionally, a trait combination phenotype (IHS full criteria) revealed a locus on
18q12 (HLOD 3.29), and the age at onset trait revealed a locus on 4q28 (HLOD 2.99). Furthermore, suggestive or nearly
suggestive evidence of linkage to four additional loci was observed with the traits phonophobia (10q22) and aggravation
by physical exercise (12q21, 15q14, and Xp21), and, interestingly, these loci have been linked to migraine in previous
studies. Our findings suggest that the use of symptom components of migraine instead of the end diagnosis provides a
useful tool in stratifying the sample for genetic studies.
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Migraine (MIM 157300) is the most common cause of
chronic episodic severe headache, affecting 10%–12% of
the adult population.1 The genetic component of migraine
has been well established in family and twin studies.2–6
Several loci linked to common forms of migraine with
significant evidence of linkage have been reported,7–15 yet,
to date, no genes responsible for susceptibility to the com-
mon types of migraine, migraine without aura (MO) and
migraine with aura (MA), have been described. Thus far,
three genes, CACNA1A (MIM 601011), ATP1A2 (MIM
182340), and SCN1A (MIM 182389), which contribute to
familial hemiplegic migraine (FHM1–3 [MIMs 141500,
602481, and 609634, respectively), a rare Mendelian sub-
type of MA, remain the only genes found in headache
disorders.16–18
Most studies aiming to unravel the genetic basis of head-
ache disorders use the end diagnoses of the International
Classification of Headache Disorders (later referred to as
“International Headache Society [IHS] classification”) as
the phenotype when monitoring for linkage or asso-
ciation19,20 (appendix A). Although diagnosis-based phe-
notypes have been successfully used to identify predis-
posing loci and even genes in some complex traits,21–23 it
is likely that they represent an oversimplified model of
the genetic background of a disease, which in reality is
complex and polygenic. In some complex diseases, the
use of clinical traits (referred to as “quantitative traits,”
“endophenotypes,” or “trait components”)—for example,
lipid values, components of language deficits, or allergy-
related phenotypes—provides an opportunity for a more
refined analysis.24–28 These traits probably reflect features
that are closer to the molecular background of the disorder
than the clinical classification, which represents a con-
sensus among clinicians. The development of alternative
phenotypes and/or endophenotypes would be especially
useful for headache disorders, for which diagnosis is typ-
ically based on the patient’s description of attacks and no
laboratory, radiological, or any other objective, quanti-
tative findings are used for diagnostics.
The diagnosis and classification of migraine and its sub-
types are based on the fulfillment of symptomatic criteria,
summarized in the IHS classification (appendixes B and
C). Since the migraine diagnosis consists of a combination
of traits and/or symptoms, a single affected individual has
to present with several traits simultaneously; furthermore,
the individual traits are not completely independent of
each other (fig. 1). The clinical traits and trait groups form-
ing the basis of the IHS classification provide a natural
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Figure 1. Schematic illustration of some relationships between
diagnoses and traits in the 2004 IHS classification. Overlapping
circles highlight the fact that each patient can have a unique
combination of symptoms, and not all symptoms are needed to
fulfill the criteria of the end diagnosis migraine. The circles and
their overlapping surface areas do not represent population prev-
alence; the figure serves purely as an illustration. a, Relationship
between MA and MO diagnostic groups indicating that some pa-
tients may be categorized as having purely MA type or purely MO
type of attacks, but a considerable number of patients have both
types. b, Relationships between traits in the IHS criteria, illus-
trating that, although criteria B–D are not shared by all patients
with MA, those with typical aura with migraine headache have to
fulfill the MO criteria as well. c, Breakdown of the vascular head-
ache trait group. The shaded area indicates patients who fulfill
IHS criteria C; at least two of the individual traits have to co-
occur (e.g., pulsation and unilaterality).
and clinically plausible way to monitor for possible trait
correlations. Although these criteria work well in clinical
settings, they still define a very broad syndrome. For ex-
ample, the criteria classify both a severe, one-sided, and
pulsating headache and a moderate, bilateral, and dull
headache as migraine, if the other IHS-defined features are
present. Allowance for variability is clearly needed for clin-
ical purposes, but a more narrow definition, especially one
that uses individual traits that can be quantified, might
serve better in dissecting the underlying pathophysiolog-
ical mechanisms of migraine. Since the use of one specific
trait, motor weakness, led to the discovery of genes caus-
ing FHM,18 a similar approach might be useful in more
common forms of migraine. A similar division of the fea-
tures of migrainous headache could contribute to the se-
lection of a more homogeneous study sample.
In summary, since migraine is a syndrome instead of a
clearly differentiated disease, we hypothesized that indi-
vidual clinical components of migraine (i.e., traits such as
pulsating pain and photophobia, among others) might
represent reflections of specific rather than shared loci and
thus independently contribute to susceptibility to mi-
graine. To test this hypothesis, the individual traits and
trait groups of the IHS criteria were used as phenotypes
for genomewide linkage analyses. These analyses were per-
formed using the same data set of 50 families as was used
in our previous study, in which evidence of linkage to
chromosome 4q24 was detected using end point diagnosis
MA as the trait.7 By use of the trait-based approach intro-
duced here, individuals from both the MA and the MO
diagnosis groups could potentially be scored as affected.
This reflects the sharing of the studied traits by migraine
diagnoses 1.1 (migraine without aura [appendix B]) and
1.2.1 (typical aura with migraine headaches [appendix C]).
Our hypothesis was that the shared components of the
two IHS diagnoses might result in migraine phenotypes
more reflective of the underlying biological processes than
would a strict adherence to the end diagnoses. Here, the
aim was to analyze which IHS traits provide best evidence
of linkage to the 4q24 locus and whether additional sus-
ceptibility loci could be localized.
Material and Methods
Diagnoses
The study sample consisted of 438 genotyped individuals (186
men and 252 women) in 50 independent, multigenerational
Finnish families and was the same set that was used in our pre-
vious genomewide screen.7 The ethics committee of Helsinki
University Central Hospital approved the study protocol. The in-
clusion criterion for the families selected for the previous ge-
nomewide screen was a high prevalence of MA within the family.
Various migraine features concerning the aura, headache, pro-
voking factors, and prodromal symptoms were recorded by one
neurologist (M.A.K.) on the basis of the validated Finnish Mi-
graine Specific Questionnaire for Family Studies.29 Detailed selec-
tion and case-definition procedures have been reported else-
where.7 In the previous study, 246 individuals received a diagnosis
of MA, and 50 individuals received a diagnosis of MO. In the
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Table 1. Frequencies of Individual Trait Components and Trait Groups
and the Sex Proportions of Those Affected, According to IHS Criteria,20
in the Study Sample
Trait or Trait Group







Full criteriaa: 225 52.3 26.2 73.8
Attack length 241 56.0 29.5 70.5
Vascular headache criteriaa: 322 74.9 33.9 66.1
Unilateral headache 327 76.0 34.3 65.7
Pulsating headache 235 54.7 27.2 72.8
Intensity, moderate and/or severe: 315 73.3 32.4 67.6
Unbearable 109 31.6 27.5 72.5
Severe 136 31.6 28.7 71.3
Moderate 70 16.3 47.1 52.9
Aggravated by physical activity 239 55.6 29.7 70.3
Associated symptomsa: 298 69.3 30.5 69.5
Nausea and/or vomitinga: 266 61.9 30.1 69.9
Nausea 266 61.9 30.1 69.9
Vomiting 173 40.2 31.8 68.2
Photo- and phonophobiaa: 229 53.3 25.8 74.2
Photophobia 265 61.6 30.6 69.4
Phonophobia 234 54.4 26.5 73.5
a A trait group.
present study, the updated IHS classification (2004) was used.
Under the new classification, 225 individuals fulfilled the IHS
criteria shared between MO (1.1 in the IHS diagnoses) and typical
aura with migraine headaches (1.2.1). This constitutes 49% of the
study sample.
Formation of Phenotypes from the Individual Traits and
Trait Groups
Altogether, nine individual traits (attack length, pulsation, uni-
laterality, aggravation by physical exercise, intensity of pain, pho-
tophobia, phonophobia, nausea, and vomiting) and five trait
groups (IHS full criteria, pain criteria, associated symptoms, nau-
sea and/or vomiting, and photo- and phonophobia) were ana-
lyzed independently as phenotypes in the linkage analysis. Table
1 summarizes the relative frequencies of the features of migrain-
ous headache in the study sample as reported by the patients,
defined by the IHS criteria, and used as traits in the analyses. The
important distinction between the individual traits and the trait
groups is that the individual traits reflect a distinct migraine fea-
ture, whereas the trait groups reflect a clinical consensus.
Since all individuals with vomiting also experienced nausea,
the nausea and the nausea and/or vomiting categories were equal,
and thus the nausea trait was not analyzed. In addition to the
IHS traits, we also used the age at onset of migraine symptoms
as a trait. Age was dichotomized to those individuals with the
onset of migraine symptoms before age 20 years (211 individuals)
and those with a later onset (64 individuals).
Genotyping
The process of the genomewide screen has been described in de-
tail elsewhere.7 Briefly, this screen covered all autosomes and the
X chromosome and used 350 polymorphic microsatellite mark-
ers, with an average of 11 cM between loci. In the fine-mapping
phase, 14 new microsatellite markers were analyzed (9 on chro-
mosome 17 and 5 on chromosome 18). For fine mapping, cap-
illary electrophoresis, as employed by the MegaBACE 1000 DNA
Sequencing System (GE Healthcare Bio-Sciences), was used to sep-
arate DNA fragments. Alleles were called by the MegaBACE Ge-
netic Profiler 1.5 software (GE Healthcare Bio-Sciences).
Linkage Analyses
Parametric and nonparametric LOD scores were calculated using
an affecteds-only strategy (i.e., all individuals not scored as af-
fected were considered as unknown) for the 350 markers geno-
typed. For parametric analysis, a dominant mode of inheritance
and locus heterogeneity was assumed. Each of the IHS traits and
trait groups were analyzed, in turn, as the phenotype. All analyses
were performed with the disease-gene frequency set at 0.001, un-
der the assumption of autosomal dominant inheritance and a
phenocopy proportion of 2.4%, reflecting the frequency of MA
in the population,7,30 in accordance with the strategy proposed
by Göring and Terwilliger31 and in line with our previous research.
Allele frequencies were calculated from the genotypes of all in-
dividuals. The mistyping option of the SimWalk2 program32 was
used to detect genotyping errors. In case of bilineal family struc-
ture, the affected married-in spouse, as well as the offspring, were
treated as unknown. The initial linkage analysis was performed
using a two-point approach—that is, by using a single marker
and the trait. The components of the IHS migraine criteria were
used as the phenotype. Two-point parametric linkage analysis was
performed both under locus homogeneity and under locus het-
erogeneity by the computer programs LINKAGE33 and HOMOG.34
To lessen the dependence of our results on the assumption of a
dominance model, we also completed an affected sib pair (ASP)
analysis. The identity-by-descent (IBD) status of each ASP was
estimated using the program Sibpair, which favors a recessive
mode of inheritance. The ANALYZE utility program31 was used
to conduct these analyses. Multipoint parametric and nonpara-
metric analyses were performed for regions showing evidence of
linkage in the parametric two-point analysis by use of the pro-
gram GENEHUNTER,35 version 2.1_r5beta. Parametric linkage
analysis was performed using the model presented above, while
allowing for locus heterogeneity. The nonparametric statistic
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Table 2. Correlation Matrix of the Analyzed Traits and Trait Groups
Trait a b c d e f g h i j k l m n
a 1.000 .944 .710 .623 .698 .639 .707 .773 .685 .685 .476 .658 .674 .663
b .944 1.000 .753 .620 .739 .649 .736 .706 .625 .625 .434 .604 .657 .623
c .710 .753 1.000 .737 .975 .747 .954 .884 .794 .794 .573 .706 .798 .720
d .623 .620 .737 1.000 .716 .720 .705 .716 .661 .661 .511 .646 .679 .643
e .698 .739 .975 .716 1.000 .734 .930 .882 .787 .787 .556 .701 .791 .714
f .639 .649 .747 .720 .734 1.000 .723 .700 .668 .668 .493 .596 .657 .601
g .707 .736 .954 .705 .930 .723 1.000 .879 .787 .787 .565 .710 .791 .724
h .773 .706 .884 .716 .882 .700 .879 1.000 .894 .894 .632 .784 .814 .784
i .685 .625 .794 .661 .787 .668 .787 .894 1.000 1.000 .707 .648 .695 .651
j .685 .625 .794 .661 .787 .668 .787 .894 1.000 1.000 .707 .648 .695 .651
k .476 .434 .573 .511 .556 .493 .565 .632 .707 .707 1.000 .481 .458 .490
l .658 .604 .706 .646 .701 .596 .710 .784 .648 .648 .481 1.000 .880 .982
m .674 .657 .798 .679 .791 .657 .791 .814 .695 .695 .458 .880 1.000 .860
n .663 .623 .720 .643 .714 .601 .724 .784 .651 .651 .490 .982 .860 1.000
NOTE.—Correlations were determined across individuals and are not dependent on relatedness of cases. Traits are as follows: a p
full criteria; b p attack length; c p vascular headache criteria; d p unilaterality; e p pulsation; f p pain intensity; g p aggravation
by physical exercise; h p associated symptoms; i p nausea and/or vomiting; j p nausea; k p vomiting; l p photo- and phonophobia;
m p photophobia; n p phonophobia.
NPLall, which estimates the statistical significance of alleles shared
IBD between all affected family members, was calculated also.
To address the multiple-testing issue and to determine the sig-
nificance of the results, we applied the equation introduced by
Kidd and Ott.36 They suggest that the lower limit of a significant
result in a genomewide scan is 3 plus the base 10 logarithm of
the number of independent tests performed. An addition of 0.3
to the significance limits is necessary to take into account the
extra df from the heterogeneity LOD (HLOD) calculation. Since
the traits we studied are not independent of each other, a cor-
relation matrix of the phenotypes was constructed (table 2), and
the software matSPD (see Web Resources) was used to calculate
the overall correlation coefficient to determine the equivalent
number of independent traits.37–39 This analysis showed that the
original 14 traits (where the one duplicate trait, nausea, is elim-
inated by the analysis) and trait combinations correspond to just
five independent variables; thus, the lower limit of significant
evidence of linkage is 4.00. That is, because of the high correlation
between the 14 traits, they behave statistically like five effectively
independent traits. Similarly, the lower limit of suggestive evi-
dence of linkage is 1.6 plus the base 10 logarithm of the number
of tests plus 0.3, which equals 2.60. These limits are only slightly
less conservative than the ones obtained using the most conser-
vative correction based on the number of tests. Finally, to further
determine the significance of the observed LOD scores, we sim-
ulated the marker with the best observed LOD score (D17S945)
in 10,000 replicates of the pedigree set, assuming no linkage and
using the program SIMULATE.40 The tested limits were the best
observed LOD score (4.65) and the approximations of the sig-
nificance limits (4.00 and 2.60). These three limits were reached
zero, zero, and five times by chance in the simulated data sets,
with the highest result 3.19, which is less conservative than our
significance limit obtained from the trait correlation matrix.
Results
Linkage to 13 migraine-related traits was analyzed in a
genomewide scan of 438 individuals from 50 migraine-
affected families enriched for MA. Significant evidence of
linkage was observed with the individual traits pulsation
(17p13), photophobia (4q24), phonophobia (4q24), and
age at onset (4q24) (fig. 2 and table 3). With the trait
combinations, suggestive evidence of linkage was ob-
served with photo- and phonophobia (4q24) and IHS full
criteria (18q12), a combination of the shared traits of di-
agnoses 1.1 and 1.2.1 of the IHS 2004 classification that
includes individuals classified with MA and/or MO as their
end diagnosis. Table 3 shows the significant and suggestive
two-point LOD scores found.
MA Locus on 4q24
Our previously reported and replicated MA locus on
4q247,15 showed significant evidence of linkage to pho-
tophobia (two-point HLOD 4.39) and phonophobia (4.10)
and suggestive evidence of linkage to pain intensity (3.71),
unilaterality (3.25), and pulsation (3.14) as well as the
photo- and phonophobia trait group (3.97) and the as-
sociated symptom trait group (2.98) (fig. 3a) with marker
D4S1647. With the trait photophobia, GeneHunter mul-
tipoint parametric (HLOD 2.05) and nonparametric (NPLall
4.13) analyses positioned the peak at 103 cM and 92 cM,
respectively (fig. 4a).
New Locus on 17p13.1
Significant evidence of linkage was found between the
pulsation trait and marker D17S945, where a two-point
HLOD score of 4.65 was detected (fig. 3b). This encour-
aging result triggered us to fine map the region with nine
additional markers, providing a map interval of 1.7 cM.
These markers supported the existence of a susceptibility
locus in this region. GeneHunter multipoint parametric
(HLOD 3.46) and nonparametric (NPLall 3.94) tests posi-
tioned the peak at 19.4 and 22.0 cM for the pulsation trait
(fig. 4b). Other IHS traits showed, at best, nearly suggestive
evidence of linkage to this locus, the highest of which was
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Figure 2. Results of the parametric two-point linkage analysis under heterogeneity for genomewide screen with the end diagnosis
MA, the trait components and trait groups, and age at onset used to determine affection status. The lower significance limits are 4.00
for significant evidence and 2.60 for suggestive evidence of linkage. Arrows denote markers with significant or suggestive results.
between the trait vomiting and marker D17S945 (HLOD
of 2.07).
Loci Providing Suggestive Evidence of Linkage
The second new locus was detected on 18q12.1 with
marker D18S877 (fig. 3c) and the IHS full criteria (two-
point HLOD 3.29). With this marker, individual traits
showed suggestive evidence of linkage, with vascular cri-
teria (3.14), attack length (3.00), and aggravation by phys-
ical exercise (2.77) showing the highest LOD scores. In
addition, vomiting and nausea showed nearly suggestive
evidence of linkage at this locus (HLOD 2.66). Neither of
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the adjacent markers of the 10-cM marker set (D18S453,
12 cM proximal, and D18S535, 11.5 cM distal) provided
supportive evidence of linkage with any trait. In spite of
this, we decided to fine map this locus with five additional
markers, providing a map interval of 3.2 cM. Two markers
supported a locus in this region, with suggestive (D18S56
and aggravation by physical exercise) and nominal
(D18S1107 and attack length) evidence of linkage. Gene-
Hunter multipoint parametric analysis positioned the
peak at 50.0 cM, with an HLOD of 1.53 (fig. 4c) with the
IHS full criteria. At this position, however, the NPLall score
was 3.40 (at 51.0 cM), suggesting that perhaps the para-
metric dominant model was not a good fit for this trait.
By use of the ASP method and the IHS full criteria, marker
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Table 3. Locations and Two-Point LOD Scores for Traits or Trait Groups
Providing a LOD Score 12.60 in the Genomewide Screen in at Least One
Analysis
Marker (Location)
















Age at onset 1.86 .001713 1.96 .005482 2.93
D4S1647 (4q24):
Age at onset 4.53 .000002 4.53 .000015 4.02
Photophobia 4.39 .000003 4.39 .000020 2.20
Phonophobia 4.10 .000007 4.10 .000040 2.81
Photo- and phonophobiaa 3.97 .000010 3.97 .000054 2.76
Intensity 3.71 .000018 3.71 .000097 2.60
Unilaterality 3.25 .000055 3.25 .000281 2.88
Pulsation 3.13 .000073 3.14 .000362 3.49
Vascular headachea 3.09 .000081 3.09 .000406 2.30
Associated symptomsa 2.98 .000106 2.98 .000524 2.28
Nausea 2.46 .000382 2.46 .001734 3.28
Vomiting and/or nauseaa 2.46 .000382 2.46 .001734 3.28
Attack length 1.18 .009874 1.24 .028772 2.61
D4S2394 (4q28):
Age at onset 2.99 .000233 2.99 .001094 .25
D4S1520 (4q31):
Phonophobia 2.66 .000257 2.66 .001199 .82
Photo- and phonophobiaa 2.62 .000257 2.62 .001199 1.06
D17S945 (17p13):
Pulsation 4.65 .000002 4.65 .000011 .82
D18S877 (18q12):
IHS full criteriaa 1.06 .013573 3.29 .000256 .26
Vascular headachea .92 .019779 3.14 .000362 .42
Attack length .95 .018236 3.00 .000500 .09
Aggravation by physical exercise 1.24 .008432 2.77 .000849 .03
D18S862 (18q21):
Aggravation by physical exercise 1.75 .002264 2.69 .001021 1.21
D18S1364 (18q22):
IHS full criteriaa .03 .364661 .17 .338041 3.04
Attack length .18 .181291 .29 .256431 2.71
a A trait group.
D18S1102, 8 cM distal of the parametric two-point HLOD
peak, provided an ASP LOD score of 3.04. Adjacent mark-
ers D18S56 and D18S535 provided ASP LOD scores of 1.72
and 2.20, respectively.
In addition to the locus on 4q24, a second region on
4q, 4q28-q31, indicated suggestive evidence of linkage
with multiple traits and age at onset. Among the traits,
the highest evidence of linkage was observed between
marker D4S1520 and the traits phonophobia (HLOD 2.66)
and photo- and phonophobia (HLOD 2.62). Furthermore,
several markers around marker D4S1520 showed nearly
suggestive evidence of linkage with the same traits.
Loci Providing Nominal Evidence of Linkage
In addition to the chromosomal loci on 4q24, 4q28,
17p13, and 18q12, four other loci with nearly suggestive
evidence of linkage were observed on 10q22, 12q21,
15q14, and Xp21. Marker D10S2327 produced a two-point
HLOD score of 2.27 with phonophobia. On chromosome
12q21, marker D12S1064 produced an HLOD score of 2.17
with the aggravation by physical exercise trait. However,
none of the surrounding markers supported linkage to
these loci. On 15q14, aggravation by physical exercise pro-
duced a two-point HLOD score of 2.14 with marker ACTC.
On Xp21, aggravation by physical exercise produced an
HLOD of 1.92, associated symptoms an HLOD of 1.91,
and unilaterality an HLOD of 1.90 with marker DXS9896.
At these two loci, a number of adjacent markers also pro-
vided nominal evidence of linkage to several traits (three
for 15q14 and seven for Xp21).
Age at Onset
In addition to the IHS traits, we analyzed the age at onset
of migraine as a trait. Age was dichotomized to consider
those patients whose migraine symptoms began before
age 20 years as affected and the others as unknown. The
analysis showed a significant two-point HLOD score of
4.52 at 4q24 (D4S1647). One other marker (D4S2394) with
Figure 3. Parametric two-point HLOD scores for chromosome 4 (a), chromosome 17 (b), and chromosome 18 (c) for all trait components
and age at onset.
www.ajhg.org The American Journal of Human Genetics Volume 79 July 2006 93
suggestive evidence of linkage was found, on 4q28 (HLOD
2.99), with adjacent markers providing nearly suggestive
evidence of linkage, corroborating the second locus on
chromosome 4. In analyzing for late onset (at age 120
years), no markers showed evidence of linkage reaching
the suggestive level.
Stratification by Sex
In a study of migraine in the Icelandic population,15 link-
age results were improved considerably when the sexes
were analyzed separately. Thus, we analyzed the data by
treating all females and males, in turn, as unknown for
all traits for the chromosomes yielding suggestive or sig-
nificant results. On the 4q24 locus, no significant differ-
ences between the sexes were found. At the 17p13 locus,
the pulsation trait showed a two-point HLOD score of 2.02
for females ( ) and 2.72 for males ( ). At thisn p 174 n p 67
locus, no other trait exceeded that score in males, but the
intensity trait reached a LOD score of 2.34 in females. On
the 18q12 locus, the IHS full criteria produced a nearly
significant two-point LOD score of 3.79 for females (n p
) but a LOD of only 1.95 for males ( ). At this167 n p 63
locus, several other traits produced suggestive results (in
males, 3.41 for the pain criteria, 3.11 for nausea, and 2.92
for intensity; in females, 2.76 for photophobia), but, with
all traits, the sex difference was smaller than the one ob-
served with IHS full criteria. In addition, attack length
produced a LOD score of 3.35 in females and 3.23 in males.
No other significant differences between the sex-specific
phenotypes were found for the two loci.
Discussion
Although introduction of the IHS criteria has done much
to ease the diagnostics of migraine disorders and has had
a major impact on clinical trials and epidemiological re-
search in this field, none of the features occur in all pa-
tients who meet a strict definition of IHS migraine, and
no single symptom is required for diagnosis. In other
words, although there is considerable correlation between
individual symptoms (table 2), migraine is a symptom
complex with variable symptom profiles, and individuals
presenting with dissimilar symptoms can equally satisfy
the same diagnosis (appendixes B and C). In fact, contro-
versy exists about whether MO and MA are actually two
separate entities.41,42 Furthermore, some individuals may
not completely satisfy the IHS criteria but are nonetheless
considered affected in a clinical setting. We therefore hy-
pothesized that examination of individual symptoms and
their subgroupings (i.e., trait components) would provide
considerably greater power than use of the IHS end diag-
nosis to identify genes underlying migraine susceptibility.
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Figure 4. Multipoint parametric HLOD scores (solid lines) and nonparametric NPLall scores (dotted lines) for chromosome 4 and phono-
phobia (a), chromosome 17 and pulsation (b), and chromosome 18 and IHS full criteria (c).
The trait-component analysis identified several traits
that also show linkage to the previously reported MA locus
on chromosome 4q24. Interestingly, the restratification
revealed one novel locus (17p13) with significant evidence
of linkage to the pulsation trait and two other loci with
suggestive evidence of linkage to the traits age at onset
(4q28) and IHS full criteria (18q12).
These findings suggest that dissecting the end diagnosis
into intermediate phenotypes and/or traits might help to
dissect the genetic basis of headache disorders and thus
help to stratify study samples into less heterogeneous
groups. Here, we were able to identify new loci to which
only a subset of migraine-associated symptoms were
linked. This supports the well-accepted hypothesis in com-
plex traits that specific gene variants in different loci
contribute in different combinations to the individual
susceptibility.43,44 However, this can be verified and further
studied only after specific alleles within these loci have
been identified. Trait-based approaches have been used in
several complex traits, such as asthma,45 schizophrenia,46
autism,26 and hyperlipidemias.27 The migraine end diag-
nosis is composed of a number of possibly biologically
diverse components; thus, it is plausible to hypothesize
different biological processes behind these components.
Also, migraine has a distinct set of diagnostic criteria that
provide a good starting point for this type of analy-
sis.19,20 In addition, some biochemical evidence for such
an approach has been found in another common primary
headache disorder. In tension-type headache, patients
with the pulsating subtype seem to have higher calcitonin
gene–related peptide levels than those of patients with
nonpulsating headache.47
Prompted by the differences in the results of the linkage
analysis between individual traits and the end diagnosis
MA,7 we analyzed the differences between the affection
groups contributing to the peaks at 17p13 and 18q12. Of
the individuals in the set pointing to the locus at 17p13,
there were 66 individuals with pulsating headache who
were coded as unknown in the original study, either be-
cause of their lack of aura symptoms or because the mi-
graine was inherited in a bilineal fashion. Conversely,
there were 51 individuals with nonpulsating headache
who were coded as affected in the original study. Com-
bined, this means a total difference of 49.7% (117 of 235)
in the pulsation group classified as affected in this study
compared with our previous genomewide scan. Similarly,
there were 62 affected individuals in the set pointing to
the 18q12 locus who were coded as unaffected in the pre-
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vious study because of a non-MA diagnosis or bilineal fam-
ily structure and, conversely, 61 individuals who did not
fulfill the full shared IHS criteria who were coded as af-
fected in the original study. This resulted in a 52% (123
of 225) combined difference between the group showing
the 18q12 locus and the end diagnosis group.7 Most of
the difference between these groups is the result of the
addition of patients with MO fulfilling the IHS full criteria.
In contrast, from the total of 246 individuals with MA, 62
had an attack length of !4 or 172 h. This causes them to
fall outside of the 1.2.1 (typical aura with migraine head-
ache) diagnostic group, which is new to the IHS 2004
classification. One could speculate that the change in the
classification eliminated excess heterogeneity from the
MA group and thus revealed the 18q12 locus.
It is likely that analyzing the trait components of head-
ache is feasible only in highly selected samples—for ex-
ample, in the present study, in which families with a high
incidence of IHS migraine were considered. For instance,
if a gene for pulsating headache exists, it will most likely
be a small component of the total genetic load that pre-
disposes a patient to the migraine syndrome. In the gen-
eral population, the coexistence of this pulsating factor
and other contributing factors is likely to be rare, but, in
study samples already enriched for the presence of mi-
graine, both elements may have a chance to co-occur and
predispose the patients in the family to a migraine head-
ache that pulsates (“beats with the heart”). Thus, as for
other complex traits, the highly selected families with mi-
graine may be better for identifying some migraine sus-
ceptibility genes and thus make identification of those
genes a realistic goal. This, in the end, could even help to
validate the clinical decisions that form the basis of the
current migraine criteria.
It is interesting that, even though several traits provided
evidence of linkage at the same locus, individual traits
within the main IHS categories provided evidence of link-
age at different loci. For example, the traits in the asso-
ciated-symptoms category (nausea and/or vomiting and
photo- and phonophobia) provided evidence of linkage
at different loci; vomiting and nausea showed nearly sug-
gestive evidence of linkage on chromosome 18q12, and
photo- and phonophobia on chromosome 4q24. Simi-
larly, intensity and pulsation, both traits of the vascular
headache criteria, provided evidence of linkage on differ-
ent chromosomes: 4q24 and 17p13, respectively. This
could suggest that, even if the grouping of IHS symptoms
is logical and practical in clinical practice, it may not re-
flect the genetic background of the susceptibility of in-
dividual traits. This is not very surprising in light of what
is known about the heterogeneity of the clinical findings
in Mendelian forms of migraine. In FHM-affected families,
family members with the same underlying mutation can
have different phenotypes, ranging from severe hemiple-
gic symptoms to MO to having no migraine at all.18 In
other complex traits, the idea of using subgroups of clin-
ical classifications (e.g., DSM-IV in schizophrenia) is under
active study, even though the approach has yet to provide
support for stratifying the sample for susceptibility clas-
sification. However, much of the trait relationship be-
tween susceptibility loci remains speculative as long as
the underlying allelic variants are not identified; because
the linkage information is provided by relatively few mei-
oses, there is a possibility that some of these trait differ-
ences weaken or disappear once association analyses are
performed.
In further analyses, it was found that, at the 18q12 locus,
a few large families provided clearly negative LOD scores
(three families had LOD scores ranging from 1.65 to
2.17), likely contributing to the large difference between
the LOD scores under locus homo- and heterogeneity. By
analyzing the data without those families, the difference
between the scores decreases considerably, with the ho-
mogeneity LOD score rising closer to the level of the
HLOD score. We also observed a large difference between
the sex-specific LOD scores, with a considerably higher
female score. The reason for this difference is not clear, as
it might reflect a true sex difference at this locus or merely
follow from the smaller sample size of males. The sex-
specific analysis is a relevant option in migraine because
of the high difference in prevalence between the sexes.1
At present, several loci, 4q21-q24,7,15 5q21,11 6p12.2-
p21.1,14 11q24,8 14q21.2-q22.3,13 and 15q11-q13,9 with
significant evidence of linkage to common forms of mi-
graine have been reported, with only the chromosome
4q21-q24 region detected in two independent studies. In-
terestingly, the most significant new locus identified in
this study, on 17p13, has shown nominal evidence of link-
age both in our previous study7 and in an Australian
study.10 It remains to be seen whether this locus harbors
a specific variant(s) contributing to the sensation of pul-
sating pain. Our results also seem to corroborate several
other previous findings. The locus on 18q12 has been im-
plicated in an Icelandic study,15 in which the same marker
(D18S877) gave a LOD score of 1.50. That study was con-
ducted using 103 families with MO-affected members,
which ties well with our approach and results. Also, a
marker 13 cM away (D18S53) gave a LOD score of 2.30 in
an Australian study.10 The general observation in migraine,
for which different studies provide different loci, is typ-
ical for complex traits for which finding a causative var-
iation has proven difficult, such as hypertension25 and
schizophrenia.48
Furthermore, it is interesting to note that several of our
findings agree with those from an empirical clustering ap-
proach called “latent class analysis” (LCA), introduced in
a recent article by Nyholt et al.49 and applied to migraine
symptom data in genome scans in two separate collections
of migraine-affected Australian families.10,11 LCA is a sta-
tistical method, closely analogous to cluster analysis, for
finding subtypes of related individuals (latent classes)
from multivariate categorical data.50 Briefly, a latent class
cluster model describes the relationship between a set of
observed variables and an unobserved, latent variable. The
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Table 4. Results of Previous Genomewide Scans in Migraine with Suggestive or Significant LOD Scores









Study Trait in This Study
3q 10 LCA-severea D3S1311 2.28b 1.23 Intensity
4q 15 Loose MOc D4S1534 2.87b 2.00 Pulsation
4q 15 Females-only loose MOc D4S2409 4.08b 2.00 Pulsation
4q 7 MA D4S1647 4.20d 4.53 Age at onset
5q 11 LCA-severea D5S2501 3.03b .03 Intensity
6p 14 MA and MO D6S452 5.41d .83 Vomiting
10q 11 LCA-severea D10S2327 2.32b 2.27 Phonophobia
11q 8 MA D11S4464 4.24d .53 Nausea and/or vomiting
14q 13 MO D14S978 3.70d .18 Attack length
18p 10 LCA-severea D18S53 2.30b .15 Aggravation by physical exercise
18q …e MA and MO D18S877 … 3.43 IHS full criteria
a LCA refers to latent class analysis, as presented elsewhere.49
b Nonparametric multipoint results.
c Refers to a reduced end diagnosis; in the study,15 it included patients who did not fulfill either vascular headache criteria
or associated symptom criteria of the IHS classification.
d Parametric two-point results.
e A marker in the present study, with a distance of 13 cM to the D18S53 marker in the study by Lea et al.10
categories of this latent variable are called “latent classes,”
or clusters. Therefore, LCA groupings consist of individ-
uals with different numbers and combinations of symp-
toms and thus reflect a measure of severity, different from
the traditional end point diagnosis based on strict IHS
diagnostic criteria and also different from the individual-
trait analysis used here. The LCA approaches migraine
from a different viewpoint than does our trait-component
analysis, as the LCA classes are, in effect, new classifica-
tions combining features from both end diagnosis and
trait components, formed on the basis of heritability es-
timates. The important point, however, with respect to
our approach, is that the LCA analysis49 named a typical
trait most correlated with each class in a manner ap-
proaching the present analysis, and it is interesting to note
that several results from these two analyses agreed with
each other.
Interestingly, the Australian LCA study of twins11 im-
plicated a locus on 10q22 (nonparametric multipoint LOD
score of 2.13), which was attained with marker D10S2327,
which also gave a two-point LOD score of 2.78 in this
study. They also reported this marker to be “most asso-
ciated with phonophobia and photophobia,”11(p.500) and it
is intriguing that the same marker and same clinical trait
produce suggestive results in two different populations.
Our 12q21 peak marker D12S1064 had a nominal LOD
score of 0.74 in our previous study,7 which also reported
the Xp21 peak marker DXS9896 (LOD 1.08). Marker ACTC
on chromosome 15 lies next to a genomic region con-
taining three GABA receptor genes that were linked to
migraine in an Italian study of 10 families with MA.9 As
can be expected, many loci reported in other studies (table
4) did not show evidence of linkage beyond the nominal
level. Similarly, no linkage to the FHM1,18 FHM2,16 and
FHM317 loci on chromosomes 19p13, 1q23, and 2q24 was
found in this study. Traits with the highest evidence of
linkage at these loci were age at onset (LOD score 0.53),
photo- and phonophobia (0.93), and photophobia (0.62),
for the FHM1, FHM2, and FHM3 loci, respectively. In our
earlier 2002 study, none of the three loci showed evidence
of linkage.7 The newly identified regions contain several
counterparts to the known FHM genes. Other interest-
ing candidates for additional research include genes par-
ticipating in energy metabolism and neurotransmitter
release.
Further studies performed with these traits are needed
to confirm whether trait analysis can reclassify patients
into more-homogeneous groups. The findings here sug-
gest that trait information collected to establish the IHS-
based diagnosis can provide an additional tool for strati-
fying a migraine study sample. This should be applicable
not only to family studies but also to case-control studies.
It is hoped that subsequent studies will confirm the va-
lidity of this approach.
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Appendix A
Migraine Subtypes According to the International Clas-
sification of Headache Disorders, 2nd Edition, 200420
1.1 Migraine without aura
1.2 Migraine with aura
1.2.1 Typical aura with migraine headache
1.2.2 Typical aura with nonmigraine headache
1.2.3 Typical aura without headache
1.2.4 Familial hemiplegic migraine
1.2.5 Sporadic hemiplegic migraine
1.2.6 Basilar-type migraine




1.3.3 Benign paroxysmal vertigo of childhood
1.4 Retinal migraine
1.5 Complications of migraine
1.5.1 Chronic migraine
1.5.2 Status migrainosus




1.6.1 Probable migraine without aura
1.6.2 Probable migraine with aura
1.6.3 Probable chronic migraine
Appendix B
IHS Criteria for Migraine without Aura, 1988 and 200419,20
1.1 Migraine without aura
A. At least five attacks fulfilling criteria B–D
B. Headache attacks lasting 4–72 h (untreated or un-
successfully treated)




3. Moderate or severe intensity (inhibits or prohibits
daily activities)
4. Aggravation by walking stairs or similar routine
physical activity
D. During headache, at least one of the following:
1. Nausea and/or vomiting
2. Photophobia and phonophobia
E. At least one of the following:
1. History, physical- and neurological examinations
do not suggest secondary cause of headache
2. History, physical- and neurological examinations
do suggest such disorder, but it is ruled out by
appropriate investigations
3. Such disorder is present, but migraine attacks do
not occur for the first time in close temporal re-
lation to the disorder
Appendix C
Comparison of the Criteria for IHS Diagnoses 1.2 Migraine
with Aura of the 1988 Classification and the New 1.2.1
Typical Aura with Migraine Headache of the 2004
Classification
1.2 Migraine with aura (1988)
A. At least two attacks fulfilling criterion B
B. At least three of the following four characteristics:
1. One or more fully reversible aura symptoms in-
dicating focal cerebral cortical and/or brain stem
dysfunction
2. At least one aura symptom develops gradually over
14 min, or 2 symptoms occur in succession
3. No aura symptom lasts 160 min. If more than
one aura symptom is present, accepted duration
is proportionally increased
4. Headache follows aura with a free interval of !60
min (it may also begin before or simultaneously
with the aura)
C. At least one of the following:
1. History, physical- and neurological examinations
do not suggest secondary cause of headache
2. History, physical- and neurological examinations
do suggest such disorder, but it is ruled out by
appropriate investigations
3. Such disorder is present, but migraine attacks do
not occur for the first time in close temporal re-
lation to the disorder
1.2.1 Typical aura with migraine headache (2004)
A. At least two attacks fulfilling criteria B–D
B. Aura consisting of at least one of the following, but
no motor weakness:
1. Fully reversible visual symptoms including pos-
itive features (e.g., flickering lights, spots, or
lines) and/or negative features (i.e., loss of vision)
2. Fully reversible sensory symptoms including pos-
itive features (i.e., pins and needles) and/or neg-
ative features (i.e., numbness)
3. Fully reversible dysphasic speech disturbance
C. At least two of the following:
1. Homonymous visual symptoms (note: additional
loss or blurring of central vision may occur) and/
or unilateral sensory symptoms
2. At least one aura symptom develops gradually
over 5 min, and/or different aura symptoms
occur in succession over 5 min
3. Each symptom lasts 5 and 60 min
D. Headache fulfilling criteria B–D for 1.1 Migraine with-
out aura begins during the aura or follows aura within
60 min
E. Not attributed to another disorder (note: history and
physical and neurological examinations do not sug-
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gest any of the disorders listed in groups 5–12, or
history and/or physical and/or neurological exami-
nations do suggest such disorder but it is ruled out
by appropriate investigations, or such disorder is pre-
sent but attacks do not occur for the first time in close
temporal relation to the disorder)
Web Resources
The URLs for data presented herein are as follows:
matSpD, http://genepi.qimr.edu.au/general/daleN/matSpD/
Online Mendelian Inheritance in Man (OMIM), http://www.ncbi
.nlm.nih.gov/Omim/ (for migraine, CACNA1A, ATP1A2, SCN1A,
FHM1, FHM2, and FHM3)
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Here, we present the results of two genome-wide scans in two diverse populations in which a consistent use of recently introduced
migraine-phenotyping methods detects and replicates a locus on 10q22-q23, with an additional independent replication. No genetic
variants have been convincingly established in migraine, and although several loci have been reported, none of them has been consis-
tently replicated. We employed the three known migraine-phenotyping methods (clinical end diagnosis, latent-class analysis, and trait-
component analysis) with robust multiple testing correction in a large sample set of 1675 individuals from 210 migraine families from
Finland and Australia. Genome-wide multipoint linkage analysis that used the Kong and Cox exponential model in Finns detected a
locus on 10q22-q23 with highly significant evidence of linkage (LOD 7.68 at 103 cM in female-specific analysis). The Australian sample
showed a LOD score of 3.50 at the same locus (100 cM), as did the independent Finnish replication study (LOD score 2.41, at 102 cM). In
addition, four previously reported loci on 8q21, 14q21, 18q12, and Xp21 were also replicated. A shared-segment analysis of 10q22-q23
linked Finnish families identified a 1.6-9.5 cM segment, centered on 101 cM, which shows in-family homology in 95% of affected Finns.
This region was further studied with 1323 SNPs. Although no significant association was observed, four regions warranting follow-up
studies were identified. These results support the use of symptomology-based phenotyping in migraine and suggest that the 10q22-
q23 locus probably contains one or more migraine susceptibility variants.
Introduction
Migraine (MIM 157300) is the most common cause of
chronic episodic severe headache. It affects some 15% of
the adult population and has a well-established genetic
component1–4 on the basis of family and twin studies. It
is more prevalent among women, with a ratio of roughly
one male to every three female migraineurs.1 Migraine is
the most common neurological cause of a doctor visit
and places a heavy financial, social, and psychological bur-
den on a significant part of the general population. The es-
timated annual cost of migraine in Europe is V27 billion.5
Although evidence from family studies and twin studies
have demonstrated the contribution of genetic factors to
migraine susceptibility,3,6,7 identification of specific genetic
variants for common forms of migraine has not been forth-
coming. No variants predisposing to common forms of mi-
graine have been convincingly established, and no whole-
genome association (WGA) studies have been reported for
any headache disorders to date. Genome-wide linkage stud-
ies have pointed to several loci in both migraine with and
without aura.8–15 Unfortunately, so far there has been little
concordance between linkage reports because most studies
have identified a locusor two, which have not been convinc-
ingly replicated in other studies. Applying findings from
other complex disorders suggests that the lack of progress
in gene identification may be attributable to etiologic or
phenotypic heterogeneity, gene-environment interaction,
or epistasis. Another possible reason is genetic (locus) het-
erogeneity, in which only a subset of pedigrees segregates
markers linked to a particular risk locus. Then, even if the
study sample consists of a large number of families, individ-
ual large families within the sample carrying rare, relatively
high-impact gene variations predisposing to migraine can
be overly represented in the linkage signal. This would ex-
plain some of the difficulties with replication, and better un-
derstanding of how to account for these factors would help
in targeting future studies as well as help in interpreting re-
sults from whole-genome associationstudies. Finally, we hy-
pothesize that one of the reasons behind this inconsistency
might be related to the difficulty of phenotyping headache
disorders, causing heterogeneity in sample ascertainment.
One of the major impediments to gene identification of
migraine is the lack of valid biological markers with which
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tral Hospital, 00029 Helsinki, Finland; 6Folkhälsan Research Center, 00290 Helsinki, Finland; 7Department of Psychiatry and Columbia Genome Center,
Columbia University, New York, NY 10032, USA; 8Section on Developmental Genetic Epidemiology, National Institute of Mental Health, NIH, Bethesda,
MD 10032, USA; 9Department of Public Health, University of Helsinki, 00014 Helsinki, Finland; 10Department of Mental Health and Alcohol Research,
National Public Health Institute, 00300 Helsinki, Finland; 11Department of Molecular Medicine, National Public Health Institute, 00290 Helsinki, Finland;
12The Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; 13Wellcome Trust Sanger Institute, Cambridge CB10 1SA, UK
14These authors contributed equally to this work.
*Correspondence: aarno@sanger.ac.uk
DOI 10.1016/j.ajhg.2008.03.003. ª2008 by The American Society of Human Genetics. All rights reserved.
The American Journal of Human Genetics 82, 1051–1063, May 2008 1051
a presumptive diagnosis of migraine can be made. A
migraine diagnosis is based on fulfillment of symptom
criteria formulated by the International Headache Society
(IHS).16,17 The criteria define two main subtypes of
migraine, migraine with aura (MA) and migraine without
aura (MO), which together account for a majority of all
migraine. Most studies performed so far have used the
migraine end diagnosis as the primary phenotype, i.e., by
considering only patients with either MA or MO diagnosis
as affected in analysis. Although the IHS classification works
well and is fundamental in clinical practice, it may not be an
optimal strategy for uncovering underlying genetic mecha-
nisms and pathways contributing to the disease. The second
edition of the IHS classification17 introduced the same basic
symptom criteria (see Table 1) for MO and typical aura with
migraine headache (a major subgroup of MA). This, com-
bined with studies suggesting migraine with and without
auraaremanifestationsof thesame underlying disorder,18,19
have led to joint genetic analysis of patients from both diag-
nosis groups. This, in turn, gave rise to the idea of concen-
trating on one or few cardinal migraine symptoms, which
might better reflect the underlying pathophysiology.
Two alternative analytic strategies, one utilizing latent
classes,18 the other examining trait components,11 have
recently been developed for use in genetic studies of
migraine. In the latent-class analysis (LCA) approach, indi-
viduals are classified into empirically derived groups on
the basis of patterns of IHS symptom clustering observed
in a large Australian twin sample.18 Although considerably
more individuals were classified as being affected with ‘‘mi-
grainous headache’’ viaLCA(prevalence36% versus15%for
clinically determined migraine), additional studies in Aus-
tralian18 and Dutch20 twin populations have shown that
the LCA classification is able to demonstrate linkage to
loci undetectable with only the end diagnosis. An alternate
strategy is the trait-component analysis (TCA) approach,
which takes direct advantage of the available clinical infor-
mation in the IHS symptom data in order to classify the
patients into groups. This approach has the advantage of
reflecting known variables obtained directly from patients
with no intervening hypotheses about latent structure and
relationships of the traits. It is also simple to implement
from patient questionnaires or interviews and has proved
to be successful in demonstrating linkage to loci undetect-
able with traditional methods in a previous Finnish study.11
Encouraged by our previous results with these alternative
phenotyping strategies and their potential to facilitate
data integration from different phenotyping schemes, we
genotyped and analyzed two new, independent genome-
wide linkage scans from Finland and Australia. The samples
are of roughly equal size but have differences in their ascer-
tainment strategies and pedigree structures, allowing us to
test the phenotyping methods in a variety of conditions.
Further, the special population history of Finns provides
an advantage to potential restriction of any linked locus
through extended haplotype sharing.
Material and Methods
Patients
The Finnish study sample for the genome-wide scan consisted of
690 migraine patients and their relatives (407 women and 283
men) in 58 independent, multigenerational families. The Austra-
lian sample consisted of 661 individuals (420 women and 241
men) in 125 independent nuclear families. The Finnish replication
sample consisted of 324 migraine patients (202 women and 122
men) in 27 independent, multigenerational families. In total, we
studied 1675 individuals from 210 independent families. All par-
ticipants gave informed consent, and approval to conduct the
research was obtained from the Helsinki University Central Hospi-
tal Ethics Committee for the Finnish study and from the Queens-
land Institute of Medical Research (QIMR) Human Research Ethics
Committee and the Australian Twin Registry for the Australian
study. For the follow-up association study, two study samples
from the Finnish population were used. The first study sample
consisted of 39 unrelated trios with discordant parents selected
so that both the affected parent and an affected offspring carry
the family-specific segregating ‘‘risk haplotype’’ and that the unaf-
fected parent did not. The case-control set contained 256 unre-
lated MA cases selected from the Finnish patient collection and
230 controls from a Helsinki-based-population control sample.
Diagnoses and Phenotypes
The Finnish families were selected from a large Finnish migraine pa-
tient collection, ascertained from neurology clinics nation wide
during the last 15 years. The patients have been collected from fam-
ilies with three or more affected members fulfilling migrainecriteria
upon admission. Data on IHS attack symptoms as well as other
clinical features were collected with the validated Finnish Migraine
Specific Questionnaire for Family Studies (FMSQFS)
21 and by a neu-
rologist’s examination of index patients. The same neurologist
(M.K.) diagnosed all Finnish patients. The replication sample con-
sists of large families selected from the same patient collection, with
a preference for more severe migraine patients, including those
with hemiparesis symptoms, because of findings in the Finnish
genome-wide sample.
Table 1. Diagnostic Criteria for Migraine without Aura and
for the Headache Associated with Typical Aura with Migraine
Headache According to the International Classification
of Headache Disorders, Second Edition
1.1. Migraine without Auraa
A. At least five attacks fulfilling criteria B–D
B. Headache attacks lasting 4–72 hr (untreated or unsuccessfully
treated)
C. Headache has at least two of the following characteristics:
1.Unilateral location
2.Pulsating quality
3.Moderate or severe intensity (inhibits or prohibits daily activities)
4.Aggravation by walking stairs or similar routine physical activity
D. During headache, at least one of the following:
1.Nausea and / or vomiting
2.Photophobia and phonophobia
E. [Exclusion of secondary causes of headache]
a For typical aura with migraine headache (1.2.1): ‘‘Headache fulfilling
criteria B–D for 1.1 Migraine without aura begins during the aura or follows
aura within 60 min.’’
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The Australian families were selected from two population-
based twin cohorts, one of nuclear families of twins born between
1902 and 196422 and one of twins born between 1964 and 1971,23
with an overall prevalence of 15.3% of IHS migraine without aura.
The included pedigrees were selected on the basis of having at
least one pair of siblings affected for the common LCA-derived
‘‘migrainous headache’’ phenotype (prevalence of 36%18) and
then prioritized on the maximum number of available siblings,
irrespective of affection status. Data on IHS attack symptoms16,17
were gathered with an extensive semistructured telephone inter-
view that included diagnostic questions for migraine (Australian
questionnaires for the older and younger cohorts, see Web
Resources), developed by an experienced migraine researcher
(K.R.M.).24 Using a similar screening approach, Stewart et al.25
obtained a 92.6% positive predictive value of their telephone in-
terview diagnosis compared with their clinical examination. For
the younger cohort, data for two IHS diagnostic variables (Table 1),
nausea and vomiting (ICHD-II code: 1.1.D.1), were recorded
together. For the older cohort, data on three variables, pain inten-
sity (1.1.C.3), typical attack length (1.1.B), and whether patients
have had at least five attacks during lifetime (1.1.A), were unavail-
able, but symptom patterns of the younger cohort were used to
extrapolate those phenotypes for the older cohort. Data on
whether an individual’s headache was aggravated by walking stairs
or similar routine physical activity (1.1.C.4) were missing for both
cohorts, and thus that trait was excluded from the study. We used
an answer to a visual aura-specific question to determine the MA
end diagnosis.
Three different phenotype groups were prepared. ‘‘MA end diag-
nosis’’ covers all migraine with aura patients and includes individ-
uals from diagnosis groups ‘‘pure MA,’’ ‘‘unclassified MA,’’ and
‘‘mixed migraine’’ as affected (see Table 2 for definitions). Table 2
details the diagnosis distribution within the study samples, includ-
ing a detailed diagnosis breakdown for the two Finnish study sam-
ples, in which the larger amount of available clinical information
and expertise allows for a higher diagnostic specificity for the clin-
ical diagnosis. The Australian study questionnaire has fewer
migraine-specific questions and is designed to identify migraine
with high sensitivity but does not allow for distinguishing be-
tween different subtypes of MA. The latent-class definitions were
estimated from each patients’ symptom distribution with the
same algorithm as in the original LCA study.18 In brief, of the
four latent cluster groups in LCA (termed CL0, CL1, CL2, and
CL3), all individuals satisfying the IHS MA or MO diagnostic crite-
ria are encompassed by groups CL2 and CL3, and the combination
of these two groups will be referred to as ‘‘LCA migrainous head-
ache.’’ Group CL3, which has the majority of MA patients, is
referred to as ‘‘LCA severe migraine.’’ Trait-component phenotypes
were recorded directly from the questionnaire data of all patients
fulfilling any migraine diagnosis. Table 3 summarizes the propor-
tions of the different phenotypes.
Genotyping
All genotyping was performed in the Finnish Genome Center,
with the same equipment and conditions. The genotyping proce-
dure was conducted with standard methods on the ABI or the
MegaBACE genotyping systems. Genotyping was based on the
LMS-MD10 microsatellite marker set (Applied Biosystems, Foster
City, CA, USA). The marker set uses 387 markers for a 9.5 cM aver-
age intermarker distance and covered all autosomes and the
X chromosome. For the ABI system, genotyping was performed
with the ABI 3730 capillary sequencing instrument, and PCR
products were resolved with the ABI 3730 data collection software
and sized with the Genemapper software package from Applied
Biosystems. For the MegaBACE system, capillary electrophoresis
employed by the MegaBACE 1000 DNA Sequencing System (GE
Healthcare Bio-Sciences, Piscataway, NJ, USA), was used for sepa-
rating DNA fragments. Alleles for this system were called by the
MegaBACE Genetic Profiler 1.5 software. In addition, seven more
markers were genotyped at chromosome 10q22-q23, resulting in
a coverage of 2.21 cM average intermarker distance from marker
Table 2. Distribution of Migraine Diagnoses within









n of Total n of Total n of Total
Pure MAa 169 24% 44 14% 191 24%
Pure MO 79 11% 35 11% 78 10%
Unclassified MAb 89 13% 33 10%
Mixed migrainec 110 16% 78 24%
Equivalent migraine 7 1% 2 1%
Headache 26 4% 11 3%
No headache 169 24% 61 19% 230 28%
Possible migrained 27 4% 18 6%
Unknown 19 3% 42 13% 305 38%
MA end diagnosis 368 53% 155 48% 191 24%
Total 690 100% 324 100% 804 100%
Note the Australian symptom data do not allow the strict separation of
migraine with aura patients into unclassified MA, mixed migraine, and
pure migraine with aura subgroups.
a Pure MA refers to patients with all attacks fulfilling IHS criteria for
migraine with aura.
b Unclassified MA refers to an additional, non-IHS diagnosis group for
patients that cannot be grouped into any of the defined IHS categories.
Patients in this category suffer from attacks in which clearly aural features
are present but not in a form recognized by the current diagnostic criteria.
c Mixed migraine refers to a patient group in which attacks both with and
without aura are commonly present.
d Possible migraine refers to a patient group with episodic headache with
some migrainous features, who may or may not fulfill one of the probable
migraine (1.6) diagnoses of the IHS criteria but miss required aspects of
migraine with or without aura.
Table 3. Number of Affecteds, Frequencies of Individual
Trait Components, and the Gender Proportions of Those
Affected for All Traits and Trait Groups within the Study
Samples
Phenotype (n) of Total Finns Australians Males Females
Total subjects (1675) - 61% 39% 39% 61%
MA end diagnosis (621) 37% 41% 31% 21% 49%
Latent class CL23a (790) 47% 48% 45% 29% 60%
Latent class CL3 (599) 36% 36% 36% 15% 49%
Attack length (781) 47% 45% 49% 35% 60%
Unilaterality (727) 43% 48% 36% 30% 52%
Pulsation (778) 46% 49% 42% 35% 54%
Intensity (1033) 62% 67% 53% 46% 71%
Nausea/vomiting (870) 52% 55% 48% 34% 63%
Photophobia (918) 55% 59% 47% 37% 66%
Phonophobia (826) 49% 50% 47% 31% 61%
a Refers to a combination of latent classes CL2 and CL3.
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D10S218 to D10S2470. The Finnish replication sample was geno-
typed only for these markers. All genotypes were verified by hu-
man inspection, and the PedCheck1.126 computer program was
used for detecting genotyping errors.
For the follow-up association study, an Illumina Golden Gate
assay (Illumina, San Diego, CA, USA) was used to genotype 1536
single-nucleotide polymorphisms (SNPs) in altogether 564 indi-
viduals across the region defined by the shared haplotype
(chr10, 78.233–88.884 Mb, NCBI build 35) at the Broad Institute.
These 1536 SNPs on chromosome 10 (build 35, 78.23388.884
Mb) were selected as tag-SNPs with Haploview’s Tagger-option
with CEU population in the HapMap SNP set (v21), and we
selected to tag SNPs with minor allele frequency R10% and r2
threshold of R0.8. The selected 1536 tag SNPs tagged 94% of
the 8290 SNPs (MAF R0.10) with r2 R0.8 and 99% of the SNPs
with r2 R0.5. The Illumina BeadStudio software version 3.1.0.0
(Illumina) was used for calling the SNP genotypes, and each SNP
was evaluated for quality of the genotypes. Only samples that
had success rate of R97% and SNPs with 95% were considered
in the statistical analyses of the SNP data, and thus of the 1536
original SNPs, 1323 passed our rigorous quality control. Because
of the difficulty involved in genotyping the region around the
known CNV at ~81.3 Mb, there were no successfully genotyped
SNPs between 81,058,202 and 81,674,055 base pairs, resulting in
a 615 kilobase gap in the assay coverage.
Linkage and Association Analysis
For the genome-wide analyses, multipoint nonparametric linkage
analysis was performed with the MERLIN computer program.27
The MERLIN NPLpairs and NPLqtl Z score statistics are implemented
in the general framework of Whittemore and Halpern.28 These Z
scores are used by MERLIN to construct a likelihood ratio test for
linkage and define a LOD score statistic with the exponential mod-
eling procedure of Kong and Cox.29
For the Finnish families, in line with our previous research,8,11
we employed an affecteds-only strategy (i.e., all individuals not
classified as affected were considered to have an ‘‘unknown’’ phe-
notype) to allow for reduced penetrance, lack of environmental
exposure, etc. We used the nonparametric MERLIN NPLpairs Z
score statistic30 to test for increased allele sharing among affected
individuals. To avoid biasing our results on possible overrepre-
sented rare variants in a few large families, we also analyzed the
Finnish genome-wide sample as nuclear families. For consistency
with the previous Australian genome-wide linkage scan,8 in order
to use the information from unaffected individuals, we used a
nonparametric quantitative trait linkage (NPLqtl Z-score) statistic
for the analyses of the Australian families in order to obtain addi-
tional linkage information from unaffected individuals. In this
analysis, affected individuals were coded as ‘‘1,’’ unaffected indi-
viduals were coded as ‘‘0,’’ and those with missing phenotypes
were coded as ‘‘x.’’ The validity of this, as well as the original re-
gression Haseman-Elston approach31 for binary traits, has been
proven consistently.32 For the combined genome-wide analysis
of Finnish and Australian pedigrees, we used nuclear families to
avoid biasing the signal because of the larger Finnish families, and
the NPLpairs Z-score statistic was used with the usual ‘‘affection’’
phenotype coding of 0, 1, and 2 to represent unknown/missing,
unaffected, and affected individuals, respectively. In addition,
we performed a sex-specific analysis by alternatively considering
only the affected females or males as ‘‘true’’ affecteds and treating
the affecteds of the other gender as having an ‘‘unknown’’ pheno-
type. In addition, a haplotype shared-segment analysis was
performed in the Finnish families. The GENEHUNTER software,33
version 2.1_r5beta, was used for construction of pedigrees showing
the paternal and maternal haplotypes for the additional markers at
this locus for the families showing a family-specific NPLall score
greater than 1.00 at the location of the highest LOD score.
For the follow-up association study, PLINK software version
1.0034 was used for all analyses. We employed the DFAM analysis
(dfam) to detect association in the combined set of trios and the
case-control subjects. Results were corrected through adaptive
permutation (perm) with PLINK default settings.
Significance Limits
To account for all the phenotypes tested, we needed to apply robust
correction for multiple testing. To start, rather than to use the signif-
icance thresholds of Lander-Kruglyak (L-K),35 conservative for mi-
crosatellite-based linkage scans due to the unrealistic assumption
of having complete (100%) inheritance information, we estimated
the significance thresholds for affected sibpair analysis of 400
markers by using the formulae presented by Feingold et al.36 The
L-K threshold for significant evidence of linkage (p ¼ 0.000022,
corresponding to a standard LOD score of 3.63) is decreased to
p ¼ 0.00009 (corresponding to a LOD score of 3.05). Similarly, the
threshold for suggestive linkage is reduced from p ¼ 0.00074
(LOD score of 2.19) to p ¼ 0.0023 (LOD score of 1.74).37 These
theoretically derived thresholds are consistent with those obtained
via simulation by ourselves8 and others.38–41 To correct for the
multiple phenotypes (including the sex-specific analyses) used in
this study, we applied the program matSpD (see Web Resources) to
estimate the equivalent total number of independent tests per-
formed (six), resulting in robust Bonferroni-corrected significance
thresholds of 6.18 [5.40 þ log10(6)] for highly significant evidence
of linkage, 3.83 [3.05þ log10(6)] for significant evidence of linkage,
and 2.52 [1.74 þ log10(6)] for suggestive evidence. For the replica-
tion set, we applied the L-K replication threshold of LOD 1.8
(nominal evidence of linkage, p¼ 0.01, for five independent tests),
equal to fine mapping a 10 cM area.35 For the follow-up association
study, we used the snpSpD program (see Web Resources) to estimate
the number of independent SNP tests after accounting for LD
(761.7), resulting in Bonferroni-corrected significance threshold
of 6.73 3 105.
Results
Genome-wide multipoint linkage analysis of 387 microsa-
tellite markers was performed in two independent study
samples; this was followed by an analysis of a locus-specific
Finnish replication sample. All samples were analyzed
separately as well as jointly. A locus on 10q22-q23 showed
significant evidence of linkage in Finns as well as in the joint
analysis and suggestive evidence of linkage in the Austra-
lian study. A sex-specific analysis, considering only females
as affected, improved the linkage signal to the level of
highly significant evidence of linkage. No other loci showed
linkage in both samples. Population-specific loci on 2p12,
8q12, and Xp22 showed suggestive evidence of linkage.
Genome-wide Population-Specific Linkage Analysis
We first wanted to identify regions linked to any of the
migraine traits in the individual study populations. In
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the Finnish study sample, the MERLIN NPLpairs analysis
showed significant evidence of linkage to a locus on
10q22-q23. The highest LOD score (5.50) was observed at
103 cM with the TCA unilaterality phenotype, with the
95% CI placing the locus between 99 cM and 114 cM. Sig-
nificant evidence of linkage at this locus was also shown by
the MA end diagnosis, LCA migrainous headache, and five
additional TCA phenotypes (see Table 4). In the Finnish
study sample, no other chromosomal region showed
significant evidence of linkage, and only two regions
showed suggestive evidence of linkage (on 2p12, NPLpairs
LOD score 2.60 at 100 cM with TCA pulsation phenotype;
1.93 for MA end diagnosis, and 1.74 for LCA migraine and
on Xp22, NPLpairs LOD score 2.96 at 39 cM with TCA
pulsation phenotype, 1.19 for MA end diagnosis, and 1.72
for LCA severe migraine), although a previously detected
locus on 18q129–12 showed sufficient evidence for replica-
tion (NPLpairs LOD 2.46 at 86 cM with TCA attack-length
phenotype, 0.21 for MA end diagnosis, and 0.41 for LCA
migrainous headache). Encouragingly, the 10q22-q23 locus
is robustly replicated in the Australian study sample with
a highly suggestive NPLqtl score of 3.50 at 100 cM with
the TCA pulsation trait, with the 95% CI located between
94 cM and 115 cM. Other phenotyping methods provided
modest signals in the Australian study sample at the
10q22-q23 locus. In the Australian sample, suggestive evi-
dence of linkage was found to a region on 8q12 (NPLqtl
LOD of 2.63 at 86 cM with the TCA pain intensity pheno-
type, 0.29 for MA end diagnosis, and 1.27 for LCA migrain-
ous headache), and a previously detected locus on 14q21
was replicated (NPLqtl LOD 2.23 at 26 cM with TCA pain
intensity phenotype, 0.24 for MA end diagnosis, and 1.68
for LCA migrainous headache). The genome-wide results
for all traits are shown in Figure 1.
Genome-wide Joint Analysis of Australian
and Finnish Study Samples
Results of a joint MERLIN NPLpairs analysis yielded signifi-
cant evidence of linkage to the same region as in the
Table 4. Phenotypes Showing Genome-wide Significant LOD













TCA unilaterality 5.18 0.00 0.62
TCA pulsation 4.24 3.50 4.62
TCA pain intensity 5.03 1.32 3.75
TCA nausea/vomiting 3.90 0.25 2.88
TCA photophobia 4.22 0.11 2.40
TCA phonophobia 5.03 0.00 1.63
Note that numbers in italics represent genome-wide significant evidence of
linkage (LOD > 3.83).
Figure 1. Maximum LOD Scores in the Genome-wide Screen
The graphs show values across all phenotypes and phenotyping methods for the Finnish study sample in the NPLpairs analysis, the Aus-
tralian study sample in the NPLqtl analysis, and the NPLpairs analysis performed on both study samples together. The dotted line denotes
the level of significant evidence of linkage (LOD > 3.83).
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individual analysis, between 98 cM and 117 cM at 10q22-
q23. The highest LOD score (4.62) was found at 102 cM
with the TCA pulsation phenotype, and significant evi-
dence of linkage was also detected with TCA pain-intensity
phenotypes (see Table 4). Neither of the regions showing
suggestive linkage in only one sample showed evidence of
linkage above nominal level (2p12 highest NPLpairs LOD
score 0.57, for 8q12, 1.01; and for Xp22, 1.36) in the joint
analysis. Comparison of results from each of the three
phenotyping methods in the joint analysis is presented in
Figure 2.
Fine Mapping the Locus on 10q22-q23
Seven additional markers were genotyped in both initial
study samples to increase the available linkage informa-
tion across the implicated 10q22-q23 region. When in-
cluding those markers in the joint-linkage analysis, the
highest peak was found at 106 cM (NPLpairs LOD score of
4.11 with the TCA pulsation phenotype, 1.28 for MA end
diagnosis, and 2.16 for LCA migrainous headache). These
results are detailed in Figure 3.
Finnish Replication Study
We genotyped an independent Finnish replication
sample of 27 families for the seven additional microsatel-
lite markers at the 10q22-q23 locus to further strengthen
the evidence of linkage. Because the families providing
most of the linkage signals to the 10q22-q23 locus in the
genome-wide study were found to suffer from a severe
form of migraine that included some hemiparesis symp-
toms (although not severe enough to qualify as familial
or sporadic hemiplegic migraine), this clinical phenotype
was used as the basis of selecting the families for the repli-
cation study (see Table 5). In the linkage analysis, the high-
est peak was found at 102 cM with the TCA pulsation
Figure 2. Genome-wide Comparison of the Three Genotyping Methods in the Combined Study Sample
The graphs show the highest LOD score detected with each phenotyping method in the joint analysis of the two genome-wide screens in
the NPLpairs analysis performed with both study samples together. The horizontal lines and boxes indicate the maximum LOD scores at
10q22-q23 for each method. The dotted line denotes the level of significant evidence of linkage (LOD > 3.83).
Figure 3. Positioning the Linkage Peaks on Chromosome 10
The graphs show maximum attained LOD scores in each study sam-
ple in the Merlin multipoint analyses, including the seven addi-
tional microsatellite markers. The bracket denotes the area covered
by the family-specific haplotype segregating with the affection
status.
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phenotype (NPLpairs LOD score of 2.41), sufficient for rep-
lication (LOD > 1.8).
Sex-Specific Findings
In line with previous studies11,12 that have suggested
sex-specific effects at linked loci, we performed a sex-spe-
cific analysis for chromosome 10. In the Australian study,
sex-specific analyses yielded no improvement in the link-
age signal. However, in the Finnish study sample, consider-
ing only affected females yielded a considerable increase in
the LOD score, resulting in highly significant evidence of
linkage with a number of phenotypes, including the MA
end diagnosis. The highest NPLpairs LOD score was 7.68
(at 103 cM, TCA phonophobia phenotype, 4.37 for MA
end diagnosis, and 5.33 for LCA migrainous headache).
In contrast, considering only affected males, the linkage
signal was below the level of nominal evidence of linkage
(highest NPLpairs LOD score 0.20 at the same location).
For the Finnish females, all of the studied phenotypes
except LCA severe migraine showed significant evidence
of linkage. For the joint analysis, considering only females
and nuclear families produced a significant LOD score of
4.11 (at 106 cM with the TCA photophobia phenotype,
2.52 for MA end diagnosis, and 3.19 for LCA migrainous
headache). Female-specific results are detailed in Figure 4.
Haplotype Analysis at 10q22-q23
Because the Finnish study sample is from a population
with a limited number of founders and multiple bottle-
necks in the population history, we performed a haplotype
shared-segment analysis to further restrict the linked re-
gion and identify the most probable location of the disease
predisposing variants. The analysis was conducted in those
21 Finnish families that had a family-specific nonparamet-
ric linkage (NPL) score greater than 1.00 (as measured by
GENEHUNTER) at the location of the highest linkage sig-
nal (97.5 cM), both from the genome-wide sample and
the replication sample. These families contain 178 individ-
uals, of which 99 (or 56%) are considered affected accord-
ing to our clinical MA end diagnosis. Ninety-five percent
(94 out of 99 subjects) shared the family-specific haplotype
between markers D10S1786 (103.3 cM) and D10S1686
(104.9 cM). Considering the locations of the flanking
markers (D10S569 at 97.5 cM and D10S1687 at 107.3
cM), the detected haplotype is between 1.6 and 9.8 cM
wide (1.6 – 9.6 Mb). Restricting the area to this region
Table 5. The Number and Proportion of Migraineurs










n in total sample 441 (-) 690 (-) 324 (-)
with hemiparesis
symptoms
42 (9.5%) 67 (9.7%) 51 (15.7%)
with hemisensory
symptoms
87 (19.7%) 117 (17.0%) 70 (21.6%)
Figure 4. Female-Specific Multipoint Linkage Results on
Chromosome 10
The graphs show the results obtained with the TCA pulsation pheno-
type, which gives the highest evidence of linkage in each sample.
Figure 5. Haplotype Distribution among the Finnish Families
with Family-Specific LOD Scores over 1.00 at the Location of
the Highest Linkage Signal in Finns, 103 cM
This figure shows the family-specific haplotype segregating with the
affection status on chromosome 10q22-q23, for the roughly 30 Mb
area spanning the markers D10S1652 and D10S185 around the
linkage peak. The lightly shaded area represents the haplotype block
shared by affected members of the family, and the darker shading
indicates the region shared by all affected family members across
families. ‘‘N/a’’ denotes an unavailable genotype, and ‘‘n’’ denotes
multiple different alleles in affected family members. The bottom
of the figure shows the largest transcribed genes in the region, in
scale relative to the distances between the microsatellites.
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was accomplished on the basis of three and four informa-
tive recombinations, respectively. Results of this analysis
are detailed in Figure 5.
Follow-up Association Study
The trio and case-control samples were analyzed with
the DFAM analysis option of PLINK,34 which allows for
the combination of trio and case-control data. None of the
SNPs showed association exceeding the significance
threshold of 6.73 3 105. The highest association was de-
tected with SNP rs1873695 (p value 9.22 3 104; KCNMA1
intronic), with several adjacent SNPs showing a similar
level of association (rs2131218: 0.0035, rs16934025:
0.0019). Three other regions show association scores under
the 0.005 level with several adjacent markers: rs10458664
(0.0035, outside any known gene), rs7906586 (p ¼ value
0.0025, outside any known gene), and rs2691052 (0.002,
outside any known gene) (see Figure 6 for results).
Discussion
In the present study, we detected highly significant evi-
dence of linkage to 10q22-q23 and replicated the finding
in two diverse populations. The locus was detected with
all three phenotyping methods used, which alternatively
concentrate on the presence of aura, IHS symptom cluster-
ing, or the individual migraine symptoms. The consistency
of linkage findings across studies with different ascertain-
ment schemes and phenotyping methods provides com-
pelling evidence for the strength of this finding.
As is often the case in complex traits, the linkage peaks de-
fining the detected 10q22-q23 region are relatively broad
(between 8 cM and 21 cM wide, depending on the method
of analysis), and the number of susceptibility loci within
this region cannot be predicted. However, given that the
analysis peaks all converge on a narrow (under 5 cM) area,
which contains the area defined by the shared-segment
analysis, there is therefore strong evidence for constraining
the peak between 97.5 cM and 104.9 cM (see Figure 3). This
interval contains two obvious functional candidate genes.
KCNMA1 is a Maxi-K, calcium-level detecting potassium
channel, which is involved in ion transport in a similar
manner to the three known genes involved in the molecu-
lar pathology of familial hemiplegic migraine (see Table
S1A), a related Mendelian disorder (CACNA1A, ATP1A2,
and SCN1A, MIM 141500, MIM 602481, and MIM
609634, respectively). NRG3, located directly in the middle
of the narrowest peak, is a gene belonging to the neuregulin
family of growth and differentiation factors that are related
to epidermal growth factor, which plays a role in
oligodendrocyte survival.
Overall, there is an encouraging consistency between
the results of this study and the previous Finnish11 and
Australian8 studies. An overview of current and previous
results at 10q22-q23 can be seen in Figure 7. The three
other chromosomal areas showing evidence of significant
or suggestive linkage to migraine in more than one report
and in more than one population prior to this study are
on chromosomes 4q21-q31, 15q11-q13, and 18q12. The
previously reported chromosome 4q locus seems to be ex-
ceptionally broad; whereas the linkage in the Icelandic
population is reported at 4q21,12 previous Finnish studies
identified two peaks at 4q249 and at 4q28-q31,11 making
the total linked region up 50 cM wide. In this study, we
Figure 6. Results of the Follow-Up
Association Study that Used 39 Trios,
256 Unrelated Cases, and 230 Controls
in the DFAM Association Analysis
The dotted line at the top of the figure de-
notes the minimum known length of the
family-specific segregating microsatellite
haplotype (see Figure 6), and the solid
line denotes its maximum possible length.
The bottom of the figure shows the largest
transcribed genes in the region, in scale
according to the isoform with the largest
genomic size, as well as the area of the
known CNV.
Figure 7. Previously Reported Migraine Linkage Results at the
10q22-q23 Locus Plotted Together with Results of This Study
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were unable to replicate this locus, although closer exami-
nation of the family-specific results reveals the existence of
a subset of families (approximately one-fourth of the total
sample in both Australians and Finns) with family-specific
Z scores up to 2.4, even though the overall evidence of
linkage was nominal. This was also the case with the previ-
ously reported 17p13 locus.11 Similarly, the previously
reported 15q11-q13 locus was undetectable in our study.
The chromosome 18q12 locus has been detected in both
the Icelandic12 and Finnish samples9,11 (although the Ice-
landic linkage was observed after a broader definition of
migraine was applied and only females considered as
affecteds), as well as in the previous Australian study.10
This locus is also replicated here, with the same TCA at-
tack-length phenotype as in the previous Finnish study,
bringing the total number of study samples showing link-
age to this locus to four. Finally, three loci previously linked
to migraine in only one study sample are also replicated,
two in their respective populations: the locus on 8q21 de-
tected in Australians (NPLqtl LOD score of 2.63) is within
10 cM from a previously detected Australian locus,8 a previ-
ously reported locus on 14q21 detected in a large Italian
family14 is replicated in the Australian sample (NPLqtl LOD
score of 2.21 at 26 cM), and the peak on Xp22 (NPLpairs
LOD score of 3.05 in Finns) is only 7 cM from a locus on
Xp21, detected in the previous Finnish study.9,11 In total,
of the seven loci reported in Finns so far (4q, 10q*, 12q,
15q, 17p, 18q*, and Xp*), this study replicates three (de-
noted by asterisks), as well as three of the five reported in
Australians (5q, 8q*, 10q*, 13q, and 18p-18q*). Finally,
given that only one (2p12) of the four loci with suggestive
or higher evidence of linkage in this study (2p, 8q, 10q,
and Xp) has not been reported previously, overall the
extended phenotyping methods seem to facilitate replica-
tion, especially considering that only one locus (4q21-q24)
has been replicated with end-diagnosis-based approaches.
An overview of results at each OMIM-listed migraine loci
can be seen in Table S1B.
A closer look into previous migraine scans showed that
the 10q22-q23 locus had been implicated in our two
scans8,11 with suggestive evidence of linkage. The present
and the two previous studies suggest that complementing
the classical clinical migraine diagnosis with alternative
phenotyping strategies can facilitate the identification of
susceptibility-locus identification. Both the trait-compo-
nent analysis and the latent-class analysis approaches
have proven useful in this respect, although they have dif-
ferent premises and represent conceptual approaches. It is
of interest to note that if only the MA end diagnosis had
been used as the study phenotype, the 10q22-q23 locus
would have been detected with suggestive or significant
evidence of linkage in only one of the five recent migraine
study samples in the Australian and Finnish populations
(including the three reported here; corresponding success
rates 2/5 for LCA, and 5/5 for TCA).8,11 There are two
likely explanations for the greater sensitivity of TCA and
LCA over the clinical diagnosis: (1) LCA and especially
TCA may better reflect underlying processes in migraine
pathophysiology, and/or (2) these two methods can utilize
the questionnaire-based information in a more optimal
way to find informative individuals within the MA and
MO patient pools, thus including more cases and informa-
tive meioses for the linkage analysis. Although advantages
and disadvantages exist for any analytical approach, these
and previous results suggest that the trait-component
analysis may offer substantial gains over analysis of clini-
cal (migraine with aura) or empirical (e.g., LCA) end diag-
noses especially when the diagnostic information is in-
complete. Given that both the end diagnosis and the
latent classes are based on combining information from
phenotype profiles, it is perhaps not surprising that they
both lose more power compared to TCA when the amount
of available information is less than complete. This could
explain the differences in results between the phenotyping
methods in the current Australian study sample. Further-
more, using individual trait components directly allows ad-
ditional efforts to be concentrated on increasing the size of
the study samples, without the need to collect progressively
more and more detailed clinical diagnostic information to
optimize the formulation of the end diagnosis. On the other
hand, it is possible that the TCA findings are the result of de-
tecting genes involved in the symptom-specific processes
and not involved in the primary pathophysiology of
migraine.
The role of pulsating pain trait is of particular interest.
Repeatedly, pulsation seems to be the most sensitive indi-
vidual trait for linkage-based locus identification, provid-
ing all of the highest results in the Australian sample and
many of those in the Finnish sample. This is evident in
the previous two other genome-wide scans as well; the
best signal in the previous Australian study (5q21)8 is pre-
dominantly driven by pulsation, as is the best locus in the
previous Finnish study (17p13),11 which showed signifi-
cant evidence of linkage only with pulsation. In addition,
it plays a major role in the 10q22-q23 results in this study.
The reason for this remains speculative. One possible ex-
planation is that pulsating pain is a symptom that is
more easily recognized by patients and thus is more consis-
tently recorded in interviews and questionnaires. This does
not, however, exclude the possibility that pulsation is in-
deed the most characteristic symptom of a particular type
of migraine and reflects some yet-unknown neurovascular
mechanism and is thus associated with specific pathophys-
iological pathways. It should also be noted that pulsation
or any other TCA trait was not used in the sample ascer-
tainment; that is, the sample selection process is naive
with respect to the traits. Another interesting finding is
the role of hemiparesis symptoms; because the families
contributing most to the 10q22-q23 locus suffered from
a more severe form of migraine, they have a higher propor-
tion of hemiplegic symptoms. After the families for the
replication study were selected for a higher prevalence of
this severe form, a similar effect was observed in the repli-
cation study, further underlining the contribution of this
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clinical phenotype to the 10q22-q23 locus. Thus, we were
able to extract a part of the clinical spectrum of migraine,
concentrate on it in case selection, and predict and subse-
quently demonstrate linkage to a particular genetic locus
with a small number of patients targeted for that particular
aspect, which is both a novel and an encouraging finding.
In addition, on the basis of the known ion-channel-
centered molecular pathology of familial hemiplegic
migraine,42–44 this supports KCNMA1 as a compelling can-
didate gene. Lastly, the difference between overall and
sex-specific linkage results at 10q22-q23 seem to reflect a
predominantly female-dominated inheritance pattern in
the Finnish families linked to this locus; such a finding is
somewhat to be expected because of the higher prevalence
of migraine in women. However, this is not enough to ex-
plain the considerable increase in linkage signal when con-
sidering only females as affected. The same effect, though
to a smaller degree, can also be seen in the Australian study
sample, as well as in a previous Finnish11 and an Icelandic
study.12 These results suggest that using gender as a covari-
ate in future migraine studies might provide increase in
power for the detection of new variants. Sex might also
be an indicator for male-specific environmental or behav-
ioral characteristics that hide the signal in men, perhaps
related to the better ability of women to detect and elabo-
rate on symptoms and signs in headache and migraine;
whether this is related also to higher prevalence of mi-
graine in women also needs to be examined.
Although no SNPs showed significant association in the
follow-up study, four potentially interesting regions sup-
port additional studies. The highest association, although
not high enough to be considered significant, was ob-
served with one obvious candidate gene, KCNMA1. The
three SNPs with the next highest scores were located out-
side known coding genes. However, given the high linkage
signal in the region and the variance among the family-
specific affected haplotypes, it is possible that this locus
contains multiple susceptibility variants affecting mi-
graine but that the sample used is too small to sufficiently
discern between them. Thus, larger studies are warranted
to see whether these findings can be replicated. The poten-
tial, suggestive association to KCNMA1 is intriguing be-
cause the established FHM mutations are all located in
proteins involved in ion transport.
A timely question is how linkage signals, as the chromo-
some 10q22-q23 locus reported here, correspond to associ-
ation signals in WGA studies. Recent studies provide an
opportunity to compare loci identified with these two dif-
ferent strategies that are based on different hypothesis. Al-
though linkage studies are best suited to position relatively
penetrant and possibly rare variants, WGA studies are de-
signed to test the ‘‘common-diseases-common-variant’’
hypothesis. Although the number of WGA studies is still
limited, some trends can be observed; there are examples
of identification of both previously unidentified loci and
confirmation of loci identified in linkage studies. Impor-
tantly, the WGA studies have identified new robustly rep-
licated loci in regions not previously linked or associated
to disease traits.45–49 However, in cases such as prostate
cancer (8q24)50–52 Crohn’s disease (16q12, NOD2),53,54
type II diabetes (10q23-q26),55–57 and MS (5p13),58,59
some of the strongest associations are observed in regions
where linkage has previously been detected and replicated
in several studies. Thus, it is relevant to hypothesize that
the linkage to chromosome 10q22-q23 region detected
consistently in several migraine study samples could repre-
sent a region where a relatively highly penetrant and per-
haps common variant(s) is/are associated to migraine. An-
other possibility is that a strong linkage observed in several
study samples indicates that there are several susceptibility
variants or even genes within the linked locus.
Regardless of the various constraints involved, we de-
tected strong linkage at the 10q22-q23 locus in all three
samples assessed in this study. The detection of linkage
to the 10q22-q23 locus with different phenotyping
methods and different ascertainment protocols provides
strong support for the presence of a gene(s) in this region
influencing migraine susceptibility. In addition, our study
demonstrates the advantages of using of IHS clinical traits
directly in migraine genetics and allowed the confirmation
of a number of previously reported genomic regions being
coinherited with migraine.
Supplemental Data
Two tables are available at http://www.ajhg.org/.
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of a migraine specific questionnaire for use in family studies.
Eur. J. Neurol. 8, 61–66.
22. Heath, A.C., Bucholz, K.K., Madden, P.A., Dinwiddie, S.H.,
Slutske, W.S., Bierut, L.J., Statham, D.J., Dunne, M.P., Whit-
field, J.B., and Martin, N.G. (1997). Genetic and environmen-
tal contributions to alcohol dependence risk in a national
twin sample: Consistency of findings in women and men. Psy-
chol. Med. 27, 1381–1396.
23. Heath, A.C., Howells, W., Kirk, K.M., Madden, P.A., Bucholz,
K.K., Nelson, E.C., Slutske, W.S., Statham, D.J., and Martin,
N.G. (2001). Predictors of non-response to a questionnaire
survey of a volunteer twin panel: Findings from the Australian
1989 twin cohort. Twin Res. 4, 73–80.
24. Merikangas, K.R., Dartigues, J.F., Whitaker, A., and Angst, J.
(1994). Diagnostic criteria for migraine. A validity study. Neu-
rology 44, S11–S16.
25. Stewart, W.F., Staffa, J., Lipton, R.B., and Ottman, R. (1997).
Familial risk of migraine: A population-based study. Ann. Neu-
rol. 41, 166–172.
26. O’Connell, J.R., and Weeks, D.E. (1998). PedCheck: A program
for identification of genotype incompatibilities in linkage
analysis. Am. J. Hum. Genet. 63, 259–266.
27. Abecasis, G.R., Cherny, S.S., Cookson, W.O., and Cardon, L.R.
(2002). Merlin–rapid analysis of dense genetic maps using
sparse gene flow trees. Nat. Genet. 30, 97–101.
28. Whittemore, A.S., and Halpern, J. (1994). A class of tests for
linkage using affected pedigree members. Biometrics 50,
118–127.
The American Journal of Human Genetics 82, 1051–1063, May 2008 1061
29. Kong, A., and Cox, N.J. (1997). Allele-sharing models: LOD
scores and accurate linkage tests. Am. J. Hum. Genet. 61,
1179–1188.
30. Weeks, D.E., and Lange, K. (1988). The affected-pedigree-
member method of linkage analysis. Am. J. Hum. Genet. 42,
315–326.
31. Haseman, J.K., and Elston, R.C. (1972). The investigation of
linkage between a quantitative trait and a marker locus. Behav.
Genet. 2, 3–19.
32. Elston, R.C., Song, D., and Iyengar, S.K. (2005). Mathematical
assumptions versus biological reality: Myths in affected sib
pair linkage analysis. Am. J. Hum. Genet. 76, 152–156.
33. Kruglyak, L., Daly, M.J., Reeve-Daly, M.P., and Lander, E.S.
(1996). Parametric and nonparametric linkage analysis: A uni-
fied multipoint approach. Am. J. Hum. Genet. 58, 1347–1363.
34. Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira,
M.A., Bender, D., Maller, J., Sklar, P., de Bakker, P.I., Daly,
M.J., and Sham, P.C. (2007). PLINK: A tool set for whole-
genome association and population-based linkage analyses.
Am. J. Hum. Genet. 81, 559–575.
35. Lander, E., and Kruglyak, L. (1995). Genetic dissection of com-
plex traits: Guidelines for interpreting and reporting linkage
results. Nat. Genet. 11, 241–247.
36. Feingold, E., Brown, P.O., and Siegmund, D. (1993). Gaussian
models for genetic linkage analysis using complete high-reso-
lution maps of identity by descent. Am. J. Hum. Genet. 53,
234–251.
37. Rao, D.C., and Province, M.A. (2000). The future of path anal-
ysis, segregation analysis, and combined models for genetic
dissection of complex traits. Hum. Hered. 50, 34–42.
38. Abecasis, G.R., Yashar, B.M., Zhao, Y., Ghiasvand, N.M., Zare-
parsi, S., Branham, K.E., Reddick, A.C., Trager, E.H., Yoshida,
S., Bahling, J., et al. (2004). Age-related macular degeneration:
A high-resolution genome scan for susceptibility loci in a pop-
ulation enriched for late-stage disease. Am. J. Hum. Genet. 74,
482–494.
39. Abecasis, G.R., Burt, R.A., Hall, D., Bochum, S., Doheny, K.F.,
Lundy, S.L., Torrington, M., Roos, J.L., Gogos, J.A., and Kar-
ayiorgou, M. (2004). Genomewide scan in families with
schizophrenia from the founder population of Afrikaners re-
veals evidence for linkage and uniparental disomy on chro-
mosome 1. Am. J. Hum. Genet. 74, 403–417.
40. Suarez, B.K., Duan, J., Sanders, A.R., Hinrichs, A.L., Jin, C.H.,
Hou, C., Buccola, N.G., Hale, N., Weilbaecher, A.N., Nertney,
D.A., et al. (2006). Genomewide linkage scan of 409 Euro-
pean-ancestry and African American families with schizophre-
nia: Suggestive evidence of linkage at 8p23.3-p21.2 and
11p13.1-q14.1 in the combined sample. Am. J. Hum. Genet.
78, 315–333.
41. Wiltshire, S., Cardon, L.R., and McCarthy, M.I. (2002). Evalu-
ating the results of genomewide linkage scans of complex
traits by locus counting. Am. J. Hum. Genet. 71, 1175–1182.
42. Ophoff, R.A., Terwindt, G.M., Vergouwe, M.N., van Eijk, R.,
Oefner, P.J., Hoffman, S.M., Lamerdin, J.E., Mohrenweiser,
H.W., Bulman, D.E., Ferrari, M., et al. (1996). Familial hemi-
plegic migraine and episodic ataxia type-2 are caused by
mutations in the Ca2þ channel gene CACNL1A4. Cell 87,
543–552.
43. De Fusco, M., Marconi, R., Silvestri, L., Atorino, L., Rampoldi,
L., Morgante, L., Ballabio, A., Aridon, P., and Casari, G. (2003).
Haploinsufficiency of ATP1A2 encoding the Naþ/Kþ pump
alpha2 subunit associated with familial hemiplegic migraine
type 2. Nat. Genet. 33, 192–196.
44. Dichgans, M., Freilinger, T., Eckstein, G., Babini, E., Lorenz-
Depiereux, B., Biskup, S., Ferrari, M.D., Herzog, J., van den
Maagdenberg, A.M., Pusch, M., and Strom, T.M. (2005). Muta-
tion in the neuronal voltage-gated sodium channel SCN1A in
familial hemiplegic migraine. Lancet 366, 371–377.
45. Scott, L.J., Mohlke, K.L., Bonnycastle, L.L., Willer, C.J., Li, Y.,
Duren, W.L., Erdos, M.R., Stringham, H.M., Chines, P.S., Jack-
son, A.U., et al. (2007). A genome-wide association study of
type 2 diabetes in Finns detects multiple susceptibility vari-
ants. Science 316, 1341–1345.
46. Maller, J., George, S., Purcell, S., Fagerness, J., Altshuler, D.,
Daly, M.J., and Seddon, J.M. (2006). Common variation in
three genes, including a noncoding variant in CFH, strongly
influences risk of age-related macular degeneration. Nat.
Genet. 38, 1055–1059.
47. Gudmundsson, J., Sulem, P., Steinthorsdottir, V., Bergthors-
son, J.T., Thorleifsson, G., Manolescu, A., Rafnar, T., Gudb-
jartsson, D., Agnarsson, B.A., Baker, A., et al. (2007). Two var-
iants on chromosome 17 confer prostate cancer risk, and the
one in TCF2 protects against type 2 diabetes. Nat. Genet. 39,
977–983.
48. Todd, J.A., Walker, N.M., Cooper, J.D., Smyth, D.J., Downes,
K., Plagnol, V., Bailey, R., Nejentsev, S., Field, S.F., Payne, F.,
et al. (2007). Robust associations of four new chromosome re-
gions from genome-wide analyses of type 1 diabetes. Nat.
Genet. 39, 857–864.
49. Saxena, R., Voight, B.F., Lyssenko, V., Burtt, N.P., de Bakker,
P.I., Chen, H., Roix, J.J., Kathiresan, S., Hirschhorn, J.N.,
et al. (2007). Diabetes Genetics Initiative of Broad Institute
of Harvard and MIT, Lund University, and Novartis Institutes
of BioMedical Research. Genome-wide association analysis
identifies loci for type 2 diabetes and triglyceride levels.
Science 316, 1331–1336.
50. Amundadottir, L.T., Sulem, P., Gudmundsson, J., Helgason, A.,
Baker, A., Agnarsson, B.A., Sigurdsson, A., Benediktsdottir,
K.R., Cazier, J.B., Sainz, J., et al. (2006). A common variant as-
sociated with prostate cancer in European and African popula-
tions. Nat. Genet. 38, 652–658.
51. Haiman, C.A., Patterson, N., Freedman, M.L., Myers, S.R.,
Pike, M.C., Waliszewska, A., Neubauer, J., Tandon, A.,
Schirmer, C., McDonald, G.J., et al. (2007). Multiple regions
within 8q24 independently affect risk for prostate cancer.
Nat. Genet. 39, 638–644.
52. Gudmundsson, J., Sulem, P., Manolescu, A., Amundadottir,
L.T., Gudbjartsson, D., Helgason, A., Rafnar, T., Bergthorsson,
J.T., Agnarsson, B.A., Baker, A., et al. (2007). Genome-wide as-
sociation study identifies a second prostate cancer susceptibil-
ity variant at 8q24. Nat. Genet. 39, 631–637.
53. Hugot, J.P., Laurent-Puig, P., Gower-Rousseau, C., Olson, J.M.,
Lee, J.C., Beaugerie, L., Naom, I., Dupas, J.L., Van Gossum, A.,
Orholm, M., et al. (1996). Mapping of a susceptibility locus
for Crohn’s disease on chromosome 16. Nature 379,
821–823.
54. Rioux, J.D., Xavier, R.J., Taylor, K.D., Silverberg, M.S., Goyette,
P., Huett, A., Green, T., Kuballa, P., Barmada, M.M., Datta,
L.W., et al. (2007). Genome-wide association study identifies
new susceptibility loci for Crohn disease and implicates au-
tophagy in disease pathogenesis. Nat. Genet. 39, 596–604.
55. Wiltshire, S., Hattersley, A.T., Hitman, G.A., Walker, M., Levy,
J.C., Sampson, M., O’Rahilly, S., Frayling, T.M., Bell, J.I.,
1062 The American Journal of Human Genetics 82, 1051–1063, May 2008
Lathrop, G.M., et al. (2001). A genomewide scan for loci
predisposing to type 2 diabetes in a U.K. population (the
Diabetes UK Warren 2 Repository): Analysis of 573 pedigrees
provides independent replication of a susceptibility locus on
chromosome 1q. Am. J. Hum. Genet. 69, 553–569.
56. Grant, S.F., Thorleifsson, G., Reynisdottir, I., Benediktsson, R.,
Manolescu, A., Sainz, J., Helgason, A., Stefansson, H., Emils-
son, V., Helgadottir, A., et al. (2006). Variant of transcription
factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes.
Nat. Genet. 38, 320–323.
57. Helgason, A., Pálsson, S., Thorleifsson, G., Grant, S.F., Emils-
son, V., Gunnarsdottir, S., Adeyemo, A., Chen, Y., Chen, G.,
Reynisdottir, I., et al. (2007). Refining the impact of TCF7L2
gene variants on type 2 diabetes and adaptive evolution.
Nat. Genet. 39, 218–225.
58. Lundmark, F., Duvefelt, K., Iacobaeus, E., Kockum, I., Wall-
ström, E., Khademi, M., Oturai, A., Ryder, L.P., Saarela, J.,
Harbo, H.F., et al. (2007). Variation in interleukin 7 receptor
alpha chain (IL7R) influences risk of multiple sclerosis. Nat.
Genet. 39, 1108–1113.
59. Hafler, D.A., Compston, A., Sawcer, S., Lander, E.S., Daly, M.J.,
De Jager, P.L., de Bakker, P.I., Gabriel, S.B., Mirel, D.B., Ivinson,
A.J., et al. (2007). Risk alleles for multiple sclerosis identified
by a genomewide study. N. Engl. J. Med. 357, 851–862.




A high-density association screen of 155 ion
transport genes for involvement
with common migraine
Dale R. Nyholt1,, K. Steven LaForge2,3,{, Mikko Kallela4, Kirsi Alakurtti3, Verneri Anttila3,
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17Migräne- und Kopfschmerz-Klinik Königstein, Ölmühlweg 31, 61462 Königstein im Taunus, Germany, 18Department
of Neurology, Ludwig-Maximilians-University Munich, Klinikum Grosshadern, Marchioninistr, Munich 81377, Germany,
19Neurologische Gemeinschaftspraxis Leopoldstraße, Munich 81377, Germany, 20Perlegen Sciences Inc., Mountain
View, CA 94043, 21Broad Institute of MIT and Harvard, Cambridge, MA 02141-2023, USA, 22Department of Molecular
Medicine, National Public Health Institute, The Finnish Institute for Molecular Medicine, 23Department of Medical
Genetics, University of Helsinki, Helsinki 00014, Finland and 24The Wellcome Trust Sanger Institute, Cambridge
CB10 1HH, UK
Received June 6, 2008; Revised July 21, 2008; Accepted July 31, 2008
To whom correspondence should be addressed. Tel: þ61 733620258; Fax: þ61 733620101; Email: dale.nyholt@qimr.edu.au
†Deceased.
‡Present address: Affymetrix Inc., Santa Clara, CA 95051, USA.
# The Author 2008. Published by Oxford University Press. All rights reserved.
For Permissions, please email: journals.permissions@oxfordjournals.org
Human Molecular Genetics, 2008, Vol. 17, No. 21 3318–3331
doi:10.1093/hmg/ddn227
Advance Access published on August 2, 2008
The clinical overlap between monogenic Familial Hemiplegic Migraine (FHM) and common migraine sub-
types, and the fact that all three FHM genes are involved in the transport of ions, suggest that ion transport
genes may underlie susceptibility to common forms of migraine. To test this leading hypothesis, we exam-
ined common variation in 155 ion transport genes using 5257 single nucleotide polymorphisms (SNPs) in
a Finnish sample of 841 unrelated migraine with aura cases and 884 unrelated non-migraine controls. The
top signals were then tested for replication in four independent migraine case–control samples from the
Netherlands, Germany and Australia, totalling 2835 unrelated migraine cases and 2740 unrelated controls.
SNPs within 12 genes (KCNB2, KCNQ3, CLIC5, ATP2C2, CACNA1E, CACNB2, KCNE2, KCNK12, KCNK2,
KCNS3, SCN5A and SCN9A) with promising nominal association (0.00041 < P < 0.005) in the Finnish
sample were selected for replication. Although no variant remained significant after adjusting for multiple
testing nor produced consistent evidence for association across all cohorts, a significant epistatic inter-
action between KCNB2 SNP rs1431656 (chromosome 8q13.3) and CACNB2 SNP rs7076100 (chromosome
10p12.33) (pointwise P 5 0.00002; global P 5 0.02) was observed in the Finnish case–control sample. We
conclude that common variants of moderate effect size in ion transport genes do not play a major role in sus-
ceptibility to common migraine within these European populations, although there is some evidence for epi-
static interaction between potassium and calcium channel genes, KCNB2 and CACNB2. Multiple rare variants
or trans-regulatory elements of these genes are not ruled out.
INTRODUCTION
Migraine (OMIM no. 157300) is a common neurovascular
disorder with a strong genetic component. Although genetic
variants have been well established for Mendelian forms of
migraine, no susceptibility variants associated with common
forms of migraine have been consistently reported. So far,
most association studies for headache traits have been
performed in relatively small study samples and typically for
only one or two genes per study. Thus, comprehensive candi-
date gene association studies saturating large gene families or
whole genome association studies have not been reported for
headache traits as yet.
The best insight to understand the genetic background
underlying pathogenetic mechanisms in migraine is provided
by studies in Familial Hemiplegic Migraine (FHM), a Mend-
elian subtype of migraine with aura (MA) associated with
hemiparesis. Families with FHM type 1 (FHM1) (OMIM no.
141500) have missense mutations in CACNA1A (OMIM no.
601011) (1), which encodes the pore-forming a1 subunit of
neuronal voltage-gated Cav2.1 (P/Q-type) Ca
2þ channels,
type 2 (FHM2) (OMIM no. 602481) patients show mutations
in ATP1A2 (OMIM no. 182340) (2), which encodes the a2
subunit of Naþ/Kþ ATPases that are expressed in astrocytes
in the adult brain, whereas type 3 (FHM3) (OMIM no.
609634) patients have mutations in the a1 subunit of the
neuronal voltage-gated Naþ channel Nav1.1 (SCN1A) (OMIM
no. 182389) (3).
All three FHM genes are involved in the transport of ions and
suggest that disturbances of ions and neurotransmitter levels in
the synaptic cleft play a key role inmigraine pathophysiology by
influencing neuronal excitability (4,5). Experimental evidence
points to cortical spreading depression (CSD)—a wave of
neuronal and glial depolarization followed by long-lasting
suppression of neuronal activity that propagates slowly over
the cerebral cortex—as the key event for episodic activation
of the trigeminovascular system, resulting inmigraine headache
(6,7). CACNA1A FHM1 mutations are predicted to cause
increased release of glutamate (the predominant excitatory
amino acid transmitter in brain) in the cortex, thus increasing
neuronal cortical network excitability rendering the cortex
more susceptible to CSD (8). ATP1A2 FHM2 mutations result
in reduced activity or decreased affinity for Kþ of the Naþ/Kþ
pump and thus impaired clearance of Kþ and glutamate from
the synaptic cleft. SCN1A FHM3 mutations are believed to
have effects similar to CACNA1A mutations, in the sense that
they predict increased neuronal excitability.
A relevant hypothesis is that the same pathways involved in
rare Mendelian forms of migraine might also be involved in
the pathogenesis of more common forms of migraine. This
is especially appropriate as the main symptoms of headache
and aura (as well as the accompanying symptoms of nausea,
photophobia and phonophobia) of FHM attacks are very
similar to those of MA, and both types of attack occur in
FHM patients (9). In fact, migraine without aura (MO) and
MA, frequently co-occur. A Dutch study found that 42% of
active migraineurs with aura also reported having migraine
attacks without aura (10). Moreover, MO and MA frequently
coexist within a family; a Headache Centre in Italy reported
that 45% of MA families also had MO cases (11) and the
co-occurrence of FHM, MA and MO has been reported in
families (12,13). Furthermore, changes in the presenting
symptoms of migraine attacks from hemiplegic to severe
headache with or without aura in later life (12), as well as
the development of aura among subjects with MO and the
converse (12,14), suggest overlapping aetiology.
The overlap in symptomatology among migraine subtypes
and the fact that all three known FHM genes are involved in
the transport of ions, strongly suggests that ion channels and
ion transporters, may also underlie susceptibility to the more
common forms of MO and MA. The relevance of ion channels
and transporters is also apparent from the fact that effective
migraine prophylactic agents such as valproate and topiramate
act on ion channels or transporters (15).
There are several reports that rare mutations in FHM genes
may also play a role in families with MA and/or MO (16,17).
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A systematic investigation of rare predisposing variants in
common migraine has become feasible because of recently
improved technology to perform extensive sequencing in a
large numbers of samples, but has not been performed.
However, an equally relevant hypothesis is that common var-
iants in either coding or non-coding regions of ion transport
genes might predispose to migraine. Association of common
variants to common traits can be studied with tools provided
by HapMap (18) and modern genotyping techniques.
Our multicentre collaboration (the Migraine Genetics Con-
sortium; MGC) assembled the largest cohort of patients with
common migraine for a genetic mapping study to date. To
investigate the potential role of genes involved in the transport
of ions in common migraine, we performed the first compre-
hensive screen of common genetic variants in highly plausible
candidate ion transport genes. A total of 5257 single nucleo-
tide polymorphisms (SNPs) were examined in 155 genes in
a large well-characterized Finnish case–control sample con-
sisting of 841 unrelated MA cases and 884 unrelated
non-migraine controls. Twelve genes producing nominally
significant (P , 0.005) association signals in the Finnish
sample were subsequently tested for replication in four inde-
pendent migraine case–control samples from the Netherlands,
Germany and Australia involving altogether 2835 migraine
cases and 2740 controls.
Also, given the reported functional interaction between
M-type KCNQ2 and KCNQ3 potassium channels (19) and
their modulation by the KCNE2 subunit (20), plus an
account of compound heterozygosity for two novel allelic
ATP1A2 missense mutations in the proband of a FHM
family (21), we also tested for interactions between SNPs
with nominally significant (P , 0.005) association signals in
the Finnish sample.
RESULTS
Of the 5269 SNPs passing Perlegen’s quality control (QC) cri-
teria analyzed in the Finnish case–control cohort, PLINK
identified 12 SNPs with MAF , 0.01 and subsequently
excluded them from further analysis. Importantly, the
PLINK identity-by-state (IBS)-based cluster analysis deter-
mined that one cluster best fit the data, thus providing no
evidence for population stratification within the Finnish
cohort. Absence of stratification was further supported with
PLINK reporting a genomic inflation factor (based on
median chi-squared) of 1 (values .1 indicate population
structure) and mean chi-squared statistic of 0.945 (a mean of
1 is expected under the null hypothesis of no stratification).
No evidence for association with MA was observed for
SNPs within the footprints of the three FHM genes. Briefly,
none of the 25 ATP1A2 and 26 SCN1A SNPs produced point-
wise P-values ,0.05. Although five of the 87 CACNA1A
SNPs (rs10416717, rs2419233, rs7249323, rs11882861,
rs2074880) did produce nominal point-wise P-values 0.05
(0.0131, 0.01822, 0.04142, 0.04257, 0.04915, respectively),
they were not significant after adjustment for testing
multiple SNPs.
Allelic association results 2log10(P) for all 5257 SNPs are
presented in Figure 1 (also see Supplementary Material,
Table S1). The smallest observed point-wise P-value from
allelic association analysis of 5257 SNPs in the Finnish 841
MA cases and 884 controls was obtained for SNP rs13276133
(x1
2 ¼ 12.49; point-wiseP ¼ 0.00041) residing in the potassium
voltage-gated channel, Shab-related, member 2 (KCNB2) gene
on chromosome 8q13.3. The next smallest P-value obtained for
SNPs within KCNQ3 on 8q24.22 (rs13267466; P ¼ 0.00064)
and CLIC5 on 6p12.3 (rs2095771; P ¼ 0.00074) also showed
encouraging evidence for association. An additional nine
genes (ATP2C2, CACNA1E, CACNB2, KCNE2, KCNK12,
KCNK2, KCNS3, SCN5A and SCN9A) produced promising
association signals (P, 0.005) (Table 1). However, after
multiple test correction for the analysis of 5257 SNPs via
permutation, our smallest point-wise P-value (rs13276133;
P ¼ 0.00041) was not globally significant with a global
EMP2 P-value of 0.7713. Hence, none of the tested SNPs
reached global statistical significance (EMP2 P  0.05)
(Table 1).
Exploratory analysis of haplotypes spanning two to six
contiguous SNPs also did not produce significant evidence
for association (data not shown), with the smallest observed
point-wise P-value (x1
2 ¼ 13.82; point-wise P ¼ 0.00020)
obtained for the specific 3-allele G-T-T haplotype of SNPs
rs1998822–rs7076100–rs11598027 within the CACNB2
gene on chromosome 10p12.33. The omnibus 3-allele haplo-
type test for this three SNP window (correcting for haplotype
tests for all observed 3-allele combinations) only produced a
x1
2 of 18.12 with point-wise P ¼ 0.0012, compared with the
single SNP point-wise P ¼ 0.00198 for rs11598027. Given
that these results are not corrected for testing, all other two
to six SNP haplotypes, analysis of haplotypes in these data
did not produce stronger evidence for association compared
with the single SNP analyses.
In addition to the primary MA phenotype, we also per-
formed exploratory association analyses with strict Inter-
national Headache Society (IHS) migraine criteria (i.e.
excluding the 114 MA individuals with aura symptoms not
strictly fulfilling the IHS aura criteria, but diagnosed as
MA by our clinical neurologist; Table 2) and the key
trait components of pulsation, photophobia and phonophobia
(Table 1, Supplementary Material, Table S1). Although
these exploratory analyses did not provide increased evidence
for association between MA and SNPs within the three
FHM genes, they did produce the smallest observed P-value
(x1
2 ¼ 16.00; point-wise P ¼ 0.000063), obtained for SNP
rs12996816 residing in the KCNS3 gene on chromosome
2p24.2 with the pulsation phenotype; however, this result
does not surpass the primary analysis global significance
threshold of point-wise P  0.000019. Furthermore, given an
additional global multiple test correction is required for exam-
ining four additional traits; these exploratory analyses do not
alter the overall (negative) interpretation of our individual
SNP association results.
Although no single SNP or haplotype reached statistical sig-
nificance, multiple small effect association signals in multiple
genes may nonetheless be present. To examine this possibility,
we plotted the observed distribution of the 5257 rank-ordered
chi-square (x1
2) values obtained from the single SNP allelic
association analysis using MA as trait, against the distribution
of x1
2 values expected under the null hypothesis of no
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association. The resulting QQ-plot (Fig. 2) shows a definite,
although non-significant preponderance of x1
2 values ranging
from around 9.573 (point-wise P ¼ 0.00198) to 10.19 (point-
wise P ¼ 0.00141) [i.e. the top 11–15 x12 values].
Applying the false discovery rate (FDR) approach to the
5257 rank-ordered allelic association P-values produced
q-values (FDRs) of 0.673 and 0.692 for the 1st–11th and
12th–15th smallest P-values, respectively. Assigned
q-values quickly and substantially increased in magnitude
for the 16th (q-value ¼ 0.773), 17th–23rd (q-value ¼ 0.950)
and remaining 24th–5257th ranked P-values (q-value ¼
0.9997). These results indicate that there are a maximum of
four to five likely true-positives contained within the top 15
most significant allelic associations [i.e. true positive prob-
ability (1 2 q-value) multiplied by the total number in the
set with equivalent or smaller q-values: (1– 0.6922)  15 ¼
4.62]. Also, our stage-1 nominal significance threshold for
allelic association with MA in the Finnish cohort demarcates
q-values of 0.950 and 0.9997, thus supporting P , 0.005 as
a reasonable compromise between following-up true risk loci
and the total number of loci to follow-up (i.e. minimizing
the multiple-test burden while maintaining high replication
power).
A total of 66 SNPswithin 12 genes (Table 1)were selected for
follow-up in the replication cohorts (see Supplementary
Material, Tables S2a and S2b for estimates of power to repli-
cate the Finnish association results). The 66 SNPs were
primarily selected upon the basis of having the smallest allelic
association results among all the Finnish MA cases and controls
(P , 0.005). The SNPswithin these 12 genes were also selected
if they produced nominal evidence (point-wise P , 0.05) for
MA and/or produced more significant P-values, compared
with the primary MA phenotype, for association with the traits
examined in the exploratory association analyses (Table 1, Sup-
plementary Material, Table S1). In addition to the investigation
of multiple effects within each gene, we selected multiple
associated SNPs within the 12 most promising genes to help
guard against potential assay failure in the follow-up replication
studies. Counts of case–control individuals successfully geno-
typed are provided in Table 3.
All 66 SNPs, except those which failed, were tested first in
the Leiden sample with MA and MO (one SNP failed).
Following the Leiden results, 60 SNPs were successfully
tested in the population-based Brisbane sample with MA and
MO. Finally, 44 SNPs were successfully tested in the
Cologne and Munich clinic-based German MA samples. We
note that due to the Munich cohort consisting of only migraine
cases, two German-specific analyses were performed; (i)
Cologne cases versus Cologne controls and (ii) combined
Cologne cases and Munich cases versus Cologne controls.
Post hoc analyses (not presented) in the replication cohorts
containing a mixture of migraine sub-groups did not identify
significant allele frequency differences between MO, MA
and the latent class analysis (LCA)-based migraine groups,
thus supporting the combination of these sub-groups. After
QC checks, some genotype assays were failed in each cohort.
The results from association analysis of the 66 replication
SNPs are presented in Table 4. Although a small number of
SNPs showed significant evidence for replication (EMP2
P  0.05) in the Brisbane [CLIC5 SNP rs3729618 (EMP2
P ¼ 0.0459)] and Cologne cohort [KCNE2 SNPs rs1467847
(EMP2 P ¼ 0.0139) and rs1013063 (EMP2 P ¼ 0.0193)],
none of the SNPs produced consistent evidence for replication
across the cohorts. Furthermore, none of the SNPs were sig-
nificant in the combined replication cohort Cochran-Mantel-
Haenszel (CMH) test after correction for testing 66 SNPs.
Analysis of the Leiden, Brisbane and/or combined replication
MA subset did not alter the overall results. Due to the associ-
ated CLIC5 alleles in the Finnish and Brisbane cohorts being
in opposite directions, the KCNE2 associations remain as the
sole result which could justify further investigation. See Sup-
plementary Material, Table S3 for point-wise replication
association analysis results for all 66 replication SNPs in the
four individual replication cohorts and combined replication
sample.
Interestingly, a SNP  SNP epistasis analysis of the 66
replication SNPs in the Finnish case–control sample detected
an interaction between KCNB2 SNP rs1431656 on chromo-
some 8q13.3 and CACNB2 SNP rs7076100 on chromosome
10p12.33 (point-wise P ¼ 0.0000199), which remained
significant after conservatively correcting for all 2145
possible interaction tests [i.e. treating the 66 replication
SNPs as independent] (global P ¼ 0.042). Accounting for
non-independence between SNPs due to intermarker linkage
disequilibrium (LD) (22), the global P-value for the
rs1431656  rs7076100 interaction is P ¼ 0.022. This
interaction was driven by the rs1431656–rs7076100 G-A
haplotype providing increased protection against migraine
Figure 1. Allelic association results for Finnish MA cases versus controls. Horizontal red line indicates the required global significance threshold [2log10(P) ¼
4.7286] to ensure an overall type I error rate of 5%.
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Table 1. Single SNP association results for single nucleotide polymorphisms selected for replication from Finnish case–control cohort
Chr NCBI build
36 position (bp)
dbSNP rs no. Primary gene
HGNC symbol
Case minor allele Case MAF Control MAF Allelic P Allelic OR Allelic
EMP2 P
1 179680697 rs12073221 CACNA1E C 0.3165 0.275 0.008168 1.22 1
1 179691156 rs3856087 CACNA1E A 0.3356 0.2837 0.001215 1.28 0.9839
1 179702677 rs644796 CACNA1E C 0.467 0.4255 0.01537 1.18 1
1 179709099 rs505738 CACNA1E C 0.4619 0.4268 0.0382 1.15 1
1 213353044 rs4300189 KCNK2 A 0.1391 0.1599 0.08803 0.85 1
1 213365431 rs11120499 KCNK2 T 0.2218 0.2576 0.01368 0.82 1
1 213395890 rs12567520 KCNK2 A 0.09869 0.1179 0.06979 0.82 1
1 213398386 rs2363556 KCNK2 G 0.1391 0.1612 0.0698 0.84 1
1 213428215 rs1556905 KCNK2 A 0.3254 0.3502 0.129 0.90 1
1 213428830 rs10494994 KCNK2 A 0.1663 0.2043 0.004157 0.78 1
1 213458463 rs12143625 KCNK2 C 0.1901 0.2244 0.01314 0.81 1
1 213467066 rs6670661 KCNK2 G 0.3061 0.333 0.09116 0.88 1
1 213476729 rs6686529 KCNK2 G 0.1902 0.2254 0.01113 0.81 1
2 17908169 rs12996816 KCNS3 T 0.1177 0.08541 0.001656 1.43 0.9952
2 17916155 rs10178489 KCNS3 G 0.2996 0.2661 0.02894 1.18 1
2 47660997 rs17568951 KCNK12 C 0.1946 0.1534 0.001409 1.33 0.9909
2 166879155 rs11890824 SCN9A A 0.4512 0.4745 0.1714 0.91 1
2 166889773 rs11898284 SCN9A G 0.1795 0.1433 0.003754 1.31 1
2 166902637 rs12622743 SCN9A G 0.1798 0.1433 0.003573 1.31 1
3 38599347 rs3922843 SCN5A A 0.2429 0.2036 0.005644 1.26 1
3 38602829 rs7645358 SCN5A G 0.1611 0.1799 0.1435 0.88 1
3 38609146 rs7374540 SCN5A C 0.4007 0.4274 0.1114 0.90 1
3 38653505 rs7427106 SCN5A G 0.1397 0.1753 0.004134 0.76 1
3 38656222 rs9311195 SCN5A G 0.1534 0.1878 0.007321 0.78 1
3 38672343 rs9861643 SCN5A T 0.1974 0.22 0.1033 0.87 1
6 45993676 rs11758298 CLIC5 T 0.1308 0.1471 0.1677 0.87 1
6 45995399 rs1416167 CLIC5 T 0.2903 0.2571 0.02875 1.18 1
6 45996051 rs3729618 CLIC5 G 0.2905 0.2576 0.03071 1.18 1
6 46008544 rs3777567 CLIC5 A 0.2655 0.2197 0.001715 1.28 0.9966
6 46012610 rs2095771 CLIC5 A 0.25 0.2017 0.0007735 1.32 0.9358
6 46018442 rs3777580 CLIC5 C 0.321 0.2778 0.005546 1.23 1
6 46026947 rs3777585 CLIC5 T 0.1871 0.1586 0.0265 1.22 1
8 73598648 rs12550268 KCNB2 A 0.382 0.4189 0.02711 0.86 1
8 73601624 rs1431659 KCNB2 A 0.2271 0.2704 0.003311 0.79 0.9999
8 73609424 rs5007872 KCNB2 G 0.2187 0.2669 0.001311 0.77 0.9876
8 73614029 rs349358 KCNB2 C 0.1249 0.1489 0.04 0.82 1
8 73618324 rs349355 KCNB2 A 0.1244 0.1493 0.03353 0.81 1
8 73651525 rs349335 KCNB2 C 0.1013 0.131 0.006741 0.75 1
8 73653731 rs1431656 KCNB2 G 0.2525 0.3056 0.0006998 0.77 0.9172
8 73659142 rs1542709 KCNB2 A 0.2368 0.2773 0.00673 0.81 1
8 74006869 rs7006287 KCNB2 G 0.4006 0.4552 0.001205 0.80 0.983
8 74012757 rs11782118 KCNB2 A 0.365 0.4184 0.001352 0.80 0.9892
8 74016115 rs922772 KCNB2 C 0.4518 0.4072 0.008148 1.20 1
8 74017814 rs13276133 KCNB2 C 0.3556 0.4145 0.000409 0.78 0.7713
8 133408579 rs13267466 KCNQ3 C 0.1198 0.1602 0.0006373 0.71 0.897
10 18458186 rs7897594 CACNB2 G 0.3719 0.4117 0.01682 0.85 1
10 18460390 rs11596974 CACNB2 A 0.3641 0.3991 0.03481 0.86 1
10 18799543 rs7076100 CACNB2 A 0.419 0.4559 0.02933 0.86 1
10 18800641 rs11598027 CACNB2 T 0.147 0.1117 0.001975 1.37 0.9986
10 18803689 rs1409202 CACNB2 A 0.147 0.1122 0.002354 1.36 0.9998
10 18822886 rs8181477 CACNB2 C 0.4613 0.504 0.01226 0.84 1
10 18823994 rs11014504 CACNB2 C 0.4457 0.4819 0.03356 0.86 1
16 82964929 rs17740111 ATP2C2 C 0.1942 0.2347 0.003894 0.79 1
16 82971665 rs7350833 ATP2C2 C 0.2643 0.2333 0.03534 1.18 1
16 82974143 rs10459853 ATP2C2 G 0.1285 0.1619 0.005822 0.76 1
16 83002938 rs247820 ATP2C2 C 0.4388 0.4791 0.01756 0.85 1
16 83040732 rs247889 ATP2C2 A 0.4214 0.3776 0.008578 1.20 1
16 83055346 rs429313 ATP2C2 A 0.2811 0.2474 0.02536 1.19 1
16 83062088 rs394533 ATP2C2 T 0.3214 0.2874 0.03043 1.17 1
16 83063868 rs400922 ATP2C2 G 0.2935 0.256 0.01439 1.21 1
16 83065318 rs390208 ATP2C2 A 0.2843 0.2471 0.01406 1.21 1
21 34612656 rs2834442 KCNE2 T 0.2771 0.3222 0.003897 0.81 1
21 34620260 rs1013063 KCNE2 T 0.3526 0.3907 0.0205 0.85 1
21 34636414 rs1467847 KCNE2 G 0.35 0.3815 0.05496 0.87 1
21 34639061 rs2834462 KCNE2 T 0.2762 0.3171 0.008623 0.82 1
21 34643430 rs8128316 KCNE2 C 0.3909 0.4304 0.01872 0.85 1
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occurrence (Table 5). An interaction between these two SNPs
was not observed in any of the replication samples (Table 5 for
comparison of population sample allele frequencies).
However, other SNPs within these same genes, KCNB2 and
CACNB2, provided suggestive evidence for interaction in the
Brisbane cohort and marginally significant evidence for inter-
action in the combined Cologne and Munich cohort (i.e.
between CACNB2 SNP rs8181477 and KCNB2 SNPs
rs7006287 and rs11782118, point-wise P ¼ 0.004017 and
P ¼ 0.004454, respectively). A more detailed description of
the interaction analysis is provided in the Supplementary
Material, Appendix.
DISCUSSION
Triggered by the observation that all three genes for FHM, a
monogenic subtype of MA, encode ion transporters, we inves-
tigated the role of ion transport genes in the common forms of
migraine. To this end, we performed the first comprehensive
screen of common genetic variants in highly plausible candi-
date ion transport genes. We tested a total of 5257 SNPs cov-
ering 155 of such genes initially in a large well-characterized
Finnish case–control sample. The most significantly associ-
ated 66 SNPs in 12 genes were subsequently tested in four
additional independent cohorts, but no consistent replication
was detected across all cohorts.
Supplementary Material, Tables S2a and S2b contain esti-
mates of the power to replicate association for the four most
significantly associated SNPs [rs13276133, rs1431656
(KCNB2); rs13267466 (KCNQ3); rs2095771 (CLIC5)] in the
Finnish cohort, plus the single CLIC5 SNP (rs3729618) and
two KCNE2 SNPs (rs1013063, rs1467847) producing signifi-
cant evidence for replication (EMP2 P  0.05) in the individ-
ual Brisbane and Cologne cohorts, respectively. The combined
replication sample had very high (.99%) power to replicate
the four most significant Finnish association signals
[rs13276133, rs1431656 (KCNB2); rs13267466 (KCNQ3);
rs2095771 (CLIC5)], while the individual Leiden, Cologne,
combined Cologne and Munich, and Brisbane cohorts each
had 68–71%, 54–57%, 61–65% and 79–82% power to
replicate at a nominal point-wise threshold of P  0.05. At a
globally significant replication threshold (adjusted for testing
all 66 SNPs selected for replication) of P  0.001 [estimated
using SNPSpD (22)], the individual cohorts’ power to repli-
cate dropped considerably to 19–22%, 11–12%, 14–17%
and 30–34%, respectively. However, the power to replicate
(P  0.001) remains high (85–89%) in the combined replica-
tion sample.
Despite our use of large and well-characterized migraine
case–control cohorts (total of 2835 cases and 2740 controls),
only the potassium voltage-gated channel, Isk-related, member
2 (KCNE2) gene on chromosome 21q22.11 produced margin-
ally convincing evidence for replication in the Cologne cohort.
However, the lack of association evidence in the remaining
three replication cohorts, including a similar sample from
Munich, cast doubt on the robustness of this finding. Further-
more, analysis of the KCNE2 SNPs (rs1013063, rs1467847) in
the combined replication sample produced non-significant
CMH point-wise P-values of 0.187 and 0.161, and global
EMP2 P-values of 1 and 0.9995, respectively (see Supplemen-
tary Material, Table S3).
While no single SNP produced significant evidence for
association in the Finnish case–control sample, SNP  SNP
epistasis analysis of the 66 SNPs selected for replica-
tion detected a significant interaction between KCNB2
SNP rs1431656 on chromosome 8q13.3 and CACNB2
SNP rs7076100 on chromosome 10p12.33 (point-wise
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Other; migraine aura symptoms not fulfilling the International Headache
Society aura criteria, but classified as migraine with aura by a clinical
neurologist.
Figure 2. QQ-plot of Finnish case–control allelic association results for clini-
cal migraine with aura end-diagnosis (closed black circles). The solid red line
represents the expected (reference) distribution under the null. The broken red
lines indicate the point-wise 95% CI envelope based on the standard errors of
order statistics for an independent sample from the reference distribution.
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P ¼ 0.0000199; global P ¼ 0.022). Although this specific
interaction was not observed in our replication cohorts, the
significance of the rs1542709  rs7076100 interaction in the
Finnish sample and supporting evidence for inter-genic
SNP  SNP interaction in the combined Cologne and
Munich replication cohort, indicate further study of KCNB2
and CACNB2 variants and their combined contribution to
migraine susceptibility may be warranted.
To investigate how the reported results would compare to
those potentially obtained in a high-density genome-wide associ-
ation (GWA) study, we examined the SNP coverage across the
gene footprints provided by the Illumina HumanCNV370-Duo
and HumanHap550-Duo BeadChips (array marker lists were
downloaded from http://illumina.com.au on 19 December
2007). These two arrays were selected owing to both their
popularity and design. More specifically, in contrast to the
Affymetrix arrays 5.0 and 6.0 (containing 440 794 and
906 600 SNPs, respectively), which are not designed with refer-
ence to LD structure, the Illumina arrays contain SNPs selected
to tag LD bins—analogous to the approach employed in the
design of our ion transport Perlegen array. However, although
the Affymetrix 6.0 array was not designed with reference to
LD structure, it is worth noting that it has been shown to
provide similar LD coverage to the Illumina HumanHap550
[http://www.ashg.org/genetics/ashg07s/index.shtml; (23)].
Of the 370 405 SNPs present on the HumanCNV370 array,
3272 are located within the 155 gene ‘footprints’ (includes
extension of 20 kb upstream of transcription start and 10 kb
downstream of transcription end). Of the 561 467 Human-
Hap550 SNPs, 5270 are located within the 155 gene ‘foot-
prints’. Given the usable number of Illumina array SNPs
would likely be reduced after QC, these counts indicate that
our study provides at least as much coverage of common vari-
ation as that provided by the high resolution HumanHap550
array [which captures 90% of all HapMap Phase I þ II loci
(MAF . 0.05) with r2 . 0.8] and far greater coverage than
the HumanCNV370 array. Hence, the results of our detailed
association screen of 155 ion transport genes are highly rele-
vant to the burgeoning field of whole GWA studies. Indeed,
the results of our study may be readily compared with GWA
studies as they come to pass.
Furthermore, although our study was well-powered and had
excellent SNP coverage, the absence of significant association
within these 155 highly plausible migraine candidate genes at
a moderate significance threshold (approximately P , 1025)
compared to that required for GWA studies (recent guidelines
recommend P , 1027) (24,25), indicates that common vari-
ation of moderate effect in these candidate genes does not
play a major role in common migraine susceptibility within
the samples examined. These results therefore suggest that
either common variation of smaller effect in these candidate
genes, or other ‘less obvious’ genes and pathways likely
underlie the genetic susceptibility of the common forms of
migraine. Alternatively, the investigated ion transport genes
contribute to migraine through multiple, relatively rare and/
or possibly interacting variants, or variation in distant cis- or
trans-regulatory elements not tested in this study design.
Although sample sizes in excess of 10 000 cases and 10 000
controls will be required to detect rare variants (MAF , 0.1)
(26), a GWA study in large, well-characterized samples
would be an unbiased way to test the hypothesis whether
common variants in any part of the genome are associated
with common forms of migraine. Indeed, efforts are now
underway within the MGC to perform a GWA study utilizing
at least 2000 unrelated MA cases. The results of the MGC
GWA study should ultimately determine whether common
genetic variants underlie susceptibility to common migraine
and this approach would not restrict our thinking to previously
known or predicted pathways. It enables testing of less pre-
dictable regions of the genome and allows examination of
SNP  SNP interaction on a true genome-wide scale.
In addition, pathway-based approaches can be readily applied
to GWA studies to yield biological insights that are otherwise
undetectable by focusing only on individual genes and/or
regions that have the strongest evidence for association (27).
For example, a typical pathway-based approach might rank all
genes by their significance of association and then investigate
whether a particular group of genes is enriched at the significant
end of the ranked list more than that expected by chance.
Application of such pathway-based approaches, where multiple
genes in the same pathway contribute to disease aetiology, but
common variations in each of the causal genes make modest
contributions to disease risk, has enormous potential to both
detect novel and confirm hypothesized causal pathways and
disease mechanisms other than ion transportation (e.g. dopamin-
ergic and serotonergic pathways).
MATERIALS AND METHODS
Finnish discovery cohort
For this cohort, patients with a diagnosis of MA were drawn
from the ongoing Finnish Migraine Study. MA was chosen
as the principal diagnosis, as the Finnish patient pool has
been primarily ascertained for this disorder and because the
inclusion of aura as a diagnostic criterion reduces the possi-
bility that other headache disorders would be included in the
case sample (28). Patients were recruited from four headache
clinics across Finland. Index cases were selected based on
clinical examination by a neurologist from patients with at
least three affected first-degree relatives; all available family
members were also recruited into the study. Index cases and
family members were diagnosed based on the IHS criteria
(29,30) using the validated Finnish Migraine-Specific Ques-
tionnaire for Family studies (31). For the Finnish study, all
participants gave informed consent and approval to conduct
the research was obtained from the Helsinki University
Central Hospital Ethics Committee. Over 6000 individuals in
more than 800 families have taken part in this study and




Total Male Female Total Male Female
Leiden 800 192 608 946 520 426
Cologne 601 136 465 651 159 492
Munich 288 40 248 0 0 0
Brisbane 1146 203 943 1143 691 452
Total 2835 571 2264 2740 1370 1370
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recruitment is under progress. From the total cohort of migrai-
neurs in the Finnish family study, 898 unrelated individuals
with MA were selected for this case–control study. Control
subjects for the study were 900 unrelated individuals drawn
from the Finnish Twin Cohort (32). One twin was selected
from each pair, and these subjects were matched with
respect to gender and age to cases. Control subjects have all
responded negatively to the question of lifetime occurrence
of migraine and also report no family history of migraine.
Table 2 details key characteristics of patient findings for the
Finnish study (33).
Replication cohorts
Leiden cohort. The Leiden sample is a well-phenotyped
population-based migraine cohort from the Genetic Epide-
miology of Migraine (GEM) study from the Netherlands.
DNA was available from 823 unrelated migraine cases (555
MO; 268 MA) and 946 unrelated non-migraine controls. The
GEM cohort is embedded within the ‘MORGEN’ project—a
population-based study designed to monitor risk factors for
and the prevalence of chronic diseases of public health import-
ance in Dutch adults 20–65 years of age. The sample for the
MORGEN project was selected randomly within equal-size
strata of a five-year age group and gender from two Dutch
county population registries. During 1995–1996, a total of
6491 individuals (52.7%) participated in the study. Respon-
dents signed a general informed consent for the MORGEN
project, and a specific informed consent for the GEM Study.
For case-finding, MORGEN participants were mailed an
extensive self-administered questionnaire that included ques-
tions about sociodemographic characteristics, medical
history, psychosocial functioning and five migraine screening
questions [adapted from Stewart et al. (34)]. Screen-positive
participants completed a more detailed questionnaire that
focused on signs and symptoms of migraine headache and
aura as outlined in the IHS criteria. Very special care was
given to diagnose aura and those reporting visual aura symp-
toms were also asked to draw what they saw. A semi-
structured telephone interview was obtained in a random
sample of (83%) screen-positive and (5%) screen-negative
participants to clarify the signs and symptoms of migraine
headache and aura reported in the stage 2 questionnaire, and
to validate the earlier questionnaire. After a screening pro-
cedure, final (lifetime) diagnosis of migraine was made in
863 participants, 620 of whom had active migraine (10). The
lifetime prevalence of migraine in women was 33% and the
1-year prevalence was 25%. In men, the lifetime prevalence
was 13.3% and the 1-year prevalence was 7.5%. Among
patients with migraine in the past year, 63.9% had MO,
17.9% had MA and 13.1% had both MA and MO. The preva-
lence of migraine was significantly higher in women and not
associated with socioeconomic status. Migraine patients suf-
fered a median of 12 migraine attacks per year; 25% had at
least two attacks per month. The Leiden control sample was
drawn from participants who were screened negative on the
five migraine screening questions and matched the cases
with respect to age and gender. The GEM sample has been
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the cardiovascular risk profile and impact of migraine on
quality of life (35–37).
Cologne/Kiel cohort. All participants were diagnosed by the
revised criteria of the IHS (30) (601 MA patients and 651
matched, healthy control individuals) and have provided
their written informed consent; the study was approved by
the Local University Ethics Committees. All patients were
interviewed personally or by telephone by an experienced
neurologist and a detailed questionnaire was completed for
each of them. The complete patient ascertainment was per-
formed by a single highly specialized headache centre. The
questionnaire included a comprehensive assessment of (i) the
type, frequency, localization and duration of aura symptoms,
(ii) the possible existence of motor symptoms such as weak-
ness or hemiplegia, (iii) the properties, frequency, localization
and duration of the headache attack, (iv) a history of medi-
cation, (v) the existence of other possible diseases and (vi)
the family history. All control individuals were unrelated, of
German origin and were also gender-matched. Control indi-
viduals were interviewed to exclude those who suffer from
frequent headaches or migraine. From each family, the index
case, provided that he/she had a positive family history, has
been included in the case–control sample [for more detailed
cohort information see, for example, Netzer et al. (38)].
Munich cohort. All subjects were unrelated and were diag-
nosed with MA based on the revised criteria of the IHS and
have given their written informed consent. All patients were
personally seen and examined by a headache specialist. The
majority of subjects were sampled through a headache clinic
(approximately 60%) or a headache specialist in private prac-
tice (30%). The remaining patients were recruited at the
Department of Neurology (Klinikum Großhadern, Munich).
All participants received an extensive, validated questionnaire
(31) used in studies on the genetics of migraine. The question-
naire includes a comprehensive assessment of (i) premonitory
symptoms, (ii) the type, frequency, localization and duration
of aura symptoms, (iii) the presence/absence of motor symp-
toms, (iv) the properties, frequency, localization and duration
of the headache attack, (v) a history of medication, (vi) comor-
bidities, (vii) family history and (viii) ethnic origin. The study
was approved by the Local Ethics Committee in Munich.
Brisbane cohort. The Australia-wide sample is a large
population-based migraine cohort which has been used in a
number of studies addressing various aspects of migraine gen-
etics (39). The Brisbane sample is made up of two cohorts
drawn from the Australian Twin Registry. In 1993–1995, a
telephone interview comprising a diagnostic assessment of
psychiatric disorders, including alcohol use and abuse,
anxiety, depression and phobias, was conducted to an older
cohort of twins, born 1902–1964. A total of 5996 individual
twins completed the 1993 interview (40). Between 1996 and
2000, a younger cohort of twins (born 1964–1975) undertook
a similar extensive semi-structured telephone interview,
designed to assess physical, psychological and social manifes-
tations of alcoholism and related disorders (41); 6265 individ-
ual twins completed the interview. For the Australian study, all
participants gave informed consent and approval to conduct
the research was obtained from the Queensland Institute of
Medical Research (QIMR) Human Research Ethics Commit-
tee. Both cohort samples were not selected with regard to per-
sonal or family history of alcoholism or other psychiatric or
medical disorders including migraine. Migraine symptom
data were obtained during the course of the telephone inter-
views. The wording of questions was identical between
cohorts. However, the younger cohort were asked questions
relating to all IHS symptoms, whereas the older cohort had
a somewhat more restricted number of questions (no questions
regarding attack frequency, duration and pain intensity). The
two cohorts were combined, thus allowing LCA to impute
class membership in the older cohort, based on the pattern
of all 10 symptoms observed in the younger cohort. To
examine the accuracy of imputed class memberships, we com-
pared the classification results for the younger dataset utilizing
all the 10 available IHS symptoms, to the classification results
for the younger dataset utilizing only the seven IHS symptoms
that were available for the older cohort. Compared to using all
10 symptoms, when only the seven symptoms were used, these
analyses found 98.5% and 96.0% of individuals were correctly
classified as unaffected and affected, respectively; thus indi-
cating that the three missing symptoms in the older cohort
have negligible effect on the accuracy of individual LCA
classifications (42). Given that we have previously shown
LCA classified migraine to be a valid and accurate measure
for genetic research (39), we combined Brisbane cases satisfy-
ing IHS criteria (64%) with cases classified as affected via our
LCA approach (36%).
The Brisbane case–control replication sample consists of
1152 unrelated migrainous headache (39,42) cases of which
971 report visual aura and 1152 unrelated Australian twin
Table 5. Allele frequency data for rs1431656 and rs7076100 interaction
Single nucleotide
polymorphism
Allele Finland Leiden Brisbane
Cases Controls Cases Controls Cases Controls
rs1431656 G 0.25 0.31 0.27 0.26 0.28 0.27
A 0.75 0.69 0.73 0.74 0.72 0.73
rs7076100 A 0.42 0.46 0.40 0.38 0.41 0.44
T 0.58 0.54 0.60 0.62 0.59 0.56
Haplotype G–A 0.08 0.17 0.10 0.10 0.12 0.12
G–T 0.17 0.14 0.17 0.17 0.16 0.15
A–A 0.34 0.29 0.30 0.28 0.29 0.32
A–T 0.41 0.40 0.43 0.45 0.43 0.41
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controls screened negative for migraine. All controls have par-
ticipated in the same survey and indicated that neither the
study subject nor any first-degree relative had migraine.
Candidate gene selection
We targeted a comprehensive listing of ion channels and
ion-channel modulators expressed in human brain for the
association screen. Microarrays for genotyping were designed
with the goal that they will have utility in a number of dis-
orders beyond migraine in which ion-transporters are also pre-
dicted to play an important role, including epilepsy and
cardiac arrhythmias. Therefore, we targeted all the relevant
ion channels with sufficient SNP marker density to have
high power to detect association. During the month of
October 2005, we selected an inclusive list of ion-transporters
from publicly available databases, including the ion-channel
categorization on the Kyoto Encyclopedia of Genes and
Genomes (KEGG) website http://www.genome.jp/kegg/ a
text-based search of ion channels, ATPases and related pro-
teins at the University of California Santa Cruz (‘Golden
Path’) database http://genome.ucsc.edu/ and a screen of the
Ensembl database http://www.ensembl.org/index.html for
other ion-transport genes (Biological Process Gene Ontology
term ID: 0030001). These genes were then further screened
for expression in brain or heart using the eGenetics/SANBI
databases via the Ensembl website. Additional screening for
molecular function was performed using the data available
in the National Center for Biotechnology Information
(NCBI) Online Mendelian Inheritance in Man (OMIM) data-
base http://www.ncbi.nlm.nih.gov/omim. This iterative
process yielded a comprehensive listing of 155 ion channel
and ion-channel modulators (see Supplementary Material,
Table S1). Table 6 shows a breakdown of the major categories.
Polymorphism selection
Polymorphism selection for the ion-transport screen was pri-
marily based on Perlegen’s ‘LD bin-map’ of SNPs that are
validated in their assay, have a minor allele frequency
(MAF) .0.1, and have been tested in their screen of almost
1.6 million SNPs in 71 Americans of European, African and
Asian ancestry to define whole genome patterns of variability
(43). Perlegen has identified tag SNPs within each bin that are
in LD with every other SNP in the bin with r2 . 0.8 using the
algorithm of Carlson et al. (44). Such representative tag SNPs
were selected from LD bins spanning each of the 155 gene
‘footprints’ (transcriptional footprint extended 20 kb upstream
of transcription start and 10 kb downstream of transcription
end). The mean and median gene footprint was 136 280 bp
and 67 100 bp, respectively.
In designing the microarrays, one-tag SNP was selected
from bins containing one to two SNPs. For bins containing
three or more SNPs, two-tag SNPs were selected to guard
against possible assay failure of a single-tag SNP, thus mini-
mizing the potential for loss of the substantial allelic variation
contained within larger LD bins. A total of 5975 SNPs were
selected for genotyping. These 5975 tag SNPs provide an
overall mean and median per-gene resolution of one SNP
every 5034 bp and 3552 bp, respectively; and effectively test
a total of 11 148 SNPs with r2 . 0.8, thus providing a very
high resolution to test all common alleles within these genes.
Genotyping
Genotyping of the ion-transport SNPs utilized microarrays
designed by Perlegen Sciences, Inc. (Mountain View, CA,
USA) and manufactured by Affymetrix, Inc. (Santa Clara,
CA, USA). These assays have been documented to have a
.99% concordance with other genotyping methods (43,45).
Genotyping assays and QC was performed by Perlegen. A
total of 59 individuals were excluded from further analysis
due to an overall call rate of ,80% and the data quality
remaining poor after repeat genotyping of the sample. An
additional 14 individuals were excluded from further analysis
due to evidence of familial relatedness after examination of
allele sharing among pairs of individuals using the genotypic
relative risk program (46).
A total of 706 SNPs were excluded from further analysis
according to at least one of the following QC criteria:
(i) call rate of ,95%, (ii) P, 1024 for deviation from
Hardy–Weinberg equilibrium and (iii) X and Y chromosome
SNP performance (i.e. for non-pseudoautosomal X chromo-
some SNPs, females can have up to two alleles, whereas
males can have only one allele; for Y chromosome SNPs,
females should have zero alleles while males should have
one allele). The resulting 5269 tag-SNPs still provide a very
high resolution to test all common alleles within the 155 ion-
transport genes with an overall mean and median per-gene res-
olution of one SNP every 5968 bp and 4323 bp, respectively.
For the replication study, SNP genotypes were determined
in a 384-well format using the Sequenom iPLEX system
(Sequenom, San Diego, CA, USA) in which the distinction
between genotypes is based on the mass differences between
the primer extension products of the two alleles. Assays
were designed using the AssayDesign software (Sequenom);
primer information is available from the corresponding
author upon request. The multiplex polymerase chain reaction
and primer extension reactions were performed under standard
conditions according to the manufacturer’s instructions using
20 ng of genomic DNA as a template.
Power of Finnish case–control sample to detect association
To account for non-independence between SNPs due to inter-
marker LD, we determined the approximate effective number
of independent SNPs (Meff) following the SNPSpD approach
of Nyholt (22) and applying equation (5) of Li and Ji (47). Uti-
lizing observed genotype data for the final 5269 SNPs passing
Table 6. Breakdown of candidate gene categories
Genes (n) Gene category
26 Voltage-gated calcium channels
74 Voltage-gated potassium channels
14 Voltage-gated sodium channels
21 Chloride channels
20 ATPase ion transporters
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Perlegen’s QC protocols, we calculated the intermarker LD
(pair-wise r2) for SNPs located on the same chromosome.
Examination of the eigenvalues after spectral decomposition
of the resulting chromosome-specific correlation matrices
(
p
r2) determined an equivalent of 2677 total independent
SNPs to be tested for association. Consequently, to ensure
an overall type I error rate of 5%, we require a Bonferroni-
adjusted significance level (a) of P ¼ 0.05/2677 ¼ 0.000019
[2log10(a) ¼ 4.7386].
Power calculations were performed for a case–control study
assuming a disease prevalence for MA of 5% using the
Genetic Power Calculator (48). In short, power calculations
for our Finnish discovery cohort assumed loci with dominant
and multiplicative modes of inheritance and were based on
our post-QC sample of 841 cases and 884 controls. The
Finnish cohort has over 80% power to detect dominant
disease-predisposing alleles of frequency 0.10, 0.25 and 0.5
contributing a GRR of 1.78, 1.70 and 2.32, respectively. For
the general multiplicative model, there is 80% power to
detect risk alleles of frequency 0.10, 0.25 and 0.5 contributing
a GRR of 1.65, 1.45 and 1.40, respectively. These calculations
demonstrate our Finnish discovery cohort to have high power
to detect ion-transport gene associations of moderate effect.
Statistical analysis
The following statistical analyses were performed using the
PLINK analysis program (version 1.00) (http://pngu.mgh.
harvard.edu/purcell/plink/) (49). PLINK QC options were uti-
lized with default thresholds: maximum missing genotypes per
person (- -mind option) 0.10, maximum missing genotypes
per SNP (- -geno option) 0.10, MAF (- -maf option) 0.01
and Hardy–Weinberg disequilibrium (exact) P-value 0.001
in controls (- -hwe option). Cluster analysis based on pair-wise
IBS distance (- -cluster option) of the SNPs passing both
Perlegen and PLINK QC criteria was utilized to identify
possible population structure within the Finnish case–control
cohort. Single marker basic allelic association (x1
2) tests
(- -assoc option) were performed for each of the post-QC
SNPs. PLINK’s max(T) permutation procedure (- -mperm
option) was used with 10 000 iterations to obtain accurate
global empirical P-values (i.e. point-wise P-values are for
the single test only, whereas global P-values are adjusted for
testing all analyzed SNPs) (‘EMP2’ column of - -mperm
output). Genome-wide significant association is therefore
obtained at a global EMP2 P-value of 0.05 or smaller.
Although the primary analysis in the Finnish cohort tested
for association to MA, we also performed exploratory associ-
ation analysis to strict IHS criteria, and the individual migraine
trait components of ‘pulsation’, ‘photophobia’ and ‘phonopho-
bia’ to help select SNPs for replication.
The FDR approach (50–52), which allows a controlled pro-
portion of positive results to be false, while detecting more
true-positives was also used to help select and interpret the
most promising SNP associations for replication. This was
done using the default settings of the QVALUE computer
program (version 1.1) (53). A preponderance of x1
2 values sug-
gestive of association was also examined via a QQ-plot, by
plotting the distribution of observed chi-square (x1
2) values
obtained from the single SNP allelic association analysis of
MA in Finns against the distribution of x1
2 values expected
under the null hypothesis of no association.
Given that recent results from two-stage association studies
indicate the most significant SNP in the total sample is not
necessarily the most significant SNP in the first stage, to
balance guarding against not following-up a true risk locus
with the number of loci to follow-up (i.e. minimizing the
multiple-test burden to maintain high replication power),
SNPs producing nominally significant (P , 0.005) allelic
association with MA in the Finnish cohort, together with sup-
porting evidence for association to strict IHS migraine and
individual trait components were selected for genotyping in
the replication cohorts. The nominal significance threshold
of P, 0.005 was selected after examination of the QQ-plot
and FDR results.
Given PLINK’s clustering procedure (- -cluster option)
requires whole-genome level data to give accurate results
(probably .10 000 SNPs), to allow for potential population
differences between the replication cohorts, a CMH analysis
(- -mh option) was used to test for overall association in the
Figure 3. Overview of study design.
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replication samples, controlling for cohort. The CMH test for
2  2  K-stratified tables is based on an ‘average’ odds ratio
(OR) that controls for the potential confounding due to the
cluster (cohort) variable. To account for differences in
ascertainment and diagnoses in addition to potential genetic
differences at the population level, the Leiden (Dutch),
Cologne and Munich (German), and Brisbane (Australian)
cohorts were each assigned to the separate clusters, resulting
in a CMH test that controls for four separate clusters. A sche-
matic overview of our study design is provided in Figure 3.
To further examine peak association results and guard
against missing a strong association signal by only analyzing
observed/single SNP data, exploratory association analysis
of haplotypes spanning two to six contiguous SNPs were
also performed using a sliding window approach via
PLINK’s - -hap-window and - -hap-assoc options.
Given the strong prior hypothesis for involvement of these
genes in migraine, we also tested for SNP  SNP epistasis
using PLINK’s - -epistasis option. For our total 5257 SNPs
there are 13 815 396 possible SNP  SNP interactions. There-
fore, although it is possible for loci with no individual effects
to still have a component of genetic variance attributable to
epistatic effects, following the recommendation of Blangero
et al. (54), to minimize epistasis multiple-testing burden, ana-
lyses were restricted to SNPs producing nominally significant
(P, 0.005) allelic association with MA in the Finnish cohort.
Finally, the PS program (55) was used to perform power
calculations in the replication cohorts. Briefly, the power to
replicate promising association results was estimated in
the individual and combined replication cohorts utilizing the
control allele frequency and OR observed in the Finnish
case–control cohort.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG Online.
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Migraine is a common episodic neurological disorder, 
typically presenting with recurrent attacks of severe headache 
and autonomic dysfunction. Apart from rare monogenic 
subtypes, no genetic or molecular markers for migraine have 
been convincingly established. We identified the minor 
allele of rs1835740 on chromosome 8q22.1 to be associated 
with migraine (P = 5.38 × 10−9, odds ratio = 1.23, 95%  
CI 1.150–1.324) in a genome-wide association study of 2,731 
migraine cases ascertained from three European headache  
clinics and 10,747 population-matched controls. The association 
was replicated in 3,202 cases and 40,062 controls for an 
overall meta-analysis P value of 1.69 × 10−11 (odds ratio = 
1.18, 95% CI 1.127–1.244). rs1835740 is located between 
MTDH (astrocyte elevated gene 1, also known as AEG-1) and 
PGCP (encoding plasma glutamate carboxypeptidase). In an 
expression quantitative trait study in lymphoblastoid cell lines, 
transcript levels of the MTDH were found to have a significant 
correlation to rs1835740 (P = 3.96 × 10−5, permuted threshold 
for genome-wide significance 7.7 × 10−5). To our knowledge, 
our data establish rs1835740 as the first genetic risk factor  
for migraine.
The recent boom of genome-wide association studies (GWAS) has 
had a major impact on our current view of genetic susceptibility to 
 common traits and complex disorders. However, central nervous 
 system disorders are under-represented among the conditions for 
which such associations have been found1. To our knowledge, no 
GWAS or common, robustly established linked genetic variants have 
been reported for major episodic neurological disorders (ICD-10 
codes G40–G44, migraine, epilepsy and ataxias). However, there is 
substantial genetic information for rare Mendelian forms of migraine, 
epilepsy and ataxia, which classifies them as channelopathies associ-
ated with compromised neurotransmitter homeostasis2. So far, there 
is no evidence for the contribution of ion channel variants in common 
forms of these diseases3,4.
Migraine is an episodic neurological disorder with complex 
pathophysiology, affecting 8% of males and 17% of females5 in the 
European population. Migraine ranks among the 20 most disabling 
diseases and has been estimated as the most costly neurological 
disorder, with a considerable impact on public health6. Clinically, 
the International Classification of Headache Disorders (ICHD-II7) 
recognizes two main common forms of migraine: migraine with 
aura and migraine without aura. The two forms are distinguished 
from each other based on the presence of aura, a period of vari-
able and diverse neurological symptoms that precede the headache 
phase. Individuals may have attacks of only migraine without aura, 
or only migraine with aura, or they may have a combination of both 
types in variable proportions. There is debate among the scientific 
community whether migraine with aura and migraine without 
aura attacks represent two distinct disorders or if they are merely 
variations of a single disease having a common complex genetic 
background. Migraine headache is believed to be caused by activa-
tion of the trigeminovascular system and the aura by cortical spread-
ing depression, a slowly propagating wave of neuronal and glial 
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depolarization8–10. However, these are considered to be downstream 
events, and it is unknown how migraine attacks are initiated.
To identify variants associated with the common forms of 
migraine, we carried out a two-stage GWAS in seven European 
migraine case collections (six clinic-based and one population-
based) (Supplementary Fig. 1). In the discovery stage, we studied 
3,279 migraineurs (1,124 Finnish, 1,276 German and 879 Dutch 
individuals) recruited from headache clinics and genotyped using 
Illumina arrays against population-matched controls (10,747 
individuals) recruited from preexisting population-based GWAS 
(Supplementary Note). In the replication stage, a further 3,202 cases 
and 40,062 population-matched controls from Iceland, Denmark, 
The Netherlands and Germany were studied.
Diagnoses were made by headache experts using a combination 
of questionnaires and individual interviews that were based on 
the ICHD-II guidelines7. Due to the overlap between individuals 
having migraine with aura and those having migraine without aura, we 
analyzed the following diagnostic subgroups: (i) ‘all migraine’, defined 
as all individuals with migraine irrespective of subtype; (ii) ‘migraine 
with aura only’, defined as individuals who only have attacks where 
aura is present; (iii) ‘both migraine with aura and migraine without 
aura’, defined as individuals with attacks both with and without aura; 
and (iv) ‘migraine without aura only’, defined 
as individuals with only attacks of migraine 
without aura.
We used a multipopulation Cochran-
Mantel-Haenszel (CMH) association analysis 
and a significance threshold of P  5 × 10−8 
in our analyses. In the discovery sample, 
2,731 cases and 10,747 controls (Table 1) 
passed quality control steps, and 429,912 
 markers were successfully genotyped (Online 
Methods). A quantile-quantile plot of the 
CMH analysis (Supplementary Fig. 2) and 
an overall inflation factor ( ) of 1.08 were 
used as final quality control measures.
Only one marker, rs1835740 on chromo-
some 8q22.1, showed significant association 
with migraine in the multipopulation CMH 
analysis (Fig. 1 and Supplementary Fig. 3). 
Eleven further loci were found with P  5 × 10−5 
(Supplementary Table 1). The minor allele 
(A) of marker rs1835740 was associated with 
migraine with P = 5.38 × 10−9 and odds ratios 
ranging between 1.21 and 1.33 (Table 2). 
Two nearby markers with the highest link-
age disequilibrium (LD) to rs1835740 
(rs982502, r2 = 0.59, P = 1.34 × 10−4 and 
rs2436046, r2 = 0.69, P = 1.78 × 10−5) 
also showed association with migraine (Supplementary Table 2). 
Haplotype analysis detected a 27-kb haplotype (P = 5.35 × 10−8) 
(Supplementary Fig. 4 and Supplementary Table 3). In the 
HapMap Phase II data11, the variant is located between two close 
recombination hotspots, and analysis using the ssSNPer program12 
demonstrated that no long-range LD to rs1835740 exists within a 
5-Mb window, strongly suggesting that the causative variant in this 
region is tagged by the minor allele of rs1835740 (Fig. 1). The 2-Mb 
window around rs1835740 was also imputed against the 1000 Genomes 
data (August 2009 release), but no other marker showed evidence of 
association exceeding that for rs1835740 (Fig. 1). Conditional analysis 
of the SNPs around rs1835740 showed no additional independent 
signals (Supplementary Table 2). The proportion of genetic vari-
ance explained by the rs1835740 variant was estimated to be between 






Individuals with  
both MA and  
MO (%)
Individuals  
with MA  
only (%)
Individuals  
with MO  
only (%)
Discovery stage
Finland Cases 1,064 19.8 80.2 94.4 5.6 0.0
Controls 3,513 47.4 52.6 – – –
Germany Cases 1,029 18.9 81.1 70.2 29.8 0.0
Controls 2,317 45.1 54.9 – – –
The Netherlands Cases 655 17.2 82.8 65.9 34.1 0.0
Controls 4,917 41.7 58.3 – – –
Total GWAS Cases 2,731 18.8 81.2 78.5 21.5 0.0
Controls 10,747 44.3 55.7 – – –
Replication stage
Iceland Cases 900 22.5 77.5 63.0 21.8 15.2
Controls 35,221 57.4 42.6 – – –
Denmark Cases 1,116 22.4 77.6 26.3 43.3 30.5
Controls 1,353 44.5 55.5 – – –
The Netherlands Cases 349 18.3 81.7 59.8 40.2 0.0
Controls 2,082 43.9 56.1 – – –
Germany Cases 837 11.6 88.4 0.0 0.0 100.0
Controls 1,406 37.3 62.7 – – –
Total replication Cases 3,202 19.1 80.9 33.8 25.6 41.0
Controls 40,062 55.6 44.4 – – –
Overall meta-analysis Cases 5,933 19.0 81.0 54.4 23.7 22.1
Controls 50,809 53.2 46.8 – – –










































Figure 1 Cochran-Mantel-Haenszel association results for combined 
analysis of the three study populations between 97.5 Mb and 99.0 Mb 
on chromosome 8q22.1. Diamonds show the position and P value for 
each marker in the region, with colors representing the extent of linkage 
disequilibrium (measured in r2) with the marker rs1835740, and blue 
circles indicate the locations and P values of the imputed markers.  
For rs1835740, P values are shown for both the original GWAS and the 
meta-analysis of all migraine samples in the study (denoted by asterisk). 
The blue graph shows the local recombination rate based on HapMap 
Phase II data11. The red line denotes the threshold for genome-wide 
significance (P  5 × 10−8). This figure was generated using a modified 
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1.5% and 2.5%, depending on the heritability estimate used, and 
the population attributable risk was estimated to be 10.7% using 
previous methodology13.
To confirm and extend our results, we performed a replication 
study on the only marker with genome-wide significance in the 
discovery stage: rs1835740. The diagnostic subgroups used in the 
discovery stage were also applied to the replication stage. Replication 
was successful in two ‘migraine with aura only’ subsets (Danish, 
P = 0.015, OR = 1.29 and Icelandic, P = 0.038, OR = 1.36), in the 
Icelandic ‘migraine without aura’ set (P = 0.0292, OR = 1.18) and in 
the Icelandic ‘all migraine’ group (P = 0.010, OR = 1.18) (Table 2). 
Overall, the A allele of marker rs1835740 was overrepresented 
(OR = 1.05–1.36; Table 2) in each subset of all replication samples 
except in the Danish ‘both migraine with aura and migraine without 
aura’ group (OR = 0.99). The effect was consistently stronger in the 
‘migraine with aura only’ groups than other migraine subgroups 
(Fig. 2). It should be noted that the majority of the groups that did 
not reach formal replication were small and had limited power. 
Meta-analysis was conducted using the CMH test for each diagnosis 
 subgroup alone as well as for all migraine samples together, with the 
latter group showing a final P = 1.69 × 10−11 (Table 2).
Marker rs1835740 is located between two potentially interesting can-
didate genes, MTDH and PGCP. We analyzed the effect of this marker’s 
genotype on the expression of genes within a 2-Mb window in fibro-
blasts, primary T cells and lymphoblastoid cell lines (LCL) obtained from 
umbilical cords14. In the expression quantitative trait locus (eQTL) ana-
lysis, the rs1835740 genotype was found to have significant correlation 
Table 2 Association results for marker rs1835740 using the CMH test
Diagnosis n (cases) n (controls) Case alleles (MAF) Control alleles (MAF) P OR 95% CI
GWAS
Finland All migraine 1,064 3,513 548/1,576 (0.258) 1,553/5,461 (0.221) 0.000447 1.22 1.093–1.368
Germany All migraine 1,029 2,317 515/1,537 (0.251) 998/3,632 (0.216) 0.00142 1.22 1.079–1.378
The Netherlands All migraine 655 4,917 329/963 (0.255) 2,086/7,742 (0.212) 0.000876 1.26 1.098–1.437
Discovery stage
MA only 589 10,747 313/859 (0.267) 4,637/16,385 (0.216) 3.07 × 10−5 1.33 1.164–1.528
Both MA and MO 2,142 10,747 1,071/3,193 (0.251) 4,637/16,385 (0.216) 2.69 × 10−6 1.21 1.115–1.304
All migraine 2,731 10,747 1,384/4,052 (0.255) 4,637/16,385 (0.216) 5.38 × 10−9 1.23 1.150–1.324
Replication stage
Denmark MA only 483 1,353 244/722 (0.253) 562/2,144 (0.208) 0.015 1.29 1.050–1.583
Both MA and MO 293 1,353 121/465 (0.206) 562/2,144 (0.208) 0.951 0.99 0.785–1.255
MO only 340 1,353 153/527 (0.225) 562/2,144 (0.208) 0.333 1.11 0.900–1.362
All migraine 1,116 1,353 518/1,714 (0.232) 562/2,144 (0.208) 0.069 1.15 0.989–1.344
Iceland MA only 137 35,221 70/204 (0.255) 14,212/56,230 (0.202) 0.0380 1.36 1.017–1.812
Both MA and MO 196 35,221 82/310 (0.209) 14,212/56,230 (0.202) 0.7256 1.05 0.812–1.350
MO only 567 35,221 261/873 (0.230) 14,212/56,230 (0.202) 0.0292 1.18 1.017–1.376
All migraine 900 35,221 413/1,387 (0.229) 14,212/56,230 (0.202) 0.010 1.18 1.041–1.334
The Netherlands MA only 212 2,082 100/324 (0.236) 909/3,255 (0.218) 0.406 1.11 0.873–1.399
Both MA and MO 137 2,082 66/208 (0.241) 909/3,255 (0.218) 0.382 1.14 0.853–1.513
All migraine 349 2,082 166/532 (0.238) 909/3,255 (0.218) 0.250 1.12 0.925–1.350
Germany MO only 837 1,406 396/1,278 (0.240) 629/2,183 (0.224) 0.3206 1.08 0.932–1.241
MO onlya 837 541 396/1,278 (0.240) 218/864 (0.201) 0.0307 1.23 1.019–1.480
Meta-analysis
All “MA only” 1,421 49,403 727/2,109 (0.256) 20,320/78,464 (0.206) 6.98 × 10−8 1.29 1.173–1.408
All “Both MA and MO” 2,768 49,403 1,340/4,176 (0.243) 20,320/78,464 (0.206) 1.09 × 10−5 1.17 1.089–1.248
All “MO only” 1,744 37,980 810/2,678 (0.232) 15,403/60,557 (0.203) 0.0105 1.12 1.028–1.230
All “All migraine” 5,933 50,809 2,877/8,963 (0.243) 20,949/80,647 (0.206) 1.69 × 10−11 1.18 1.127–1.244
MA, migraine with aura; MO, migraine without aura. Genome-wide significant values and successful replications are shown in boldface.
aValues in this row were calculated after excluding an outlier control sample. The German replication control set consisted of several small samples. The largest of these had a considerably deviat-
ing minor allele frequency (MAF) (MAF = 0.238, n = 865) compared to other German (average MAF = 0.216, n = 3,260) and Central European control sets (average MAF = 0.212, n = 9,560). 
Thus, values with both including and excluding the outlier control sample are presented in the case allele and control allele columns. The meta-analysis value includes all control samples (without 
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Figure 2 For each dataset, the horizontal line indicates the 95% CI, and 
the number above the line indicates the point estimate of the odds ratio. 
MA only, individuals whose attacks are always accompanied with aura; 
both MA, MO, individuals with attacks with and without aura; MO only, 
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to the transcript levels of the nearby MTDH gene in LCLs (Table 3 and 
Supplementary Table 4), with the risk allele A being associated with 
higher expression levels (Fig. 3). This is in line with previous studies, 
which have proven that expression analyses in LCL cells are informative 
in neurological and neuropsychiatric traits15–17. No significant associa-
tion was detected in fibroblasts or primary T cells. The eQTL analysis 
suggested that rs1835740 is a cis regulator of MTDH in LCLs.
The location of the associating sequence variant, rs1835740, 
between two genes involved in glutamate homeostasis, PGCP and 
MTDH, suggests that this region contains elements that could regulate 
either or both of these flanking genes; the eQTL analysis pointed to 
the latter. Although MTDH has mainly been studied in relation to 
carcinogenesis18, previous studies in cultured astrocytes have shown 
that MTDH downregulates SLC1A2 (also known as EAAT2 and 
GLT-1)18–22, the gene encoding the major glutamate transporter in 
the brain. Furthermore, knock-out mice lacking the EAAT2 protein 
from their brains have been shown to suffer from lethal spontaneous 
epileptic seizures23. Despite the limitations in extrapolating eQTL 
findings from LCL cells directly to brain tissue, these data suggest a 
plausible link between the identified variant and glutamate regulation. 
This is a tempting hypothesis, as this neurotransmitter has long been 
suspected to play a key role in migraine pathophysiology24.
Although the evidence provided here is indirect, accumulation of 
excess glutamate in the synaptic cleft through downregulation of EAAT2 
or an increase in PGCP activity (or both) would provide a putative mech-
anism for the occurrence of migraine attacks. It is reasonable to speculate 
that this accumulation can increase susceptibility to migraine through 
increased sensitivity to cortical spreading depression, the likely mecha-
nism for the migraine aura9,10, as well as through glutamate involvement 
in central sensitization, which has been postulated to be the underlying 
mechanism of allodynia during a migraine attack25.
Neither this study nor our previous study3 
yielded evidence for association of ion channel 
genes to common forms of migraine. Thus, 
even if the contribution of ion channel genes 
is well established in Mendelian forms of parox-
ysmal neurological disorders, such as familial 
hemiplegic migraine (FHM)26–29, their direct 
role in more common forms of paroxysmal neu-
rological disorders remains open. Interestingly, 
previous studies suggested that the imbalance of 
glutamate release and clearance is a key component of the pathogenesis 
of FHM; the underlying mutation in FHM lies in CACNA1A, ATP1A2 
or SCN1A30,31. The results of the present study support the hypothesis 
that complementary pathways such as the glutamate system may tie the 
Mendelian channelopathies with the pathogenetic mechanisms of more 
common forms of episodic neurological disorders, such as migraine. 
Alterations in the functionally related EAAT1 transporter have been iden-
tified in other episodic phenotypes (such as episodic ataxia 6 (ref. 32) and 
a phenotype with episodic ataxia, hemiplegia and seizures33), providing an 
example of the link between EAAT transporters and episodic disorders. 
Future studies should be conducted to specifically test this hypothesis.
In summary, to our knowledge, we have identified the first robust genetic 
association to migraine. As our cases were mainly selected from specialized 
headache clinics, subsequent studies are needed to establish the contribu-
tion of rs1835740 in population-based migraine cohorts. These population-
based cohorts may represent a different severity spectrum and possibly 
also a somewhat different underlying combination of genetic susceptibility 
variants. The effect of rs1835740 is stronger in individuals with migraine 
with aura than in those with migraine without aura, but further studies are 
needed to confirm the role of the variant in different migraine subgroups. 
This variant explains only a small fraction of the overall genetic variance in 
migraine, and future GWAS, perhaps with different ascertainment schemes, 
will likely identify additional loci explaining more of the genetic variance.
METHODS
Methods and any associated references are available in the online 
version of the paper at http://www.nature.com/naturegenetics/.
Accession codes. Migraine, OMIM 157300.
Note: Supplementary information is available on the Nature Genetics website.
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Figure 3 A box-plot of the quantified expression values for MTDH, ordered 
based on the sample genotype of rs1835740. Normalized expression levels 
in lymphoblastoid cell lines using Illumina’s WG-6 v3 Expression BeadChip 
array are shown. In each group, the small pyramid indicates the median 
value, the shaded area represents the lower and upper quartiles, and the 
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Study design. We jointly analyzed samples from three migraine with aura 
collections from Finland, Germany and The Netherlands with population-
matched controls obtained from preexisting studies. This discovery phase 
was followed by a replication study of the top SNP, rs1835740, in samples 
from individuals with migraine from Denmark, Iceland, The Netherlands and 
Germany. Characteristics of each study sample are described in Table 1, and 
the recruitment and ascertainment of cases and controls are described in the 
Supplementary Note.
Discovery stage genotyping. DNA was extracted from the subjects’ blood 
samples using standard methods. Genotyping of the GWAS samples 
was done at the Wellcome Trust Sanger Institute on the Illumina 610K 
(for the Finnish and German samples) and the Illumina 550K (for the Dutch 
samples) SNP microarrays following the Infinium II protocol from 
the manufacturer (Illumina Inc.). Genotype calling was performed using 
the Illuminus software34.
Replication stage genotyping. For the replication study, all Danish cases 
and 459 migraine-free controls were genotyped using the Centaurus plat-
form (Nanogen Inc.), and 904 additional controls were genotyped at deCODE 
genetics using the Illumina HumanHap650 BeadArray. The Icelandic cases and 
controls were genotyped using the Illumina HumanHap 317K, 370K, 610K or 
1M bead arrays at deCODE genetics. The Dutch replication cohort was geno-
typed using the TaqMan technology (Applied Biosystems, Life Technologies) 
at Leiden University Medical Center. The German replication cases were 
genotyped using Illumina HumanHap 610K array at the Institute of Human 
Genetics at the Helmholtz Zentrum, Munich.
Expression study. The GenCord resource, a collection of cell lines derived 
from umbilical cords of 75 newborns of Western European origin born at the 
maternity ward of the University of Geneva Hospital, was used for the expres-
sion study. Sample collection was performed on full-term or near-full-term 
pregnancies to ensure homogeneity for sample source age. Three cell types 
were derived: (i) primary fibroblasts, (ii) LCLs and (iii) primary T cells14. Total 
RNA was extracted from these cells and two one-quarter-scale MessageAmp 
II reactions (Ambion) were performed for each extraction with 200 ng of 
total RNA. 1.5 g of cRNA was hybridized to Illumina’s WG-6 v3 Expression 
BeadChip array to quantify transcript abundance35. Intensity values were log2 
transformed and normalized independently for each cell type using quantile 
normalization for sample replicates and median normalization across all indi-
viduals. Each cell type was renormalized using the mean of the medians of 
each cell type’s expression values. DNA samples were extracted from umbilical 
cord tissue LCLs with the Puregene cell kit (Gentra-Qiagen), and genotyping 
was performed using the Illumina 550K SNP array (Illumina Inc.) to obtain 
the SNP genotypes for the samples.
Statistical analysis of the genome-wide scan data. Stringent per-SNP and 
per-sample limits were implemented in order to obtain high-quality data. 
Quality control measures were as follows: exclusion of samples with call rates 
<97%, non-comparable ancestry as measured using multidimensional scaling 
plots from PLINK36, possible contamination as identified by being an extreme 
heterozygosity outlier and cryptic relatedness (low-level relatedness to a large 
number of samples) and non-cryptic relatedness of π̂ >12.5%. From the initial 
3,279 cases and 12,369 controls, 2,731 cases and 10,747 controls passed all 
quality control criteria, and 531 cases and 1,622 controls were excluded. The 
majority of case exclusions were due to quality issues on the 550K chips, and the 
majority of control exclusions were due to low-level relatedness in the Dutch 
control set. SNPs were excluded for having a minor allele frequency of <1%  
or for departing from Hardy-Weinberg equilibrium with P < 10−6 in cases or 
controls. Only completely overlapping SNPs from the three populations were 
used, leaving a total of 429,912 SNPs for analysis. To ascertain whether the 
control samples were properly matched to the cases, a population-specific 
inflation factor and an overall genomic inflation factor ( ) were estimated 
using the median 2 value from a 1 degree-of-freedom allelic 2 test. For the 
Finnish samples,  = 1.05; for the German samples,  = 1.07; for the Dutch 
samples,  = 1.09; and the overall  = 1.08, suggesting reasonably well matched 
controls in each case. Differences between cases and controls were assessed 
between each SNP and disease status using a two-tailed CMH test for 2 × 2 × K 
stratified data (where K = 3), as implemented in PLINK v1.06. To exclude 
long-range LD for the identified variant, we used the program ssSNPer12 to 
demonstrate that no SNP within a 5-Mb window had high LD to rs1835740 
in HapMap Phase II data.
Conditional analysis for secondary effects. In addition to rs1835740, two 
other SNPs on 8q22.1, rs2436046 and rs982502, showed a CMH P < 10−3 
(Table 2 and Fig. 2). Based on our data, rs2436046 (r2 = 0.68) and rs982502 
(r2 = 0.59) are in moderate LD with rs1835740. To evaluate whether these 
signals were independent from the top SNP association signal, the associa-
tion between migraine and SNP alleles was tested using logistic regression, 
conditioning on rs1835740 as implemented in PLINK v1.06. Conditioning on 
rs1835740, no evidence of additional independent signals was found either 
for rs2436046 or rs982502 (P = 0.89 and P = 0.47) (Supplementary Table 3), 
suggesting that the moderate association of rs2436046 and rs982502 observed 
in the CMH test is the result of these SNPs being in LD with rs1835740.
Meta-analysis of discovery and replication samples. The CMH test was used 
for the meta-analysis, with a nominal covariate used to distinguish each sample 
collection from the others. For the replication in Icelandic and Danish samples, 
association analysis was carried out using a likelihood procedure37, and results 
were adjusted for relatedness by dividing the 2 statistics by an inflation factor 
estimated through simulation38.
Imputation. For each cohort, imputation of the untyped markers in the 
2-Mb region around rs1835740 was carried out using IMPUTE v2 with 
the recommended options39. Haplotypes from the 1000 Genomes Project 
(August 2009 release) and haplotypes from HapMap Phase 3 were used as 
reference panels.
eQTL analysis. Association between genotypes and expression was analyzed 
using Spearman rank correlation for all SNPs with a 2-Mb window centered on 
the transcription start site of the gene. Significance was assessed by comparing 
the observed P values at a 0.001 threshold with the minimum P values from 
each of 10,000 permutations of the expression values relative to genotypes35.
URLs. Control populations: Finland—Health2000 study, http://www. 
nationalbiobanks.fi; Finland—Helsinki Birth Cohort study, http://www.
nationalbiobanks.fi; Germany—KORA S4/F4 study, http://www.helmholtz- 
muenchen.de/kora; Germany—PopGen study, http://www.popgen.de; 
Germany—HNR study, http://www.recall-studie.uni-essen.de/recall_info.html; 
Illumina iControlDB, http://www.illumina.com; The Netherlands—Rotterdam I 
and III studies, http://www.epib.nl/research/ergo.htm; the Netherlands—Lumina 
study, http://www.lumc.nl/hoofdpijn. Other URLs: International Headache 
Genetics Consortium, http://www.headachegenetics.org; ssSNPer, http://gump.
qimr.edu.au/general/daleN/ssSNPer/; GWAS plotter, http://www.broadinstitute.
org/node/555; HapMap Phase 2 and 3 data, http://www.hapmap.org.
34. Teo, Y.Y. et al. A genotype calling algorithm for the Illumina BeadArray platform. 
Bioinformatics 23, 2741–2746 (2007).
35. Stranger, B.E. et al. Population genomics of human gene expression. Nat. Genet. 
39, 1217–1224 (2007).
36. Purcell, S. et al. PLINK: a tool set for whole-genome association and population-
based linkage analyses. Am. J. Hum. Genet. 81, 559–575 (2007).
37. Gretarsdottir, S. et al. The gene encoding phosphodiesterase 4D confers risk of 
ischemic stroke. Nat. Genet. 35, 131–138 (2003).
38. Grant, S.F. et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk 
of type 2 diabetes. Nat. Genet. 38, 320–323 (2006).
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Supplementary Figures and Figure Legends 
Supplementary Figure 1. Study design 
In the initial study, migraine with aura (MA) patients from three clinic-based collections 
were analyzed in a joint genome-wide association analysis. The most significant 
association signal was replicated in an independent Danish clinic-based sample and an 
Icelandic population-based sample, containing MA and migraine without aura (MO) 
samples, as well as in a German clinic-based MO-specific sample.  
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Supplementary Figure 2. Quantile-quantile plot of the results in the Cochran-
Mantel-Haenszel analysis 
 Asterisk denotes marker rs1835740. Black line represents the distribution of p-values 
under the null given study inflation factor lambda of 1.08. 
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Supplementary Figure 3. Genome-wide Cochran-Mantel-Haenszel results for 
association between each marker and migraine with aura in the combined analysis 
of the three initial study populations 
Red line denotes the threshold of genome-wide significance (p ≤ 5 × 10-8). Only marker 
rs1835740 on 8q22.1 exceeded this threshold.
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Supplementary Figure 4. Nine SNP sliding window haplotype analysis and local 
haplotype structure around marker rs1835740 on chromosome 8q22.1 
In the upper part of the figure, the black pyramids show single-marker association results 
for each marker. The horizontal lines show the length and overall p-values for the nine 
marker sliding windows in the haplotype analysis. The lower part of the figure shows the 
Haploview D’ matrix in the GWA study analysis data, with estimated LD blocks using 
the Gabriel et al. method1. Black stars denote the location of rs1835740 and the black 
arrows denote the 3’ end of PGCP in either part of the figure. 
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Supplementary Tables 
Supplementary Table 1. Association signals with p ≤ 5 × 10-5 and with multiple 
nearby associating SNPs  
SNP Chr Location p-value OR 95% CI Location Gene
rs12084862 1 244269837 8.20E-06 1.17 1.09-1.25 intragenic SMYD3
rs17528324 2 118572626 4.13E-06 1.27 1.15-1.41 intragenic INSIG2
rs17862920 2 234492734 1.26E-05 0.776 0.693-0.870 intragenic TRPM8
rs2038761 6 2625766 2.02E-05 0.865 0.809-0.925 intragenic MYLK4
rs6456880 6 29071227 2.18E-05 0.873 0.819-0.929 intragenic ZNF311
rs7753655 6 49644523 4.29E-06 0.852 0.796-0.912 intergenic -
rs10888075 8 13804790 1.04E-05 1.21 1.11-1.31 intergenic near SGCZ
rs10111769 8 21003036 1.49E-05 1.15 1.08-1.23 intergenic -
rs2042600 11 19709275 2.28E-05 0.876 0.824-0.932 intragenic NAV2
rs3794331 13 44951545 2.70E-05 1.28 1.14-1.43 intragenic COG3
rs473422 15 56453633 1.03E-05 0.864 0.820-0.922 intergenic near AQP9
Footnote: Locations and distances in basepairs, according to NCBI build 36. Only the SNP with 
the lowest p-value is reported for each locus.
Supplementary Table 2. Conditional analyses for the two SNPs with moderate 
linkage disequilibrium to rs1835740 in chromosome 8q22.1 
Chr SNP A SNP B r2 SNP A p-value SNP B p-value SNP B given A
8 rs1835740 rs2436046 0.69 5.12 x 10-9 1.78 x 10-5 0.892
8 rs1835740 rs982502 0.59 5.12 x 10-9 1.34 x 10-4 0.466
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Supplementary Table 3. Nine SNP sliding window haplotype analysis on the 
chromosome 8q22.1 associated region from Supplementary Figure 2 
Haplotype First SNP Last SNP Chi-sq. D.f. Overall p-value
1 rs1431890 rs1835740 43.07 16 2.730E-04
2 rs10504970 rs982502 43.10 17 4.643E-04
3 rs920576 rs1155199 41.37 13 8.291E-05
4 rs2436051 rs7845920 48.48 14 1.093E-05
5 rs16895256 rs7845940 47.68 12 3.553E-06
6 rs17737465 rs1431884 46.52 10 1.156E-06
7 rs2436046 rs6990629 51.62 9 5.327E-08
8 rs2436047 rs1155021 48.93 10 4.196E-07
9 rs1835740 rs1835742 53.46 10 6.107E-08
10 rs982502 rs11783877 45.23 8 3.327E-07
11 rs1155199 rs4734357 41.91 8 1.410E-06
12 rs7845920 rs7822798 39.34 9 9.995E-06
13 rs7845940 rs7838062 32.98 8 6.208E-05
The nine SNP window in bold is the one referred to in the text. N.B. haplotype value 
shown in text is for the single haplotype, above values for the association of the whole 
haplotype distribution.
Supplementary Table 4. SNPs with nominal or higher p-values for association with 
expression levels of MTDH/AEG-1
SNP Gene SNP coordinate Gene start Distance SRC p-value
rs11783750 MTDH/AEG-1 98 865 219 98 725 583 139 636 0.0018741
rs10105830 MTDH/AEG-1 98 307 895 98 725 583 417 688 0.0004235
rs1835740 MTDH/AEG-1 98 236 089 98 725 583 489 494 0.0000396*
rs7845920 MTDH/AEG-1 98 247 132 98 725 583 478 451 0.0014652
Footnote: * indicates surpassing the significance threshold 7.7 x 10-5 (corresponding to a 0.001 
permutation threshold after 10,000 permutations). SRC = Spearman rank correlation. Locations 
and distances in basepairs, according to NCBI build 36. Numbers in bold are statistically 
significant. 
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Supplementary Note: Clinical subject ascertainment and control 
samples
Ethical aspects  
Written informed consent was obtained from all participants, and the study was approved 
by the respective local research ethics committees of the Helsinki University Central 
Hospital, Pain Clinic Kiel in Kiel, the Department of Neurology at Klinikum Großhadern, 
Ludwig-Maximilians-University in Munich, and the University of Leiden Medical 
Centre. Informed consent was obtained from all patients. 
Initial study 
The initial genome-wide association study consisted of three patient samples, collected 
from headache clinics in Finland, Germany and the Netherlands.  
In Finland, 1,124 Finnish migraine with aura (MA, and MA/MO) patients were recruited.
Each patient belongs to a multigenerational family with at least three family members 
with migraine. Patients were examined by a neurologist, and fulfilled the validated 
Finnish Migraine Specific Questionnaire for Family Studies (FMSQFS2). In cases of 
insufficient or conflicting information, a follow-up interview was conducted by 
telephone. All patients were diagnosed by the same headache specialist (M. Kallela) 
according to the current International Headache Society diagnostic criteria (ICHD-II)3.  
In Germany, patient recruitment was done at two sites, in Kiel and in Munich. At the Pain 
Clinic in Kiel, a total of 994 German MA and MA/MO patients were recruited to a 
patient collection maintained at the Universities of Bonn and Cologne. All patients were 
diagnosed according to the ICHD-II3 by headache specialists4. The detailed migraine 
anamnesis was obtained either by face-to-face interviews or by telephone interviews 
standardized by using a comprehensive migraine questionnaire. The second German set 
of 282 MA and MA/MO cases were recruited and examined by a headache specialist at 
the Klinikum Großhadern of the Ludwig-Maximilians-University, Munich. Phenotyping 
was based on a German translation of the FMSQFS2. Whenever the information was 
insufficient or conflicting, an additional telephone interview was performed. Information 
was obtained on all aspects of the ICHD-II3 criteria as well as on other aspects (such as 
age at onset, prodromal symptoms, triggers, acute and prophylactic medication, family 
history, general past medical history, co-morbidity and place of birth).  
In the Netherlands, 879 MA and MA/MO patients were available from the clinic-based 
Leiden University Migraine Neuro Analysis (LUMINA) study. Self-reported migraineurs 
were recruited via the project’s website. A set of screening questions validated previously 
in a population-based study5 was used first. Participants fulfilling the screening criteria 
completed then the extended questionnaire focusing on signs and symptoms of migraine 
headache and aura as outlined in ICHD-II3. Individual diagnoses were made using an 
algorithm based on these criteria. The algorithm diagnosis was validated by a semi-
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structured telephone interview performed by experienced study physicians or by well-
trained medical students. Specific attention was paid to migraine aura. A subset of the 
patients was asked to participate upon visiting the outpatient clinic.  
Replication studies 
The replication phase of the study consisted of four separately recruited migraine patient 
samples from Denmark, Iceland, the Netherlands and Germany. 
The Danish replication sample comprised 825 MA subjects of which 776 were 
successfully genotyped. Of these, 483 patients suffered from only MA attacks and 293 
from both MA and MO attacks. Patients were selected from the Danish National Patient 
Register and from case files from neurological clinics, 1,365 took part in a screening 
telephone interview. If the proband was diagnosed with MA, the proband and selected 
relatives were diagnosed according to the ICHD-I6 in a validated telephone interview (M. 
Kirchmann or A.H.). 305 Danish MO patients were selected from case files at the Danish 
Headache Center and diagnosed as mentioned above (ICHD-II3) in an extensive semi-
structured telephone interview performed by trained physicians. In addition 81 MO 
subjects were identified during recruitment of the MA families. Thus, 386 MO patients 
were recruited and 340 successfully genotyped.  
The Icelandic replication samples were recruited from three sources: first, a list of 
patients provided by two neurologists (401 potential participants), second, responses to 
an advertisement in the newsletter of the Icelandic Migraine Society (137 participants), 
and third, responses to a brief screening questionnaire mailed to a random sample of 
20,000 Icelanders, aged 18–50 years and living in the Reykjavik area. All Icelandic 
recruits were asked to answer the comprehensive validated deCODE Migraine 
Questionnaire 2 or 3 (DMQ2 or DMQ37). The questionnaire was designed based on 
ICHD-II3. The reliability of the MA and MO diagnoses based on the DMQ3 was assessed 
using a physician-conducted interview as an empirical index of validity. In total 1,612 
subjects reporting five or more headache attacks were genotyped. Of them, 712 subjects 
reported atypical symptoms, preventing reliable IHS classification through questionnaire 
data only, and were excluded from the analysis. In total, the Icelandic sample consists of 
567 MO patients, and 333 MA patients either with or without the MO attacks.  
The German replication cohort includes 837 MO cases from the Department of 
Neurology of the Ludwig-Maximilians-University, Munich, Germany. Phenotyping 
followed the same protocol as described for the Munich patient sample.  
The Dutch replication sample includes 356 Dutch MA or MA/MO patients that were 
recently recruited through the clinic-based Leiden University Migraine Neuro Analysis 
(LUMINA) study. The diagnosis and classification followed the same procedure as in the 
initial Dutch sample.  
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Control samples  
Population-matched control samples were obtained from previously genotyped studies 
(for links to studies, see URL section of Online Methods). 1,881 Finnish controls 
originated from the Helsinki Birth Cohort study8 and 2,173 controls from the Health2000 
study, genotyped on the Illumina 660K or 610K platforms. 840 German controls were 
obtained from the KORA S4/F4 study9, 380 controls from the HNR study10 and 677 from 
PopGen study11, all genotyped on the Illumina 550K platform. In addition, 444 controls 
were obtained from Illumina iControlDB by querying all Caucasian samples genotyped 
on the Illumina 550K platform on June 30th, 2008 and filtering these samples based on 
stratification as observed from multidimensional scaling plots of all existing German 
samples, and keeping only those identified as being of German descent. 974 Dutch 
controls were obtained from the Rotterdam study I12, genotyped on the Illumina 550K 
platform and imputed to cover all markers on the 610K platform. For each replication 
study, the group providing a replication dataset supplied a matched control cohort; the 
controls for the Danish and Icelandic replications were provided by deCODE, and 
German controls were obtained from the MARS study13 and from GlaxoSmithKline14 and 
Rotterdam study III.
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